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 Abstract 
Abstract 
 
 Rheumatoid arthritis (RA) is an autoimmune chronic inflammatory disease, of 
unknown aetiology. Several disease-modulating approaches have been developed in 
the past years, however these are expensive, usually accompanied by unwanted 
side-effects and 30% of the patients fail to respond. The transcription factor NF-kB is 
a key factor in the development and perpetuation of the disease, as it regulates a 
number of inflammatory genes. The activity of certain signalling pathways can be 
modulated by delivering into cells inhibitors coupled to Protein Transduction Domains 
(PTDs). The aim of this study was to develop a secretable PTD-fusion NF-κΒ inhibitor 
that is produced and secreted by genetically engineered mammalian cells in sufficient 
amounts to subsequently transduce and regulate NF-κΒ activity in neighbouring cells. 
Such methodology could be useful for the management of RA by transplantation of 
engineered cells or directly using gene delivery into the synovial joints. 
 In this study, PTD-fusion proteins were fused to the IL-2 secretion signal and 
their ability to be secreted from mammalian cells was explored. Secretable forms of 
TAT-IgG2A and TAT-eGFP were generated as control PTD-fusion proteins, and the 
TAT-srIκΒα (super repressor IκBα, a NF-κΒ inhibitor) was generated as an NF-κΒ 
PTD-fusion inhibitor. Western blotting analysis of supernatants from transiently 
transfected 293T cells revealed that TAT-IgG2A, TAT-eGFP and TAT-srIκΒα are 
secreted with variable efficiencies. When concentrated, PTD proteins were able to 
transduce mammalian cells, as demonstrated with Jurkat cells by confocal 
microscopy and western blotting analysis. 
 The TAT PTD domain was replaced to a more stable, furin cleavage-resistant 
and less positively charged PTD domain, the TAT3 PTD domain, to ensure that PTD-
fusion proteins will be secreted more efficiently. This change of the PTD domain did 
not increase secretion levels of the srΙκBα. Subsequently, the Latent Associated 
Peptide (LAP) of TGFβ, was fused to the TAT3-srIκΒα inhibitor, via a matrix 
metalloproteinase (MMP) cleavage linker. This LAP-MMP-PTD-fusion NF-κΒ inhibitor 
was again poorly secreted. In turn, the srIκΒα inhibitor was replaced with a small 
synthetic NF-κΒ inhibitor, termed Nemo Binding Domain (NBD), in the form of LAP-
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MMP-TAT3-NBD NF-κΒ inhibitor. Western blotting analysis of supernatants from 
transiently transfected 293T cells revealed that the LAP-MMP-TAT3-NBD was 
efficiently secreted.  
 The ability of LAP-MMP-TAT3-NBD to inhibit NF-κΒ was tested in vitro with the 
use of a cell-assay based on HeLa cells that are permanently transfected with the 
luciferase gene driven by an NF-κB regulated promoter. In this assay, HeLa cells that 
were treated with the secreted LAP-MMP-TAT3-NBD, showed reduced levels of 
luciferase activity after IL-1β stimulation. Subsequently, using a replication-deficient 
lentiviral vector, genetically engeneered DBA/1 fibroblasts (DTF) able to produce the 
secreted LAP-MMP-TAT3-NBD were generated. The NF-κB inhibitory properties of 
the secreted LAP-MMP-TAT3-NBD were tested in vivo in the Carrageenan-induced 
paw oedema, Antigen Induced Arthritis and Air-Pouch acute inflammation models. 
Paws of mice that were treated with engineered cells or lentivirus encoding LAP-
MMP-TAT3-NBD demonstrated milder paw swelling, suggesting that LAP-MMP-
TAT3-NBD had a protective role in the induction of inflammation. However, the LAP-
MMP-TAT3-NBD did not demonstrate anti-inflammatory effects in the Air-Pouch 
model. 
 In this study, I present a method to design PTD-fusion proteins that can be 
efficiently secreted from mammalian cells and I demonstrate a novel gene therapy 
approach for the local delivery of a therapeutic agent. 
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1.1 Rheumatoid Arthritis 
 
 
1.1.1 Epidemiology 
 
 
RA affects approximately 1% of the population worldwide. Several 
epidemiological studies in European and Northen American populations have 
reported a consistent prevalence between 0.5% and 1% (Cimmino et al., 1998; 
Simonsson et al., 1999). However, there are some exceptions to the above 
frequencies of RA occurrence. Native American-Indian populations demonstrate the 
highest recorded frequencies of RA. More specifically, RA affects 5.3% of Pima 
Indians (Del Puente et al., 1989) and 6.8% of Chippewa Indians (Ferucci et al., 2005). 
In contrast, South African (Brighton et al., 1988) and South East Asian populations 
have revealed the lowest levels of RA occurrence (0.2% - 0.3%) (Felson, 2008).  
Over the last decades, a large number of epidemiological studies have tried to 
identify risk factors, including genetic and environmental factors that are associated 
with the development of RA. The most compelling evidence that genetic factors 
contribute to the onset of the disease derive from twin studies. The concordance 
rates for monozygotic is approximately 15% and for dizygotic 4% (Andersson et al., 
2008; Silman et al., 1993). Interestingly, a recent well designed study calculated that 
approximately 50-60% of the occurrence of RA in twins is explained by the 
contribution of genetic factors (MacGregor et al., 2000). This suggests that although 
genetic factors play a significant role, environmental factors have a substantial 
contribution in the development of RA.      
The disease onset can be at any time in life, however RA is more prominent in 
the fifth decade and it is approximately three times more common in women. 
Environmental factors that have been studied in relevance to the development and 
expression of RA include smoking, socioeconomic factors, infectious agents, 
hormonal factors, dietary factors and ethnicity. However, the impact of most of these 
factors on the risk of developing RA still remains uncertain (Alamanos and Drosos, 
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2005). Population studies have associated RA patients with decreased quality of life, 
increased morbidity (Krause et al., 2000), and it is estimated that 50% of those who 
have developed the disease are no longer in full-time employment 10 years after the 
onset of the disease (Bingham and Moore, 2004 ). Adding the expensive direct 
medical costs, RA is responsible for a significant socioeconomic burden (Dunlop et 
al., 2003).  
 
 
1.1.2 Clinical features 
 
 
Synovial joints are the most movable parts in the human body. In the joints, the 
epiphysis of the bones is surrounded by cartilage and the two articular bones are 
protected by the synovial membrane, which form the joint capsule (Figure 1.1). The 
outer layer of the joint capsule consists mainly of cartilage fibres, whereas the inner 
layer is mainly populated by synovial cells. There are two different types of 
synoviocytes. Type A cells, which can act as phagocytes and interact with T-cells as 
antigen presenting cells, and type B cells, which are fibroblastoid in appearance. This 
highly vascularised membrane is responsible for the maintenance of negative 
pressure and presence of lubricant fluids in the joint (Edwards, 1994). 
The typical clinical picture of RA, initially, includes bilaterally symmetric painful 
swelling of the wrists and of the metacarpophalangeal and proximal interphalangeal 
joints of the hands (Figure 1.2). Patients usually experience morning stiffness of the 
joints and complain that they can no longer make a fist. The synovial membrane 
becomes hyperplastic and hypertrophic, where extensive angiogenesis and immune 
cell infiltration occurs. It is characterized by low-grade inflammation, with periodic 
flares in the intensity of inflammation, which eventually involves the majority of the 
joint. Chronic inflammation causes cartilage destruction and bone damage, which 
leads to deformity and disability  (Smith and Haynes, 2002) (Figure 1.1, Figure 1.2).  
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Figure 1.1: Schematic representation of RA pathogenesis. In the normal knee joint, the 
synovium consists of a synovial membrane (usually one or two cells thick) and underlying 
loose connective tissue. Synovial-lining cells are designated type A (macrophage-like 
synoviocytes) or type B (fibroblast-like synoviocytes). In early rheumatoid arthritis, the 
synovial membrane becomes thickened because of hyperplasia and hypertrophy of the 
synovial lining cells. An extensive network of new blood vessels is formed in the synovium. T-
cells (predominantly CD4+) and B-cells (some of which become plasma cells) infiltrate the 
synovial membrane. These cells are also found in the synovial fluid, along with large numbers 
of neutrophils. In the early stages of rheumatoid arthritis, the synovial membrane begins to 
invade the cartilage. In established rheumatoid arthritis, the synovial membrane becomes 
transformed into inflammatory tissue, the pannus. This tissue invades and destroys adjacent 
cartilage and bone. The pannus consists of both type A and type B synoviocytes and plasma 
cells. Taken from Choy and Panayi, 2001. 
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Figure 1.2: A typical clinical picture of RA.  A) Symmetrical polyarthritis involving the finger 
joints. B) Bilateral wrist swelling. Taken from Brooks, 2002.  
 
 
 
1.1.3 Aetiology and pathogenesis      
 
 
RA is a complex disease and its aetiology remains elusive. It is generally 
believed that the interaction between environmental and genetic factors trigger the 
initiation of an inflammatory immune response, which eventually leads to the 
development of the chronic inflammatory disease. Interestingly, the onset of at least 
50% of autoimmune diseases has been attributed to unknown trigger factors 
(Stojanovich and Marisavljevich, 2008). Very little is known about the events that take 
place prior to the onset of inflammatory arthritis. This phase, known as pre-articular 
phase, can sometimes last for many years. 
  
1.1.3.1 Environmental factors 
 
Stress is considered as an important risk factor in the pathogenesis of RA. 
Stress responses are in close relationship with the hypothalamic-pituitary-adrenal 
axis, the sympathetic nervous system and the immune system (Stojanovich and 
Marisavljevich, 2008).  Immune system dysregulation has been shown in victims of 
post-traumatic stress disorder (PTSD). These patients were characterised by hyper-
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active immune responses, increased number of circulating T-cell lymphocytes and 
lower levels of cortisol (Boscarino, 2004). Interestingly, up to 80% of patients report 
uncommon emotional stress before the disease onset. It is also believed, by 
physicians and patients that stress not only contributes to the development of RA, but 
also in the severity of the disease. Unfortunately, the disease itself causes significant 
stress in the patients, creating a vicious cycle (Stojanovich and Marisavljevich, 2008). 
A very intensively studied environmental factor in relation to the pathogenesis 
of RA is cigarette smoking. Heavy smoking has been linked with an increased risk of 
RA (Hutchinson et al., 2001). Other studies have associated smoking with 
Rheumatoid Factor (RF) positive RA in both men and women, but not with RF 
negative RA (Stolt et al., 2003). It also appears that the association between smoking 
and RA is stronger with the duration of smoking habit, as even moderate smokers for 
more than 20 years have an increased risk in developing RA (Karlson et al., 1999). 
Smoking is also linked with increased activity and severity of the disease 
(Papadopoulos et al., 2005). It is not clear yet how smoking contributes to the 
initiation of RA, but it is believed that this is due to the citrullination of proteins 
(Klareskog et al., 2007). Interestingly, 60% of RA patients are positive for antibodies 
to citrullinated antigens (anti-CPA) (Klareskog et al., 2007). Recent studies have also 
shown that smoking strongly influences the development of RA in individuals that 
carry copies of certain disease-associated genes, such as the specific human 
leucocyte antigen (HLA)-DRB1 and protein tyrosine phosphatase N22 (PTPN22) 
(Costenbader et al., 2008; Padyukov et al., 2004).   
Infections are also considered as another environmental factor that triggers the 
development of RA, because of the presumed link between infection and 
autoimmunity. A wide range of studies have studied the effect of different pathogen 
infections by trying to show a link between the incidence of certain infections and the 
development of RA or the direct detection of pathogens in the synovium or blood 
stream of RA patients. Evidences exist for bacterial pathogens, such as 
mycobacteria, mycoplasma and Proteus mirabilis and viruses, such as parvovirus, 
Epstein-Barr virus (EBV), caprine arthritis - encephalitis virus (CAE) and human 
retrovirus-5 (HRV-5). However, many of these studies show contradictory results, 
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lack proper controls, and the fact that infections are detected in RA patients, it does 
not necessarily mean that they are the causative factor, as RA patients are prone to 
infections or pathogens are getting trapped into the joints or migrate into the joints, 
because they are parasitic to cells that enter the joints, such as EBV in B-cells (Carty 
et al., 2004). 
 
1.1.3.2 Genetic factors 
 
Several genetic loci have also been linked with susceptibility and severity of 
RA. These include the HLA-DR genes of the major histocompatibility complex (MHC), 
responsible for antigen presentation to T-cells, PTPN22 gene, which is an important 
negative regulator of T-cells, peptidyl arginine deiminase type IV (PADI4), which is an 
enzyme involved in the post-translational deimination of protein-bound arginine to 
citrulline, cytotoxic T-lymphocyte antigen 4 (CTLA4), which is a T-cell surface 
molecule that negatively modulates T- cell lymphocyte activation, Fc receptors for IgG 
(FcγRs), macrophage migration inhibitory factor (MIF), which is a ubiquitously 
expressed protein that has pro-inflammatory, hormonal and enzymatic activities, 
complement component 5-TNF receptor-associated factor 1 (C5-TRAF1); and various 
cytokine and cytokine-receptor genes have been reported such as those encoding 
tumour-necrosis factor (TNF), interleukin-1 (IL-1), IL-1α, IL-1β, IL-4, IL-10, IL-18 and 
IL-23 (van der Helm-van Mil and Huizinga, 2008; van der Helm-van Mil et al., 2005; 
Worthington, 2005).  
 
1.1.3.3 Biological basis of RA 
 
The majority of patients are identified with autoantibodies specific for IgG 
(known as rheumatoid factor RF) or specific for cyclic citrullinated peptides in their 
sera. This fact led the scientific community to hypothesize that RA is the result of 
production of RF, which consequently leads to the formation of RF-immune 
complexes, recruitment and activation of immune cells in the joints, which in turn 
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contribute to the inflammation and destruction of the joints (Zvaifler, 1973). This 
hypothesis however is not universal, as there are patients with RA that do not 
produce RF and healthy individuals that produce RF. However, the importance of 
autoantibodies as a catalyst for the development of RA is strongly supported by 
animal studies (Ditzel, 2004; Matsumoto et al., 2002).  
 T-cells appear to have a central role for the initiation and orchestration of the 
disease. Studies in animal models, such as the collagen-induced arthritis (CIA) model 
and SKG mouse model for arthritis have shown that the development of the disease 
is T-cell dependent (Firestein, 2004). However, T-cell independence has been 
demonstrated in other animal models of arthritis, such as the Balb/c mouse which is 
deficient in the IL-1 receptor antagonist (IL-1Ra -/-) (Horai et al., 2000). Activated T-
cells can exert their effects either directly through cell-cell interactions or indirectly 
through cytokine secretion, which affect the surrounding tissues in the joint. These 
immune cells play a central role in immune reactions, hence T-cells represent crucial 
mediators for the initiation, establishment and perpetuation of the disease (Firestein 
and Zvaifler, 2002).  
Cytokines that are produced from immune and inflammatory cells in the joint 
are also implicated in the pathogenesis of RA. It is considered that an imbalance 
between pro- and anti- inflammatory cytokines is necessary for the onset of the 
disease. Once the disease has established, the joint becomes hyperplastic and 
extensive infiltration of macrophages, mast cells, CD4+ T-cells, CD8+ T-cells, natural 
killer (NK) cells, B-cells and plasma cells occurs. The way immune cells, synovial 
cells and osteoclasts in the arthritic joint respond is orchestrated by complicated 
cytokine pathways. The complex cytokine networks in RA are summarised in an 
elegant review by McInnes and Schett, 2007. Briefly. some of the well characterized 
cytokines that contribute to the development of RA include TNFα, IL-1, interferon-γ 
(IFN-γ) and IL-17. Once the tight balance between pro- and anti- inflammatory 
cytokines is broken, cytokine networks favour the attraction, maturation and 
proliferation of immune cells, which in turn contribute to the sustained secretion of 
cytokines by surrounding tissues in the joint. The sustained secretion of cytokines 
results in the perpetuation of inflammation and bone destruction. It is worth 
 Page | 30  
 
 Chapter I 
mentioning that cytokines activate synovial fibroblasts in RA to secrete matrix 
metalloproteases (MMPs) and other proteolytic enzymes that contribute to bone 
degradation. MMP transactivation may also become permanently imprinted to 
synovial cells activated phenotype. This was shown by co-transplantation of synovial 
fibroblasts from RA patients with normal human cartilage in severe combined 
immunodeficient mice. In these studies, RA synovial fibroblast were attaching and 
invading normal human cartilage even in the absence of inflammatory cells. This 
finding can partially explain the increased aggressiveness of this condition as the 
disease progresses (Lefevre et al., 2009; Muller-Ladner et al., 1996; Ospelt et al., 
2004).  
The complexity of RA is high and the mechanisms involved in this disease are 
still poorly understood. Firestein, 2005 came up with a schematic presentation that 
can help us understand the overall picture in RA (Figure 1.3). In this model, 
environmental and genetic factors can trigger innate immunity, which can result in 
specific selection of immune cells and autoimmune response. In turn, activated 
immune cells migrate to the joints, where they exert their functions, induce and 
perpetuate inflammation. Chronic inflammation causes joint damage, presentation of 
new antigens to immune cells, selection and recruitment of more immune cells, and 
this vicious cycle finally leads to the establishment of a chronic inflammatory disease 
(Chernajovsky et al., 2002; Firestein, 2005). 
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Figure 1.3: Schematic representation of the biological basis of RA. Activation of 
autoreactive T-cells is an important event in the immunologic cascade. DC indicates dendritic 
cell; FLS, fibroblast-like synoviocyte; MΦ, macrophage; nT, naive T-cell; aT, activated T-cell 
(Taken from Firestein, 2005). 
 
             
 
1.1.4 Role of the nuclear factor-κB (NF-κΒ) in RA and inflammation 
in general 
 
 
 NF-κB is a transcription factor that has been shown to be involved in several 
signalling pathways, including inflammation, cell survival, proliferation and 
differentiation (Simmonds and Foxwell, 2008). The NF-κΒ family consists of five 
members, which include p105 (constitutively processed to p50), p100 (processed to 
p52 under tightly regulated conditions), p65 (also known as RelA), RelB and c-Rel. 
These subunits form homo- and hetero-dimers in order to produce the different forms 
of NF-κΒ transcription factor, with heterodimer p50/p65 as the commonest form 
(Hayden and Ghosh, 2004). All members of NF-κΒ contain a Rel-homology domain 
(RHD) that binds to the NF-κΒ consensus sequence (5’-GGGRNYYYCC-3’). However 
only three members (p65, RelB and c-Rel) contain transactivation domains (TADs) 
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that are able to recruit members of the transcriptional machinery and initiate the 
transcription of target genes (Chen and Greene, 2004). 
There are two main pathways that activate NF-κΒ, the canonical and the non-
canonical pathway (Figure 1.4). In the canonical pathway, inactivated NF-κΒ remains 
in the cytoplasm. Members of the IκB family (IκBα, IκBβ and IκBγ) bind to NF-κΒ and 
inhibit its nuclear translocation by hiding the nuclear localization sequence (NLS) of 
NF-κΒ (Ghosh et al., 1998). The phosphorylation of IκΒ inhibitors, by the IKK kinase 
complex, leads to their degradation by the proteasome and the subsequent release of 
NF-κΒ. Activated NF-κΒ translocates to the nucleus, where it binds NF-κΒ DNA sites 
and activates transcription of target genes (Table 1.1). 
The IKK kinase complex in the canonical pathway, which is responsible for the 
phopshorylation of IκΒ inhibitors, consists of three different subunits: IKKα (also 
known as IKK1), IKKβ (also known as IKK2) and IKKγ (also known as NEMO). IKKα 
and IKKβ have both catalytic activity, where it seems that IKKβ mainly 
phosphorylates IκΒα (May and Ghosh, 1998).  IKKγ has no catalytic activity, but is 
essential for the formation and activation of IKK complex (Rothwarf et al., 1998). The 
activation of IKK complex can occur by many different stimuli, such as stress (UV 
light, reactive oxygen intermediates), bacterial and viral infection (bacterial 
lipopolysaccharide (LPS)/ double stranded (ds) RNA) and cytokines (IL-1, TNF-α) 
(Ghosh et al., 1998) (Figure 1.4). 
The more recently described non canonical pathway is activated by 
Lymphotoxin (LT) βR, B-cell activating factor receptor (BAFFR), receptor activator of 
NF-κΒ (RANK) and CD40 (Cao et al., 2001; Hayden and Ghosh, 2004; Novack et al., 
2003). In this signaling pathway the unprocessed p100/RelB dimer can be found in 
the cytoplasm without the need of IκB inhibitors for its cytoplasmic retention. 
Activation of the non canonical NF-κΒ signaling pathway results in p100 
phosphorylation by an IKKα complex. The activation of the IKKα complex occurs by 
another kinase, the NF-κΒ inducing kinase (NIK). Phosphorylation of p100 induces its 
partial degradation by proteasome, which gives rise to p52/RelB dimers. p52/RelB 
dimers in turn are able to translocate to the nucleus and activate gene transcription 
(Xiao et al., 2006).    
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Table 1.1: Genes regulated by the NF-κΒ transcription factor 
Proinflammatory cytokines 
 
 Tumor necrosis factor α (TNFα) 
 Interleukin-1β (IL-1β) 
 Interleukin-2 (IL-2) 
 Interleucin-3 (IL-3) 
 Interleukin-6 (IL-6) 
 Interleukin-12 (IL-12) 
 Interferon β (IFNβ) 
 Lymphotoxin α (LT-α) 
 Granulocyte–macrophage colony-stimulating factor (GM-CSF)   
 Macrophage colony-stimulating factor (M-CSF) 
 Granulocyte colony-stimulating factor (G-CSF) 
 
Chemokines 
 
 Interleukin-8 (IL-8) 
 Macrophage inflammatory protein 1α 
 Macrophage chemotactic protein 1 
 Gro-α, -β, and -γ 
 Eotaxin 
 
Inflammatory enzymes 
 
 Inducible nitric oxide synthase 
 Inducible cyclooxygenase-2 
 5-Lipoxygenase 
 Cytosolic phospholipase A2 
 
Adhesion molecules 
 
 Intercellular adhesion molecule 1 (ICAM1) 
 Vascular-cell adhesion molecule 1 (VCAM-1) 
 Mucosal addressin cell adhesion molecule 1 (MAdCAM-1) 
 E-selectin 
 
Receptors 
 
 Interleukin-2 receptor (α  chain) (IL-2α) 
 T cell receptor (β chain) (TCRβ) 
 
Stress proteins 
 
 Serum amyloid A protein (SAA) 
 Complement factors B, C3 and C4 
 α1-acid glycoprotein 
 
Immunoregulatory molecules 
 
 Immunoglobulin κ (Igκ) 
 MHC class I and II 
 β2-microglobulin 
 Invariant chain i (Ii) 
 Transporter associated with antigen processing 1 (TAP1) 
Modified from Barnes et al. (1997) and May and Ghosh (1998). 
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Figure 1.4: The NF-κΒ signalling pathways. A) The canonical pathway. Receptor activation 
by several pro-inflammatory stimuli leads to activation of the IKK complex. The activated IKK 
complex phosphorylates IkB leading to its degradation by the proteasome. NF-κB then 
translocates to the nucleus to activate target genes. Β) The non-canonical pathway. Receptor 
activation leads to activation of NIK that phosphorylates and activates the IKKα complex. 
Activated IKKα phosphorylates p100, leading to its partial degradation and production of 
p52/RelB heterodimer, which translocates to the nucleus to activate target genes. 
 
      
 
 Both canonical and non canonical NF-κΒ signalling pathways are involved in 
the development of RA in multiple ways. NF-κΒ is essential for the survival, 
development and activation of immune cells, including T-cells and B-cells at their 
sites of development in thymus, bone morrow, spleen and in the periphery (Brown et 
al., 2008). The inflamed joints in RA are characterised by increased infiltration of 
immune cells, such as T-cells, B-cells, macrophages and neutrophils, highly 
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proliferating inflamed synovial fibroblasts and the formation of tertiary lymphoid 
organs (TLOs). RA synovial fluid is also rich in pro-inflammatory cytokines, 
chemokines, MMPs and metabolic enzymes and the expression of all these factors is 
under transcriptional control of NF-κΒ (Table 1.1). It is therefore generally accepted 
that NF-κΒ has a central role for the initiation, perpetuation and amplification of 
disease severity (Barnes and Karin, 1997; Simmonds and Foxwell, 2008). The 
relevance of NF-κΒ activation in the pathogenesis of RA has been shown in various 
studies. More particularly, NIK-deficient mice were largely resistant to RA, exhibiting 
less periarticular osteoclastogenesis and less bone erosion (Aya et al., 2005). p50 
knock-out (KO) mice have been used for the CIA model (where both T-cells and B-
cells are involved in the inflammatory response) and the acute inflammation model 
induced by Bovine Serum Albumin (BSA) and IL-1 (where only T-cells are involved). 
In both models, p50 KO mice have shown complete loss of humoral response and T-
cell proliferation. c-Rel KO mice, however, did not show any resistance to the 
development of the disease (Campbell et al., 2000). It is also worth mentioning that 
p65 KO mice are not viable, which demonstrates the importance of this monomer to 
the developmental process (Gerondakis et al., 2006). In the investigation of the 
relevance of NF-κΒ to the development of RA, dominant negative (dn) variants of the 
canonical pathway signalling components have been expressed in synovial fibroblast 
and macrophages from RA patients. In these studies, dnIKKβ inhibited the production 
of cytokines from both TNFα and IL-1β stimulated macrophages and synovial 
fibroblasts and dnΙκΒα inhibited the cytokine production from LPS activated human 
macrophages (Andreakos et al., 2003; Bondeson et al., 1999). The activation of NF-
κΒ signalling pathway can also be due to cellular stimuli, such as cytokine activated 
T-cells. In this case, T-cell contact with synovial fibroblast induces cytokine 
production in an IκΒα-dependent manner. T-cell and synovial fibroblast co-culture has 
demonstrated increased production of TNFα, whereas removal of T-cells caused 
rapid loss of synovial cell TNFα production (Beech et al., 2006; Brennan et al., 2002). 
NF-κΒ also facilitates synovial hyperplasia in RA by promoting proliferation and 
inhibiting apoptosis of synovial fibroblasts (Makarov, 2001). Activated NF-κΒ has 
been shown in cultured synovial fibroblasts (Fujisawa et al., 1996), in human arthritic 
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joints (Carlsen et al., 2002) and in the joints of animal models of arthritis (Campbell et 
al., 2000; Tsao et al., 1997). Furthermore, nuclear extracts and 
immunohistochemistry studies in tissues from the arthritic joints have demonstrated 
the presence of NF-κΒ in the nucleus, suggesting that NF-κΒ signalling pathway is 
active in RA (Benito et al., 2004; Danning et al., 2000).  
 
 
1.1.5 Therapeutic strategies in RA      
 
 
1.1.5.1 Anti-rheumatic drugs 
 
 Therapeutic strategies in RA target pain relief, inflammation control and joint 
damage prevention. This is achieved with anti-inflammatory agents, which fall in two 
categories; the nonsteroidal anti-inflammatory drugs (NSAIDs) and the disease-
modifying antirheumatic drugs (DMARDs), which are strong immunosuppressive 
agents (Doan and Massarotti, 2005). NSAIDs block inflammation by inhibiting the 
release of prostaglandin, are not strong anti-inflammatory agents and therefore are 
usually used for the pain and swelling relief. The production of prostaglandin is 
catalyzed by cyclooxygenase enzyme (COX), which has two isoforms, COX-1 and 
COX-2. NSAIDS are involved in the inhibition of both isoforms. For the inhibition of 
COX enzymes DMARDs have been developed, which specifically target COX-2, such 
as celecoxib. However, COX inhibition is associated with gastrointestinal side effects 
and cardiovascular toxicity (Doan and Massarotti, 2005). The most effective 
immunosuppressive agents to date are glucocorticoids. Glucocorticoids regulate the 
production of cytokines and inflammatory mediators. However, long term use of 
glucocorticoids causes osteoporosis, hypertension, cardiovascular diseases, 
cataracts, myopathy, weight gain, infections, sleep disturbances, mood changes and 
memory deficits. Therefore, use of glucocorticoids is either short-term or low-dose in 
combination with other drugs (Bijlsma et al., 2003; Kirwan, 1995). Antimalarials, such 
as hydroxychloroquine sulphate and chloroquine phosphate, are also used for the 
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management of RA. Antimalarial drugs demonstrate anti-inflammatory and disease 
regulating properties, but the exact mechanism of action is not known. Antimalarials 
exert their action after 2 months of administration and are considered as mild 
DMARDs, therefore are used in combination with other DMARDs and for long 
periods. Common side effects of antimalarials include retinal toxicity and 
gastrointestinal (Clegg et al., 1997; Sanders, 2000). The most widely used DMARD 
has become methotrexate due to its efficacy and long-term tolerability. Methotrexate 
is a DNA synthesis inhibitor, which results in induction of apoptosis of immune cells, 
depletion of cytokine production and inhibition of COX. However, 3% to 5% of 
patients treated with methotrexate will develop lung disease and fibrosis, which is the 
main side-effect (Cutolo et al., 2001; O'Dell, 1997). Another DNA synthesis inhibitor 
that is used for the management of RA is leflunomide that works similarly to 
methotrexate (Manna et al., 2000). Leflunomide shows increased hepatotoxic effects 
and studies have shown that combination of leflunomide with methotrexate is more 
efficient (Kremer et al., 2002).  
 A new generation of drugs for RA treatment are known as biologic agents or 
biologics and refer to recombinant proteins used to alter signalling pathways that are 
involved in the development and progression of RA. Biologic agents include TNFα 
inhibitors, such as infliximab, adalimumab, certolizumab pegol and golimumab which 
are monoclonal antibodies, and etanercept, which is a TNFα receptor-Ig fusion 
protein. These inhibitors bind to the soluble and membrane bound TNFα and block 
the downstream activation of TNFα signalling (Blumenauer et al., 2003; Scallon et al., 
1995; Weinblatt et al., 2003). Anakinra, which is an IL-1 receptor antagonist, appears 
to be less effective compared to anti-TNF treatment. Rituximab, which is a B-cell-
depleting agent, demonstrates similar clinical results with anti-TNF agents. 
Abatacept, which is a dimerised form of cytotoxic T-lymphocyte antigen 4 (CTLA4), 
the natural inhibitor of T-cell activation, demonstrates comparable results to anti-TNF 
treatment, however abatacept has a slower onset of action. Tocilizumab, which is an 
anti-IL-6 receptor blocker, demonstrates similar clinical results to anti-TNF agents and 
showed efficacy in patients who previously failed to respond to DMARDs or anti-TNF 
agents (van Vollenhoven, 2009). Generally, biologics demonstrate a rapid onset of 
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their effects and are more efficient when combined with other DMARDs, such as 
methotrexate. Side effects of biologic agents administration include higher risk of 
infections, increased risk of developing multiple sclerosis, hypersensitivity, and 
immune responses toward the inhibitors lead to the depletion of their effectiveness 
(Doan and Massarotti, 2005; van Vollenhoven, 2009). However, 25-30% of the 
patients do not respond to the current treatments and 30% of them will discontinue 
the treatment due to side effects and loss of effectiveness (Doan and Massarotti, 
2005). Therefore, there is still a need for the development of new therapies that will 
increase efficiency and decrease side effects and costs.  
 
1.1.5.2 Gene therapy for RA 
 
A promising area for the discovery of new therapies for RA is gene therapy. In 
this approach, genes instead of proteins or synthetic drugs are administered to the 
patient. Once the genes are delivered to the patient, then the body of the patient can 
act as a factory for the production of therapeutic agent. There are major advantages 
of gene therapy compared to protein therapy, which are summarized on Table 1.2. 
Gene therapy is a complicated procedure and several issues have to be considered 
in order to be therapeutically successful. Major considerations include the delivery 
method of the gene, the control of the gene expression, the therapeutic gene and 
safety issues (Chernajovsky et al., 2004).  
In gene therapy there are two main types of vectors for the gene delivery; the 
non-viral (plasmids) and the viral vectors. Plasmids are circular fragments of DNA 
that are isolated from bacteria. Plasmid vectors are easily produced with low costs, 
can carry big therapeutic gene inserts and be transferred to cells by a simple 
injection. Plasmids are generally considered safe and demonstrate low immunogenic 
response from the host (Ghivizzani and Evans, 2000). The transfection efficiency of 
plasmids is generally low, however it can by increased by up to 1000-fold when 
electroporation follows the DNA injection (Bessis and Boissier, 2006). Studies have 
demonstrated that transfection of skeletal muscles with plasmids that carry 
therapeutic genes, such as IL-10, TNFα soluble receptors and IL-1α receptor were 
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beneficial for the inhibition of inflammation in animal models in RA (Bloquel et al., 
2004; Jeong et al., 2004; Saidenberg-Kermanach et al., 2003). 
 
 
Table 1.2: Gene therapy advantages in comparison to protein therapy. 
Feature  Protein therapy Gene therapy 
Administration 
Effects 
Cost 
 
Regulated delivery 
Long-term delivery 
 
Safety 
 
 
Multiple doses  
Systemic 
High 
 
Yes 
Possible, but disease rebounds 
when stopped 
Possible generalised 
immunosuppression; needs 
protein engineering to achieve 
targeting 
Single dose  
Local or systemic 
Low, plasmid as a vector is inexpensive. 
Use of other vectors is expensive. 
Yes 
Yes, when delivered to long-lived cells in 
non-immunogenic vectors 
Improved safety using local delivery 
 
Modified from Chernajovsky et al., 2004. 
 
 
The viral vectors are derived from retroviruses, lentiviruses, adenoviruses and 
adeno-associated viruses (AAV). In RA, the viral vectors that have been used for 
gene therapy are replication deficient. Retroviral and lentiviral vectors have the ability 
to integrate into the host genome. The difference between retroviral and lentiviral 
vectors is that the first can only transduce dividing cells, whereas the second can also 
transduce quiescent cells. The major disadvantage of those vectors is that they can 
cause insertional mutations (Chernajovsky et al., 2004). Previous studies have shown 
that synovial fibroblast transduction and transgene expression of the effector genes 
could ameliorate the symptoms of the arthritis in animal models. The transduction of 
the cells can be done either by direct injection of the viruses into the joint or in vitro 
transduction of cultured cells, followed by their transplantation into the joints. 
Interestingly, ex vivo manipulation of synovial cells, followed by their transplantation 
into the joints proved to be more efficient compared to direct injection of the viruses 
(Ghivizzani et al., 1997; Lin et al., 2004; Makarov et al., 1995). 
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Adenoviral vectors can transduce both dividing and non-dividing cells and do 
not integrate into the host genome. Adenoviral vectors have been used in animal 
models of RA, but the main disadvantage is that they induce immune responses and 
therefore the duration of this gene therapy approach is transient (Evans et al., 2001).  
Lastly, AAV vectors can transduce both dividing and non-dividing cells, do not 
integrate into the host genome and demonstrate less significant immunogenicity 
when compared to adenoviral vectors. AAV vectors have been widely used in 
humans (Arai et al., 2000; Zhang et al., 2000), and animal models of RA (Apparailly 
et al., 2002; Cottard et al., 2000)  for the management of RA symptoms with positive 
results. 
Gene therapy for the treatment of RA can be performed in two different ways. 
One is in vivo gene therapy, when the vector is injected directly, either systemically or 
intraarticularlly. It is easy to perform, as there is no need for cells to be collected from 
the patient and does not include difficult and complex procedures. A major 
disadvantage of this approach however is that high titers of the vector are needed, 
which are difficult to produce especially in the case of retroviral and AAV vectors. The 
other gene therapy approach is ex vivo gene therapy, which involves the collection of 
cells from the patient, their in vitro culture and transduction, followed by their 
transplantation back to the patient. It is a more complex and difficult procedure, but is 
a more efficient and controlled method. In RA models, synovial fibroblast, myoblasts, 
skin fibroblasts, T-cells, DC and splenocytes have been used for ex vivo gene 
therapy (Bessis and Boissier, 2006; Chernajovsky et al., 2004). 
One of the most important issues that need to be resolved in any gene therapy 
approach for RA is the type of the therapeutic gene that will be used. In an ideal gene 
therapy approach, the gene product would specifically target the triggering 
autoantigen or the receptor specific for the immunogenic epitope. But in the case of 
RA the triggering autoantigen is not known. So far, several gene therapy approaches 
have tried to inhibit inflammation, increase tolerance, induce apoptosis of immune 
and inflammatory cells and activate tissue repair in the joints (Bessis and Boissier, 
2006; Chernajovsky et al., 2004). More specifically, for the inhibition of inflammation 
TNFα and IL-1 have been targeted using genes that encode soluble receptors that 
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bind to these cytokines (Bessis et al., 2000; Chernajovsky, 1999; Chernajovsky et al., 
1995). Vectors encoding anti-inflammatory cytokines, such as IL-4, IL-10 and IL-13 
have also been used (Bessis et al., 1998). For the tolerance induction, DC expressing 
immunosuppressive cytokines, such as IL-10, have been used (Whalen et al., 2001). 
In another study, the expression of a CTLA-4-immunoglobulin fusion protein that 
successfully blocked the interaction between CD80/CD86 and CD28, inhibited T-cell 
activation and consequently the development of RA in animal models (Quattrocchi et 
al., 2000). As described above synovial fibroblasts are characterised by high 
proliferation, which has detrimental effects to the joint. In previous studies, synovial 
cell apoptosis has been induced either by expression of the Fas ligand or IκΒα after 
injection of the genes to the cells (Okamoto et al., 1998; Zhang et al., 2000). 
Additionally, transfection of synoviocytes with the thymidine kinase gene of herpes 
virus (HSV-TK) followed by administration of ganciclovir induced cell death (Sant et 
al., 1998).  Furthermore, it would be beneficiary for the management of RA patients, 
future gene therapy studies to target the tissue damage that takes place in the 
arthritic joints and induce tissue repair. This can be achieved by inhibiting the MMPs, 
which are enzymes that play a central role in the tissue damage, with the expression 
of MMPs inhibitors. Further down the cascade, expression of growth factors, such as 
insulin growth factor (IGF)-1, fibroblast growth factor (FGF) or transforming growth 
factor (TGF)-β can stimulate tissue repair (Bessis and Boissier, 2006). 
The control and safety of gene therapy can be increased by expressing the 
therapeutic gene under the transcriptional control of an inducible promoter. The 
tetracycline ‘on’ system (Gossen et al., 1995) is especially suited to gene therapy 
applications because the inducer molecule doxycycline (Dox) is pharmacologically 
defined for in vivo use. Gene expression is induced when a chimeric transactivator 
(rtTA), composed of tetR and VP16 binds in the presence of Dox to a tetracycline 
responsive promoter (Ptet) consisting of seven repeats of the tetracycline operon 
(tetO) and a minimal cytomegalovirus (mCMV) promoter. When these components 
were combined in the ‘self-contained’ vector, pGTRTL regulated expression of 
luciferase in the region of 50 fold was observed in a DBA/1 derived embryonic 
fibroblast cell line (Gould et al., 2000). Improved components have recently been 
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generated; a repressor which reduces basal expression from the Ptet promoter in the 
absence of Dox (Forster et al., 1999), and an improved, more stable transactivator 
which activates the Ptet at a 10 times lower concentration of Dox (Urlinger et al., 
2000). Previous work in our laboratories has generated an expression cassette 
termed MIK that utilises the EMCV IRES to encode both these improved elements 
from an SV40 promoter in the vector pSVZeoMIK (Yousaf et al., 2005). When this 
vector is co-transfected into 293T cells with pGTL (a Ptet luciferase reporter vector) 
efficient luciferase regulation in excess of a 1000 fold is observed with Dox induction.  
Increased levels of safety and efficiency in gene therapy can also be achieved 
by the employment of latency-associated peptide (LAP) technology that has been 
developed in our department. More specifically, Adams et al., (2003) exploited the 
natural properties of TGF-β latent cytokine in order to generate an IFN-β latent 
cytokine. The latent IFN-β was covalently bound to LAP (LAP-IFN-β) through an 
MMP cleavage site (Figure 1.5).  
 
 
 
Figure 1.5: Schematic representation of the latent cytokine fusion-protein structure. 
The protective shell surrounding the cytokine is derived from the latency-associated peptide 
(LAP) of TGF (transforming growth factor)-β and serves to prevent cytokine interaction with 
its receptors, increasing the half-life of the cytokine in vivo. The cleavable matrix 
metalloproteinase (MMP) site can be tailored to be sensitive to the MMPs that are abundant 
in certain pathological conditions. Cleavage by MMP releases the cytokine or other 
therapeutic agent so that it acts locally, at the site of disease. 
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The latent form of the cytokine increases its half life and therapeutic index. 
Side effects can also be avoided, as the cytokine will be released only at the sites of 
the disease where the levels of MMPs are high and the latent cytokine will not exert 
any effect in normal tissues (Adams et al., 2003). Another advantage of this 
technology is that it can be extended to other therapeutic agents apart from 
cytokines. Thus, small disease modulating agents can also be genetically linked to 
LAP peptide.  
In conclusion, gene therapy is a promising area for the development of new 
therapeutic strategies in RA, as it can target different stages of the disease, can be 
regulated, localised and cost effective. Future studies that will further elucidate the 
molecular basis of the disease will help us increase the efficiency of gene delivery 
and safety of this approach. It may also be useful for gene therapy to be combined 
with conventional treatment methods in order to achieve maximum effectiveness.  
 
 
 
1.2 Protein Transduction Domain (PTD) technology 
 
 
 Over the past 15 years a new technology has emerged for the delivery of 
biological material into cells. This technology, known as Protein Transduction Domain 
(PTD) technology, emerged after the discovery that some proteins have the ability to 
penetrate the cell membranes in an unconventional way. Proteins that were found 
initially to have this property were the TAT protein, from the human immunodeficiency 
virus (HIV) 1 (Frankel and Pabo, 1988), the Drosophila Antennapedia (Antp) protein 
(Derossi et al., 1994) and the herpes simplex virus (HSV) type 1 protein VP22 (Elliott 
and O’Hare, 1998). Further analysis of these proteins led to the identification of the 
domains that are responsible for the cell penetration, which subsequently resulted in 
the development of short peptides that originate from the above mentioned proteins 
and are known as PTDs. A common characteristic of these PTDs is that they contain 
positively charged residues and form an α-helix (Brooks et al., 2005). A number of 
small cationic peptides, such as transportan (Pooga et al., 1998), KALA (Wyman et 
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al., 1997), R7 (Moulton et al., 2004), CTP (Kim et al., 2006), PTD-5 (Mai et al., 2001), 
TAT3 (also known as PTD-4) (Ho et al., 2001), YM3 (Mukai et al., 2006), M918 (El-
Andaloussi et al., 2007), even hydrophobic peptides (MTS) (Hawiger, 1999) have 
been found to be able to penetrate cell membranes, which gave birth to a rapidly 
evolving technology for delivering biological agents into cells (Table 1.3).        
 
 
 
Table 1.3: Commonly used PTDs and their origin. 
PTD Sequence Origin 
TAT 
Antp 
VP22 
R7 
PTD5 
TAT3 
Transportan 
KALA 
CTP 
YM3 
M918 
MTS 
YGRKKRRQRRR 
RQIKIWFQNRRMKWKK 
NAKTRRHERRRKLAIER 
RRRRRRR 
RRQRRTSKLMKR 
YARAAARQARA 
GWTLNSAGYLLGKINLKALAALAKKIL 
WEAKLAKALAKALAKHLAKALAKALKACEA 
GGRRARRRRRRR 
THRLPRRRRRR 
MVTVLFRRLRIRRACGPPRVRV 
AAVLLPVLLAAP 
HIV-1 TAT  
Drosophila Antennapedia  
HSV 
Synthetic 
Synthetic 
Synthetic 
Chimeric, galanin fragment plus mastoparan 
Synthetic 
Synthetic 
Synthetic 
Synthetic 
FGF 
 
 
 
Initially, Fawell et al., (1994) demonstrated that PTD fusion proteins can 
successfully transduce cells. When TAT PTD was fused chemically to β-
galactosidase (β-gal) or to horseradish peroxidase (HPR) and applied to various 
cultured cell lines and primary cells it transduced almost 100% of the cells. Various 
studies have also shown successful transduction of chemically or genetically fused 
PTDs with different types of cargo. The types of cargos that have been fused to PTDs 
vary from small peptides to big proteins, to plasmids, DNA, RNA, liposomes and lipids 
(Brooks et al., 2005). Fusion of the cargos either to the amino- or carboxy terminal 
side of the PTD has shown no difference to their ability to penetrate cell membranes. 
Although there is an increasing interest for this technology, it is very difficult to 
compare different PTDs and their ability to transduce cells, since different studies 
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have used different cargos, different cell lines, different protocols and different 
approaches for the conjugation of the PTD to the cargos (Brooks et al., 2005). The 
most interesting part of this technology is that the cargos can exert their biological 
activities once the PTD-fusion proteins enter the cells. The fusion of TAT to a non-
degradable mutant of IκΒα (known as srIκΒα) was able to inhibit NF-κΒ activity in 
cultured cells after their activation with cytokines (Kabouridis et al., 2002). Inhibition of 
the NF-κB signalling pathway has also been shown when PTD5 was fused to Nemo 
binding domain (NBD), which is an inhibitor that disrupts the formation of the IKK 
complex (Rehman et al., 2003). Additionally, a study has demonstrated the ability of 
PTD-CRE recombinase fusion proteins to induce DNA recombination in treated 
cultured cells (Shaw et al., 2008).  
 Several studies have shown the successful delivery of PTD-fusion proteins into 
cells in vivo and tried to exploit this technology for its therapeutic potential. 
Interestingly, β-gal activity was shown in a variety of tissues, including liver, spleen, 
heart, skeletal muscle, lung and brain after intravenous administration of purified 
TAT-β-gal into mice (Schwarze et al., 1999). Previous work in our laboratory has also 
revealed that administration of purified TAT-srIκΒα intravenously was able to inhibit 
inflammation and diminished infiltration of inflammatory cells in a rat pleurisy model 
(Blackwell et al., 2004). In another elegant study, when nuclear localisation sequence  
(NLS)-CRE-MTS fusion protein was administered to loxP transgenic mice, DNA 
recombination could be detected in liver, spleen, heart, brain, lung and kidneys (Jo et 
al., 2001).          
 The mechanism by which PTDs can penetrate the cell membranes is not well 
understood and there is a lot of controversy between different research groups. 
Initially, the finding that PTDs could transduce cells at 4o C, a temperature at which 
active transport is inhibited, suggested that PTDs can penetrate cell membranes in an 
energy independent way (Thoren et al., 2003). Additionally, the successful 
transduction of magnetic nanoparticles that were covered with TAT PTD and their 
diameter was 15-fold larger than the thickness of the membrane, makes impossible 
the internalisation of those nanoparticles by an energy dependent endocytosis 
mechanism, since the nanoparticles were too big for the membrane to reorganise 
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around them in order to form vesicles (Lewin et al., 2000). However, recent studies 
suggest that penetration of the membrane in most cases is an energy dependent 
process, where PTD-fusion proteins translocate to the cytoplasm within vesicle-like 
structures (Duchardt et al., 2007). It is possible that positively charged PTDs initially 
interact with the negatively charged structures on the surface of the membranes. The 
importance of the negatively charged cell-surface heparin sulphate (HS) 
proteoglycans for the internalization of PTD-fusion proteins has been shown by a 
number of studies where use of soluble heparin (Console et al., 2003; Ferrari et al., 
2003), heparin analogues, such as pentosan polysulfate (PPS) (Rusnati et al., 2001) 
and soluble polyanions, such as suramin, suramin derivatives (Rusnati et al., 1998) 
were able to competitively inhibit cell transduction. Interestingly, the inhibition of cell 
transduction was greater when cells unable to synthesize HS where used, suggesting 
that HS play an important role in the internalisation of PTDs (Tyagi et al., 2001). In a 
similar study, PTD transduction efficiency was also drastically reduced after depletion 
of cell-surface proteins with proteases (Gump et al., 2010). However, there is no 
study that has achieved complete inhibition of PTD cell transduction, which suggests 
that there are many different ways for cell internalization of these molecules. It seems 
that PTDs are opportunistic peptides that can stick unspecifically to several 
extracellular structures, such as HS, clathrin, lipid rafts, receptors, etc. and initiate 
translocation via a number of different pathways, such as phagocytosis, pinocytosis 
and receptor-mediated endocytosis for their internalisation into the cells. 
Subsequently, the vesicles are degraded through vesicle acidification and PTD-fusion 
proteins are released into the cytoplasm (Brooks et al., 2005; Duchardt et al., 2007; 
Fischer et al., 2005).  
 In general, PTDs are small peptides that have the ability to penetrate cell 
membranes. PTD peptides maintain their characteristics when chemically or 
genetically fused to different cargos. Therefore, PTD technology can be used as an 
alternative method for the delivery of biological materials into cells and are a powerful 
tool for the development of new therapeutic strategies. 
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1.3 Protein secretion pathways in mammalian cells 
 
 
 
Protein secretion is a cellular process where proteins are released to the 
extracellular space. The majority of the secreted proteins are exported from the cell 
through the endoplasmic reticulum (ER)/Golgi – dependent secretory pathway which 
is known as conventional secretion. However, a group of proteins are secreted 
through the endoplasmic reticulum (ER)/Golgi - independent pathway which is known 
as unconventional secretion (Nickel and Rabouille, 2009). 
 
 
1.3.1 Conventional secretory pathway 
 
 
 In the conventional secretory pathway, as the translation advances in newly 
synthesised proteins, a short peptide sequence (3-60 amino acids) at the amino 
terminal end of the nascent polypeptide chain is being recognised by a factor known 
as secretion signal-recognition particle (SRP). The secretion signal sequence has a 
tripartite structure, consisted of a hydrophobic region (h-region), which is surrounded 
by an n- and c- hydrophilic regions. The SRP factor, which is located between the ER 
and the cytoplasm, binds to the h-region and leads the ribosome-mRNA-nascent 
polypeptide complex onto the membrane of the rough ER. During this process the 
translation is temporary stopped (Pyhtila et al., 2008). 
 As the complex ribosome-mRNA-nascent polypeptide-SRP moves towards 
the membrane of the ER, the SRP receptor recognizes and binds strongly with the 
SRP factor. The SRP receptor consists of two subunits, the SR-α and SR-β subunits 
that regulate the entrance of the ribosome-SRP-nascent polypeptide complex into the 
translocon. The translocon is a protein complex that directs the proteins into the inner 
space of the rough ER and acts as a switching station where secretory proteins are 
allowed to pass straight through the ER lumen (White et al., 2008). More particularly, 
it has been shown that the ribosome binds with the Sec61p, which is a translocon 
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subunit and enables the transfer of the nascent polypeptide chain directly into the ER 
lumen (Rapiejko & Gilmore, 1997). As the nascent polypeptide enters the ER, the 
SRP abandons the secretion signal sequence and allows the translation to continue. 
A secretion signal peptidase cleaves off the secretion signal sequence and releases 
the protein into the ER lumen. 
Co- and post-translation modifications of the newly synthesized protein are 
occurring into the ER lumen for the protein maturation. Glycosylation modifications 
are important for the proper protein folding. Glycosylation is however completed at 
the Golgi apparatus. Cis, medial and trans cisternae of the Golgi accomplish different 
modifications to secretory proteins. The transfer form the ER to the Golgi occurs with 
coat protein complex II (COPII) vesicles that grow from the rough ER and fuse to the 
cis site of the Golgi apparatus. COPII vesicles consist of two subcomplexes, 
Sec23/24 and Sec13/31(McMahon and Mills, 2004). The secreted proteins are 
transferred to the trans site of the Golgi apparatus (trans-Golgi). At the trans site 
proteins are getting enclosed into three different types of vesicles according to the 
secretion type. The constitutive secretion vesicles move towards the cell membrane 
where they fuse and release the secreted proteins into the extracellular environment 
without any prior storage. In contrast, the regulated secretion vesicles are stored in 
the cytoplasm and their release and fusion to the cell membrane is driven by an 
intracellular signal. Finally, the endocytic vesicles contain proteins destined for the 
lysosome. Proteins that are enclosed in endocytic vesicles are recognised by the 
mannose 6-phosphate receptor (MPR) when reach the trans-Golgi. The interaction of 
the secreted protein with MPR is essential for the endocytic vesicles formation, 
transfer and fusion to the lysosomes. (Hans J. Geuze et al., 1988). 
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 1.3.2 Unconventional secretory pathway  
  
 
There are two types of unconventional protein secretion. Proteins, that contain 
secretion signal peptide, are imported into the ER but reach the cell surface 
independent to COPII vesicles and/or Golgi apparatus, while proteins without 
secretion signal peptide exit cells through ER/Golgi independent pathways (Nickel 
and Rabouille, 2009).  
 
1.3.2.1 Secretion signal peptide containing proteins 
 
Four different mechanisms of unconventional protein secretion exist for the 
secretion signal peptide containing proteins. In the first mechanism, proteins after 
leaving the ER, are packed into COPII-coated vesicles that fuse directly to the cell 
membrane. In the second mechanism, the COPII-coated vesicles fuse with an 
endosomal or lysosomal compartment before their fusion to the cell membrane. In the 
third mechanism, proteins are packed in non-COPII-coated vesicles that can directly 
fuse to the cell membrane. In the final fourth mechanism, proteins are packed in non-
COPII-coated vesicles that initially target the Golgi apparatus before their fusion to 
the cell membrane (Nickel and Rabouille, 2009). 
 
1.3.2.2 Non secretion signal peptide containing proteins 
  
 Four different mechanisms of unconventional protein secretion exist for the 
non secretion signal containing proteins. The first mechanism is a non vesicular 
pathway where proteins can be translocated from the cytoplasm to the cell membrane 
directly usually under the control of phosphatidylinositol 4,5-bisphosphate 
[Ptdlns(4,5)P2] and heparan sulfate glycosaminoglycans (HPSGs) proteins. The 
FGF2 factor is a typical example of direct translocation across the cell membrane 
secretion. The other three mechanisms are vesicular pathways. In the second 
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mechanism the secreted protein is packed into secretory lysosomes together with 
caspase 1, followed by fusion of the secretory lysosomes to the cell membrane. In the 
third mechanism, the protein secretion is the result of microvesicle shedding 
interaction, whereas in the fourth mechanism, the secreted protein and caspase 1 are 
captured in the cytoplasm during the formation of endosomal internal vesicles, which 
in turn are released as exosomes by their fusion to the cell membrane. All of the 
above three different vesicular pathways have been described for the secretion of 
mature IL-1β during inflammatory responses (Nickel and Rabouille, 2009).  
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1.4 Hypothesis and Aims  
 
 
In this study, a novel gene therapy approach for the treatment of RA is being 
investigated. This approach is based on the ability of genetically engineered cells to 
produce in sufficient amounts a secretable PTD-fusion NF-κΒ inhibitor for the 
inhibition of NF-κΒ transcriptional activity. It is hypothesised that inflammation can be 
controlled in vivo with genetically engineered cells that are able to produce the 
secretable PTD-fusion inhibitor, as the secreted PTD-fusion inhibitor can in turn enter 
neighbouring cells and down-modulate NF-κB activity (Figure 1.6). 
 
 
 
Figure 1.6: Schematic representation of a novel gene therapy approach based on 
genetically engineered cells that are able to produce and secrete in sufficient amounts 
a cell permeable NF-κΒ inhibitor as a means to control inflammation in the arthritic 
joint. The secreted PTD-fusion NF-kB inhibitor from genetically engineered cells can in turn 
enter the inflamed neighbouring cells, inhibit NF-κΒ transcriptional activity and reduce 
inflammation in the joint. 
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Both in vivo and ex vivo gene therapy approaches will be investigated for the 
generation of genetically engineered cells. The specific aims of this study are: 
 
1. Generation of the expression constructs of the secretable PTD-fusion NF-
κΒ inhibitor and the reporter PTD-fusion proteins. 
2. Determination of the secretion levels of PTD-fusion proteins from 
transiently transfected 293T cells in vitro. 
3. Investigation of the transduction properties of the secreted PTD-fusion 
proteins from transiently transfected 293T cells in un-manipulated 
mammalian cells in vitro. 
4. Generation of genetically engineered murine fibroblasts with lentiviral 
vectors that will express the secretetable PTD-fusion NF-κB inhibitor and 
the reporter PTD-fusion proteins. 
5. Investigation of biological activity in vitro from genetically engineered cells 
expressing the PTD-fusion NF-κB inhibitor.  
6. Investigation of biological activity in vivo from genetically engineered cells 
expressing the PTD-fusion NF-κB inhibitor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Chapter II:              
Materials & Methods    
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2 Materials and Methods 
 
 
All DNA restriction and modifying enzymes were purchased from New England 
Biolabs Inc. (Hitchin, UK), except Asp718 I restriction enzyme, which was purchased 
from Roche Ltd. (Penzberg, Germany). Unless otherwise stated, chemicals and 
primers were from Sigma-Aldrich Inc. (Haverhill, UK); and cell culture reagents were 
from Cambrex Corp. (Wokingham, UK). All DNA constructs were sequenced at The 
Genome Centre, Queen Mary (London, UK). 
 
2.1 Genetic Engineering  
 
 
2.1.1 Polymerase Chain Reaction (PCR) amplification 
 
PCR reactions contained 200 ng plasmid DNA template, 0.1 µg of each 
primer, 10 x PfuUltra HF reaction buffer (5 µl) (Stratagene Inc., La Jolla, CA), 2 units 
of Pfu Ultra HF DNA polymerase (Stratagene Inc.) and distilled water up to a total 
volume of 50 µl, were subjected to an initial denaturation step at 95o C for 5 minutes, 
followed by 30 amplification cycles (95º C for 5 minutes, 60º C for 1 minute, 72º C for 
90 seconds) and a final extension step at 72º C for 10 minutes using a Peltier 
Technology Thermal cycler (PTC-200, MJ Research Inc., Waltham, MA). 
For the screening of positive clones by PCR reactions, after E.coli 
transformation, PCR reactions containing 5 μl of bacterial culture, 0.1 µg of each 
primer, 5 x Green GoTaq® Flexi Buffer (5 µl) (Promega Corp., Madison, WI), 2 units 
of GoTaq® Flexi DNA Polymerase (Promega Corp.) and distilled water up to a total 
volume of 50 µl, were subjected to an initial denaturation step at 95o C for 5 minutes, 
followed by 30 amplification cycles (95º C for 1 minute, 42º C for 1 minute, 72º C for 2 
minutes) and a final extension step at 72º C for 10 minutes using a Peltier 
Technology Thermal cycler (PTC-200, MJ Research Inc.). 
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Amplification of the correct size fragment was assessed by agarose gel 
electrophoresis. 8 µl of the PCR reaction were mixed with 2 µl of 6 x bromophenol 
blue loading dye (0.25% bromophenol blue, 0.25% xylene cyanol, 30% v/v glycerol in 
distilled water) and separated on a 1% agarose gel with 0.5 x TAE buffer (0.02 M 
Tris-acetate, 0.5 mM EDTA, pH 8.3) at 60 V for ~2 hours. 5 µl (1 μg) of a 1 Kb Plus 
DNA ladder (100 - 12000 bp.) or 100 bp DNA ladder (100 - 2072 bp) (Invitrogen 
Corp., Paisley, UK) was run alongside samples. Ethidium bromide (0.5 µg/ml) was 
incorporated in the agarose gel to visualise DNA under ultraviolet light and image was 
captured using a gel documentation system (Uvitec Ltd, Cambridge, UK).  
 
2.1.2 Ethanol Precipitation 
 
In 1 volume of PCR product 10% v/v of Sodium Acetate 3 M (pH 5.2) and 3 
volumes of 100% ethanol were added. Solution was mixed and left at -20o C for 30 
minutes. Subsequently, the mixture was centrifuged at 12,000 rpm for 10 minutes 
using an Eppendorf Microcentrifuge (5415D, Eppendorf, Hamburg, Germany). After 
centrifugation, supernatant was removed and pellet washed in 1 ml of 70% ethanol. 
DNA was recovered by centrifugation at 12,000 rpm for 5 minutes. Supernatant was 
removed and the pellet was left to air dry for 10 minutes. Finally, the pellet was 
resuspended in the desired volume of distilled water. 
 
2.1.3 Oligonucleotide phosphorylation and annealing reactions 
 
Oligonucleotide phosphorylation reactions contained complementary strands 
of oligonucleotides (0.1 µg each), 10 x T4 DNA Kinase reaction buffer (70 mM Tris-
HCl, 10 mM MgCl2, 5 mM dithiothreitol, pH 7.6) (3 µl), T4 DNA Kinase (50 units), 
distilled water up to a total volume of 30 µl and incubated at 37o C for 1 hour. 
Complementary phosphorylated oligonucleotides were annealed by boiling for 5 
minutes. Subsequently, 10 x T4 DNA ligase buffer (500 mM Tris-HCl, 100 mM MgCl2, 
10 mM ATP, 100 mM Dithiothreitol, pH 7.5) (5 µl) and distilled water was added to a 
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final volume of 50 µl, followed by cooling back to room temperature. Overlapping 
oligonucleotides were ligated the next day by incubating with T4 DNA ligase (100 
units) at 4° C overnight. 
 
2.1.4 Digestion and Ligation Reactions 
 
PCR products and plasmid vectors were digested with appropriate restriction 
enzymes. Digested DNA fragments were separated on 1% agarose gels with 0.5 x 
TAE as described earlier. DNA was visualized using an ultraviolet transilluminator 
(Uvitec Ltd). DNA fragments of interest were excised from the gel and purified using 
the PureLinkTM Quick Gel Extraction Kit following manufacturer’s instructions 
(Invitrogen Corp.). Insert DNA (PCR product or double stranded oligonucleotide) was 
added in molar excess (5 to 10 fold) to vector DNA (0.2 µg) and ligated at 4° C 
overnight with T4 DNA ligase in a final volume of 30 µl. 
 
2.1.5 Preparation of Competent DH5 E. coli cells 
 
DH5 E. coli cells were rendered competent for uptake of plasmid DNA by a 
calcium chloride protocol (Sambrook et al., 1989a). DH5 E. coli cells were grown 
overnight in 5 ml Luria Bertani medium (LB; 1% bactotryptone, 0.5% bactoyeast 
extract, both from Invitrogen Corp., 0.17 M NaCl, pH 7.4) at 37° C with vigorous 
shaking. This starter culture was transferred to 500 ml of pre-warmed LB medium and 
grown at 37° C with vigorous shaking until optical density (OD) read at 600 nm 
reached values between 0.4 and 0.6. The bacterial culture was pelleted by 
centrifugation (6,000 x g, 10 minutes, 4° C, Avantie® J-E, Beckman Coulter Inc., Palo 
Alto, CA) and resuspended in 50 ml of freshly made ice-cold 0.1 M MgCl2. Cells were 
pelleted again (6,000 x g, 10 minutes, 4° C), resuspended in 50 ml of ice-cold 0.1 M 
CaCl2 and incubated on ice for 20 minutes. A final centrifugation step (6,000 x g, 10 
minutes, 4° C) was performed. Cells were resuspended in 12.5 ml of ice cold 0.1 M 
CaCl2 with 14% glycerol, aliquoted, frozen on dry ice and kept at -80° C until future 
use. 
 Page | 57  
 
Chapter II  
2.1.6 Transformation of E. coli Cells 
 
When pcDNA3 or pHRSIN-CSGW vector was used, 100 µl of competent 
DH5 E. coli cells were incubated on ice for 30 minutes with the ligated DNA (20 µl of 
ligation reaction), heat shocked at 42° C for 2 minutes, incubated on ice for 1 minute 
and grown in 5 ml LB medium at 37° C for 90 minutes, to allow recovery and plasmid 
gene expression, with vigorous shaking. 200 µl of these cultures were plated onto LB-
agar (1.5% w/v) 9 cm plates containing ampicillin (100 µg/ml) (Sigma-Aldrich Inc.) 
and grown overnight at 37° C. Individual clones were picked and grown in 5 ml LB 
containing ampicillin (100 µg/ml) (Sigma-Aldrich Inc.) at 37° C overnight with vigorous 
shaking. 
 When pFUSE vector was used, 100 µl of competent DH5 E. coli cells were 
incubated on ice for 30 minutes with the ligated DNA (20 µl of ligation reaction), heat 
shocked at 42° C for 2 minutes and grown in 5 ml low-salt LB medium (10 g tryptone, 
5 g NaCl, 5 g yeast extract in 1 L of distilled water, pH 7.5) at 37° C for 90 minutes, to 
allow recovery and plasmid gene expression, with vigorous shaking. 200 µl of these 
cultures were plated onto low salt LB-agar (10 g tryptone, 5 g NaCl, 5 g yeast extract, 
15 g agar in 1 L of distilled water, pH 7.5) 9 cm plates containing zeocin (25 µg/ml) 
(Invitrogen Corp.) and grown overnight at 37° C. Individual clones were picked and 
grown in 5 ml low salt LB (pH 7.5) containing zeocin (25 µg/ml) (Invitrogen Corp.) at 
37° C overnight with vigorous shaking.  
 
2.1.7 Purification of plasmid DNA 
 
Bacterial cells of 1.5 ml of the initial 5 ml starter culture were pelleted by 
centrifugation (12,000 rpm, 10 minutes) using an Eppendorf Microcentrifuge (5415D, 
Eppendorf). DNA was purified using the PureLinkTM HiPure Plasmid Miniprep Kit 
following manufacturer’s instructions (Invitrogen Corp.). Restriction analysis 
digestions or PCR reactions were performed on each clone for determining the 
presence of the insert and choosing the appropriate clones for large-scale culture.  
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For large-scale cultures, 1 ml of the start-up 5 ml culture was grown in 100 ml 
LB or 100 ml Low-salt LB (pH 7.50), according to the plasmid vector (pcDNA3, 
pHRSIN-CSGW or pFUSE) used, containing ampicillin (100 µg/ml) or zeocin (25 
µg/ml) respectively. Plasmid DNA was purified using the PureLinkTM HiPure Plasmid 
Maxiprep Kit following manufacturer’s instructions (Invitrogen Corp.). After DNA 
plasmid purification, plasmid DNA concentration was determined with the use of 
Pharmacia GeneQuant (Cambridge, UK) spectrophotometer at 260 nm or Thermo 
scientific Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific Inc., 
Wilmington, USA).  
 
 
 
2.2 Mammalian cell expression 
 
 
2.2.1 Cell lines 
 
The human embryonic kidney (HEK) epithelium cell line 293T (Graham et al., 
1977) and mouse DBA/1 embryonic fibroblasts with the temperature-sensitive large T 
antigen (DTF) (Triantaphyllopoulos et al., 1998) were maintained in DMEM medium 
supplemented with 10% foetal bovine serum (FBS) (Invitrogen Corp.), 100 U/ml of 
penicillin, 100 µg/ml of streptomycin (Lonza Ltd., Verviers, Belgium) and 2 mM of L-
glutamine. 57A HeLa cells (a kind gift from Prof. R. Hay, Dundee, UK) were 
maintained in DMEM medium supplemented with 10% FBS (Invitrogen Corp.), 100 
U/ml of penicillin, 100 µg/ml of streptomycin (Lonza Ltd.,), 0.4 mg/ml G418 (Invitrogen 
Corp.) and 2 mM of L-glutamine. 57A HeLa cells are stably transfected with the 
luciferase reporter gene under the control of NF-κB promoter (Rodriguez et al., 1999). 
The above cell lines were grown as adherent monolayers at 37º C in 10% CO2 and 
split 1:10 before reaching confluency. Cells were detached with 0.5 ml trypsin 
versene (Lonza Ltd.) for 2 minutes at 37o C and washed with FBS containing medium 
(1,200 rpm, 4 minutes, Eppendorf-5810R) before plating. The leukemic T-cell line 
Jurkat was maintained in RPMI-1640 medium supplemented with 5% FBS, 100 U/ml 
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of penicillin and 100 µg/ml of streptomycin (Lonza Ltd.) and 2 mM of L-glutamine. 
Jurkat cells were grown in suspension at 37º C in 5% CO2 and split 1:10 every third 
day to maintain exponential growth. 
 
2.2.2 Transient mammalian cell plasmid DNA transfection 
 
The 293T cell line was transfected by calcium phosphate DNA co-precipitation 
(Sambrook et al., 1989b). For transient transfection, 293T cells (1 x 106 cells) were 
seeded in 9 cm tissue culture plates and transfection carried out the next day. DNA 
(20 µg) was mixed with 500 µl of 2 x HBS (280 mM NaCl, 50 mM HEPES, 1.5 mM 
Na2HPO4 - pH 7.1) distilled water (up to a final volume of 950 μl) and finally 50 µl of 
2.5 M CaCl2 added drop wise with gentle shaking. The precipitation mix was left at 
room temperature for 20 minutes and incubated on the cells from which medium had 
been removed, for 5 minutes with occasional tilting. Cells were put back in culture 
with 9 ml 10% FBS containing DMEM medium for 24 hours. Subsequently, cells were 
subjected to an osmotic shock with 1 ml of serum-free 10% glycerol DMEM. Plates 
were washed twice with 5 ml serum-free medium. 5 ml serum-free medium was 
added and 24 hours post-transfection supernatant collected and cells lysed with RIPA 
lysis buffer [50 mM Tris-HCl - pH 8.0, 150 mM NaCl, 1.0% Igepal CA-630 (NP-40), 
0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulphate (SDS)], 
supplemented with a commercially available protease inhibitor cocktail (Leupeptin, 
Pepstatin A, E-64, Bestatin, Aprotinin and AEBSF hydrochloride, from Calbiochem 
Corp., La Jolla, CA), and phosphatase inhibitors (10 mM of sodium orthovanadate 
from Sigma-Aldrich Inc., and 0.3 μΜ okadaic acid from Calbiochem Corp.). 
Supernatants were filtered sterilized with 0.45 µm sterilising filters (Millipore Co., 
Billerica, MA) to remove any cellular debris and stored at -80º C until future analysis.  
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2.2.3 Production of Lentiviral vectors  
 
293T cells (3 x 106 cells) were seeded in 15 cm plates and transient 
transfection was carried out the next day. Cells were incubated with 25 µM 
Chloroquine 30 minutes prior to transfection. The lentiviruses were produced by triple 
transient transfection of 293T cells by calcium phosphate DNA co-precipitation 
(Sambrook et al., 1989b). 22.5 µg of the lentiviral vector, 22.5 µg of the pCMVR8.2 
packaging plasmid (a kind gift from Prof. I. Verma, San Diego, CA) containing the 
gag, pol, tat and rev genes as well as the accessory genes vif, vpr, vpu and nef 
(Naldini et al., 1996), and 5 µg of the envelope pMD.G plasmid (a kind gift from Prof. 
I. Verma, San Diego, CA), encoding the VSV-G envelope, were co-transfected into 
293T cells. DNA was mixed with 1000 µl of 2 x HBS [280 mM NaCl, 50 mM HEPES, 
1.5 mM Na2HPO4, pH 7.1], distilled water (up to a final volume of 1.9 ml), and 100 µl 
of 2.5 M CaCl2 added last and drop wise with gentle shaking. The precipitation mix 
was left at room temperature for 20 minutes and incubated on the cells with 10% FBS 
containing DMEM medium. After 6 hours of incubation, medium was replaced and 
cells were left to recover overnight. Medium was replaced again the next day and 
cells left in the incubator to recover for 24 hours. Viral supernatant (15 ml) was 
collected every 24 hours for the next 2 days, filtered (0.45 µm, Millipore Co.) and 
concentrated by ultracentrifugation in a Beckman XL90 (rotor 70 Ti) at 30,000 x g for 
120 minutes at 4° C. Lentivirus pellets were resuspended in a total of 100 µl FBS free 
DMEM medium and aliquots of 20 µl were stored frozen (-80° C) until further use.  
 
2.2.4 Lentiviral Titre 
 
 The Reverse Transcriptase (RT) assay (Roche Ltd.) was used for the virus 
titration. This assay relies on the ability of RT to synthesize DNA using RNA template 
and is used as a method for the quantitative determination of RT activity in biological 
samples. Briefly, lentiviruses were lysed and sample RT activity was used to 
synthesise DNA using an RNA template provided by the manufacturer. Digoxigenin- 
and biotin– labelled nucleotides were incorporated into synthesised DNA molecules 
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and freshly synthesised DNA was detected by a sandwich ELISA protocol following 
manufacturer’s instructions. The absorbance of the samples was directly correlated to 
the level of RT activity in the samples and determined at 405 nm using an ELISA 
plate reader (Bio-kinetics reader, Bio-Tek Instruments Inc., EL3122). 
 
2.2.5 Lentiviral transduction and generation of stably infected DTF cell 
lines 
 
DTF fibroblasts (50,000 cells) were seeded in 6 well tissue culture plates and 
infection was carried out the next day. Cells were incubated with concentrated 
lentivirus (20 µl) in the presence of 6 µg/ml polybrene (Sigma-Aldrich Inc.) in a 
volume of 1 ml medium for 6 hours, when 2 ml of medium were added. Cells were left 
in the incubator overnight to recover. Medium was replaced the next day, and cells 
were expanded under standard conditions. 6 rounds of consecutive infections were 
performed for the generation of stably infected DTF fibroblasts.    
 
2.2.6 Stocks of cultured cell lines  
 
Cells were trypsinised and stocks were prepared by resuspending 3 x 106 cells 
in 1 ml of FBS containing 10% DMSO. Cells were transferred in cryotubes (1 ml per 
tube) (nunc™, Thermo Fisher Scientific Inc., Roskilde, Denmark) and transferred to 
ice for 1 hour. Stocks were transferred to -80º C in polystyrene boxes for slow 
freezing overnight and subsequently stored in liquid nitrogen until further use.  
For the initiation of new cell cultures from frozen aliquots, 1 aliquot was 
removed from liquid nitrogen and thawed quickly at 37o C. Cells were recovered in a 
cell culture flask containing pre-warmed culture medium. Subsequently, culture 
medium was replaced with fresh medium in order to remove the remaining DMSO 
from the cell culture and cells left to grow until reaching 70% confluency. 
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2.3 Expression analyses 
 
2.3.1 Antibodies and other reagents 
 
The anti-GFP monoclonal antibodies (a mixture of clones 7.1 and 13.1, IgG1κ) 
were obtained from Roche Ltd., while the rabbit polyclonal were from Invitrogen Corp. 
The mouse IgG2a monoclonal anti-V5 (R960-25) was from Invitrogen Corp., mouse 
IgG1 monoclonal anti-FLAG M2 from Sigma-Aldrich Inc., mouse IgG2b monoclonal 
anti-HA (12CA5) from Abcam plc. (Cambridge, UK), goat polyclonal anti-LAP from 
R&D Systems Inc. (Minneapolis, MN), HRP-conjugated F(ab’)2 goat polyclonal anti-
mouse IgG antibody and HRP-conjugated F(ab’)2 mouse polyclonal anti-goat IgG 
antibody from Santa Cruz Biotechnology Inc. (Santa Cruz, CA), rabbit polyclonal anti-
Giantin from Abcam plc., Alexa-594-conjugated donkey polyclonal anti-rabbit and 
Alexa-488-conjugated anti-mouse were from Molecular Probes Inc. (Eugene, OR). 
The DRAQ5TM dye for nuclear staining was from Biostatus Ltd. (Leicester, UK) and 
Alexa fluor 555-conjugated cholera toxin B subunit (CTB) for visualization of lipid raft 
was from Molecular Probes Inc. Phycoerythrin (PE) anti-mouse Ly6G (GR1) 
conjugated antibodies and corresponding isotype control antibodies were from 
eBioscience Inc. (San Diego, CA). 
 
2.3.2 Supernatant concentration 
 
 When concentration was performed using Aquacide I (Calbiochem Corp.), cell 
culture supernatant was loaded into SnakeSkin® Pleated dialysis tube (Pierce Inc., 
Rockford, IL), which had a 3,500 molecular weight cut-off (MWCO). Both sides of the 
tube were secured and tube was covered with Aquacide I.  Aquacide I absorbed the 
water and salts from the sample and remaining sample was collected when the 
desired concentration levels were achieved from the tube and dialysed in 1 x 
Phosphate Buffered Saline (PBS) (MgCl2 free) (Sigma-Aldrich Inc.). 
 When concentration by Vivaspin concentrators was performed, cell culture 
supernatant was loaded into a Vivaspin 15R concentrator (Sartorius Stedim Biotech 
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S.A., Aubagne Cedex, France), which had 2,000 MWCO. Samples were 
concentrated by centrifugation (2,800 rpm, 4° C, 5810R - Eppendorf) until desired 
concentrations were achieved. 
 
2.3.3 Western blotting analysis 
 
Cell lysates and supernatants were analysed by western blotting analysis. 
Protein concentrations of cell lysates were determined using the Pierce® BCA protein 
assay kit (Thermo Fisher Scientific Inc.), following manufacturer’s instructions. 1 
volume of samples was mixed with 1 volume of reducing loading sample buffer (10% 
SDS, 40% glycerol, 125 mM Tris-HCl pH 6.8, 0.002% bromophenol blue, 0.4 M DTT) 
(Sambrook et al., 1989b). Samples were boiled for 5 minutes and equal volumes of 
samples were loaded onto a 10% SDS-PAGE electrophoresis gel [running gel; 9.9% 
polyacrylamide (PA, 30% acrylamide, 0.8% bisacrylamide, National Diagnostics Inc., 
Hull, UK), 0.375 M Tris pH 8.8, 0.1% sodium dodecyl sulphate (SDS), 0.1% 
ammonium persulfate (APS, Sigma-Aldrich Inc.), 0.0004% v/v N,N,N,N'-
tetramethylenediamine (TEMED); stacking gel; 4.95% polyacrylamide, 0.125 M Tris, 
pH 6.8, 0.1% SDS, 0.1% APS, 0.001% v/v TEMED]. 10 µl of a 10kDa to 250 kDa 
Precision Plus protein standard (Bio-Rad Laboratories Inc., Hemel Hempstead, U.K.) 
was run alongside samples. The gel was run at 125 V for 15 minutes and another 40 
minutes at 175 V in TGS buffer (25 mM Tris pH 8.3, 192 mM Glycine, 0.1% SDS) and 
subsequently transferred onto a polyvinylidene difluoride (PVDF) membrane 
(Amersham International Plc, UK) by electroblotting in 10 mM 3-(Cyclohexylamino)-1-
propanesulfonic acid (CAPS), pH 11 (Sigma-Aldrich Inc.) at 200 mA for 1 hour. The 
PVDF membranes were blocked in 5% non-fat milk (Marvel, Premier Foods Plc, St 
Albans, UK) containing 0.2% Tween-20 in PBS (50 ml) for 1 hour at room 
temperature and probed at 4º C overnight with the specific primary antibodies (1:1000 
dilution, 25 ml). After three 15 minutes washes in 0.2% PBS-Tween-20 (50 ml), 
membranes were incubated with the specific secondary antibodies (1:1000 dilution, 
25 ml) for 1 hour at room temperature. Membranes were washed 4 times; 30 minutes 
each wash, with 0.2% PBS-Tween-20 (50 ml) prior to detection with the enhanced 
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chemiluminescent technique (ECL, Amersham International plc). Membranes were 
exposed to autoradiography films (Amersham Pharmacia Biotech Inc., Amersham, 
UK) for different periods of time depending on the signal intensity and films were 
developed using an Agfa Curix 60 processor (Agfa-Gavaert Ltd., Gevaert, Belgium).  
 
2.3.4 LAP direct ELISA binding assay 
 
 ELISA plates were coated with serial dilutions of samples in a total volume of 
50 µl/well in 0.1 M carbonate/bicarbonate buffer pH 9.6 and incubated overnight at 4º 
C. Plates were washed twice with 0.2% PBS-Tween-20 and blocked with 200 µl/well 
of 2% casein in PBS for 2 hours at room temperature. Plates were washed 3 times 
with 0.2% PBS-Tween-20 and goat anti-LAP primary antibodies (R&D Systems Inc.) 
(0.4 µg/ml in PBS containing 1% casein) were added and incubated for 2 hours at 
room temperature. Subsequently, plates were washed 3 times with 0.2% PBS-
Tween-20 and mouse anti-goat HRP-conjugated secondary antibodies (0.8 µg/ml in 
PBS containing 1% casein) were added and incubated for 1 hour at room 
temperature. In turn, plates were washed 5 times with 0.2% PBS-Tween-20 and 100 
µl/well of 1:1 mixture of peroxidase B (H2O2) and tetramethylbenzidine (TMB, KPL, 
Kirkegaard & Perry Laboratories Inc., Maryland, USA) was added to the plates for 4 
minutes. The reaction was stopped with 100 µl/well 4 M H2SO4 and OD was 
determined at 450 nm in an ELISA plate reader (Bio-kinetics reader, Bio-Tek 
Instruments Inc., EL3122). Linear regression analysis was performed on the 
commercial recombinant human LAP protein standards (Sigma-Aldrich Inc.) to obtain 
a linear standard curve. Linear regression analysis was also performed on the 
supernatant sample dilutions to determine the linear portion of the supernatant 
samples dilution curve. Supernatant LAP proteins concentrations were calculated 
using OD values from the linear portion of the supernatant dilutions and applying the 
protein standards linear regression analysis. An r2 value was calculated for each 
regression performed (Microsoft® Excel 2007 software; Microsoft Corp., Redmond, 
WA).  
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2.3.5 Protein transduction 
 
 To assess uptake of secretable TAT-fusion protein, 6 x 106 Jurkat cells were 
incubated at 37o C for 2 or 4 hours with the indicated supernatant which was collected 
from cultures of transiently transfected 293T cells, filtered to remove any cell debris 
and concentrated with Aquacide I. Following incubation, cells were washed with PBS 
and treated with 0.1% trypsin in PBS for 10 minutes at 37o C to digest membrane-
attached TAT-fusion proteins. Following trypsinisation, the cells were washed 
extensively with PBS and lysed in 100 µl 1% CAPS-containing lysis buffer (150 mM 
NaCl, 50 mM Tris pH 8.0, 0.5 mM EDTA, 1% CAPS) supplemented with a 
commercially available protease inhibitor cocktail (Leupeptin, Pepstatin A, E-64, 
Bestatin, Aprotinin and AEBSF hydrochloride, from Calbiochem Corp.), and 
phosphatase inhibitors (10 mM of sodium orthovanadate from Sigma-Aldrich Inc. and 
0.3 μΜ okadaic acid from Calbiochem Corp.). 
 
2.3.6 Intracellular staining and confocal microscopy 
 
 Jurkat T-cells (6 x 106 cells) were incubated with concentrated supernatants 
from TAT-HA-srΙκΒα-V5 pFUSE, TAT-HA-eGFP pFUSE or mock transfected 293T 
cells for 4 hours at 37o C. Following incubation, cells were treated with trypsin for 10 
minutes to eliminate membrane bound protein, washed extensively and fixed in 4% 
paraformaldehyde (PFA). After fixation, cells were washed with PBS, permeabilised 
with 0.5% TritonX-100 (300 µl, 30 minutes at 4o C), blocked with 0.5% fish skin 
gelatine (300 µl) for 1 hour at room temperature and incubated with anti-GFP or anti-
V5 (1 µg/ml) antibodies for 1 hour at room temperature. Cells were washed with PBS 
and incubated with Alexa-488-conjugated anti-mouse antibodies. Following staining 
the cells were attached onto poly-L-lysine-treated slides (Sigma-Aldrich Inc.), 
mounted with CitiFluor AF1 solution (CitiFluor Ltd, London, UK) and analysed using 
the Zeiss LSM510Meta confocal microscope (Carl Zeiss Ltd., Jena, Germany). 
Images were acquired using a 100 x oil immersion objective and the LSMS10Meta 
software Carl Zeiss Ltd.) after adjusting to the same output intensities. To determine 
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subcellular co-localisation, treated Jurkat cells were either double stained with 
antibodies to the indicated TAT-protein and CTB-Alexa 555 (lipid rafts marker), or 
triple stained with anti-TAT-protein (anti-GFP or anti-V5, anti-Giantin (Golgi marker), 
and the DRAQ5TM dye to visualize the nucleus.  
 
2.4 Biological activity analyses 
 
 
2.4.1 MMP cleavage analysis 
 
Cell culture supernatant containing secreted LAP proteins was incubated with 
MMP-1 catalytic domain (human, recombinant) (1 µg/ml) (Enzo Life Sciences Ltd., 
Exeter, UK) overnight at 37º C. Samples were subsequently analysed by western 
blotting analysis, as described previously. 
 
2.4.2 Gelatin zymography  
 
Gelatinase (MMP2 and MMP9) activity in cell supernatants was analysed by 
gelatin zymography. 1 volume of samples was mixed with 1 volume of non-reducing 
loading sample buffer (10% SDS, 40% glycerol, 125 mM Tris-HCl pH 6.8, 0.002% 
bromophenol blue). Samples were loaded onto a pre-made 10% SDS-PAGE 
electrophoresis gel containing 1 mg/ml gelatin (Invitrogen Corp.). 10 µl of a 4 kDa to 
250 kDa SeeBlue® Plus2 Pre-stained standard (Invitrogen Corp.) was run alongside 
samples. Gel was run at 125  V for 15 minutes and another 40 minutes at 175 V in 
TGS buffer (25 mM Tris, pH 8.3, 192 mM Glycine, 0.1% SDS) and subsequently 
washed twice with washing buffer (50 mM Tris-HCl pH 8, 2.5% TritonX-100) for 30 
minutes each wash. Gel was incubated in developing buffer (50 mM Tris-HCl pH 7.4-
8, 10 mM CaCl2, 5 mM ZnCl2, 200 mM NaCl and 0.05% Brij-35) at 37o C overnight. 
Gels were stained with 0.5% Coomassie Brilliant Blue stain (Sigma-Aldrich Inc.) and 
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destained with distaining solution (40% methanol, 10% acetic acid). MMP activity was 
detected as white bands on the stained gels. 
 
2.4.3 57A HeLa luciferase assay 
 
57A HeLa cells (10,000 cells) were seeded in 96 well tissue culture plates and 
left to grow in 10% FBS containing medium overnight. Medium was removed, cells 
washed with PBS and supernatants from transiently transfected 293T cells or stably 
infected DTF cells applied on cells. After 2 hours of incubation at 37o C, cells were 
stimulated with recombinant human IL-1β (10 ng/ml) (PeproTech Inc., Rocky Hill, NJ) 
for 4 hours. Subsequently, supernatants were removed, cells washed with PBS and 
50 µl/well of Reporter Lysis Buffer (RLB) (Promega Corp.) were added. A single 
freeze-thaw cycle was performed to achieve complete cell lysis and 10 µl of the cell 
lysates were transferred to an opaque-walled 96 well plate. Luminescence was 
recorded on a Microtiter plate luminometer (MLX, Dynex Technologies, Chantilly, 
VA) after the injection of 50 µl/well of Luciferase Assay Reagent (Promega Corp.) by 
the luminometer injector. The luminometer performed a 2 second delay followed by a 
10 second measurement read for luciferase activity. Luciferase activity was recorded 
as Relative Luminescent Units (RLU). 
 
2.4.4 57A HeLa and DTF Co-culture luciferase assay  
 
57A HeLa cells (40,000 cells) and DTF cells (40,000 cells) were co-cultured in 
96 well tissue culture plates with black walls and left to grow in 10% FBS containing 
medium for 4 hours. Subsequently, culture medium was replaced with 100 µl of 0.5% 
FBS containing medium and cells left to grow at 37º C in 10% CO2 overnight. Cells 
were stimulated with recombinant human IL-1β (10 ng/ml) (PeproTech Inc.) and  
MMP-1 catalytic domain (human, recombinant) (1 µg/ml) (Enzo Life Sciences Ltd.,) 
was added. After 4 hours of IL-1β stimulation, 2.5 μl/well of luciferin K+ salt (30 
mg/ml; Promega Corp.) was added and luminescence recorded using an IVIS® 
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Imaging System 100 series (Caliper Life Sciences Inc., Hopkinton, MA). Luciferase 
images were overlaid on the photograph, and emission of light was quantified as 
photons per steradian per square centimeter using Living Image® software version 
2.5.50.1 (Caliper Life Sciences Inc.). 
 
 
2.5 In vivo studies 
 
 
2.5.1 Animals  
 
Healthy Swiss and BALB/c mice were obtained from Harlan UK limited 
(Bicester, Oxon, UK). Mice were treated according to approved UK Home Office and 
institutional guidelines. Animals were weighed, randomised into groups (n = 5), and 
kept for 1 week to acclimatise to the laboratory condition, before the initiation of any 
procedure. All animals were marked in the tail with an indelible pen for identification. 
Food and water was supplied ad libitum throughout the duration of the study. All 
needles and syringes used in this study were from BD Microlance (Dublin, Ireland), 
unless otherwise stated. 
 
2.5.2 Carrageenan paw oedema inflammation model 
 
 On Day 0, DTF cells were washed extensively with PBS, counted and 
resuspended in the desired volume of PBS for transplantation. Cells were maintained 
on ice until transplantation to Swiss mice. 2 x 106 cells (50 µl in PBS) were injected 
subcutaneously into the plantar region of each hind paw. Injections were performed in 
anaesthetised (AErrane - isoflurane, Baxter Healthcare Inc., Norfolk, UK) animals 
using a 25-gauge needle inserted into the pad region of the glabrous skin on the 
underside of the hind paw. The injection site was close to the centre of the plantar 
region of the hind paw. On Day 2, 50 µl of fresh 1% solution of λ-carrageenan 
(Sigma-Aldrich Inc.) in 0.9% saline was injected subcutaneously into the plantar 
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region of each hind paw, as described previously, using a 25-gauge needle and 50 µl 
gastight syringe (Hamilton Corp., Bonaduz, Switzerland). The volume of hind paws 
was measured immediately prior to cell transplantation and carrageenan injections, 
using a POCO 2T caliper (Kroeplin Längenmesstechnik, Schlüchtern, Germany). 
After carrageenan injections, the thickness of the hind paws was measured daily for 
the period of a week. Animals were humanely terminated after the final assessment. 
 
2.5.3 Air-Pouch inflammation model 
 
On Day 0, Swiss mice were injected with 2.5 ml of air subcutaneously on the 
dorsal area. The site of injection was at the base of the neck, pushing the air into the 
dorsal area towards the tail. On Day 3, a second injection (2.5 ml of air) was 
performed to reinflate the air-pouch, followed by a third injection to transplant the DTF 
cells (2 x 106 cells/animal in 100 µl PBS or 10 x 106 cells/animal in 250 µl PBS) into 
the air-pouch. Injections were performed in anaesthetised (AErrane – isoflurane, 
Baxter Healthcare Inc.) animals using a 25-gauge needle.  On Day 6, recombinant 
mouse IL-1β (20 ng) (PeproTech Inc.) was dissolved in 0.5 ml of fresh Carboxy 
Methyl Cellulose (CMC) solution and injected into the air-pouch. For the preparation 
of the CMC solution, 250 mg of CMC (BDH Ltd.) were resuspended in 50 ml of sterile 
PBS under continuous stirring condition for 45 minutes. Subsequently, the CMC 
solution was centrifuged at 1,200 rpm for 10 minutes (5810R - Eppendorf) to remove 
lumps that may had formed and stored on ice. After 4 hours of IL-1β stimulation, air-
pouches were washed with 2 ml of washing buffer (3 mM EDTA, 25 U/ml heparin in 
PBS), washing buffer collected for further analysis and animals humanely terminated. 
Cell accumulation in the washing buffer was quantified by differential counting. More 
specifically, 50 µl of the washing buffer was mixed with 450 µl of Turk’s solution [0.1% 
crystal violet (Sigma-Aldrich Inc.) and 3% acetic acid (BDH Ltd., Poole, UK) in sterile 
water] and 10 µl of this mixture placed on a Neubauer chamber and cells were 
counted by light microscopy (Nikon Eclipse TS100, Nikon Ltd. Surrey, UK). 
Measurement of specific cell populations within the inflammatory infiltrate was made 
by flow cytometry (FACS) analysis. 200 µl of the washing buffer collected from the 
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air-pouches were centrifuged at 2,000 rpm for 30 seconds using ALC Multispeed 
Centrifuge (PK 121, ALC International, Milan, Italy). Cell pellets were washed twice 
with PBS and resuspended in 20 µl of human IgG (16 mg/ml) (Sigma-Aldrich Inc.). 
Subsequently, cells were stained with PE anti-mouse Ly6G (GR1) conjugated 
antibodies (0.3 µg/ml) for 45 minutes at 4o C. Cells were washed 3 times with PBS 
and resuspended in 100 µl of FACS buffer (0.2% FBS in PBS) for FACS analysis. 
FACS analysis was performed using a BD FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA).   
 
2.5.4 mBSA Antigen Induced Arthritis model 
 
Balb/c male mice (8 weeks) were immunized with methylated bovine serum 
albumin (mBSA, Sigma-Aldrich Inc.) prepared in 1% saline (10 mg/ml) was emulsified 
with an equal volume of complete Freund’s adjuvant (CFA; 1 mg/ml of 
Mycobacteriumm tuberculosis) (Difco). On Day 11 post immunisation, 1.5 x 106 TU of 
replication-deficient lentiviral vectors in the volume of 20 µl were injected 
subcutaneously into the plantar region of each hind paw. Injections were performed in 
anaesthetised (AErrane - isoflurane, Baxter Healthcare Inc.) animals using a 27-
gauge needle inserted into the pad region of the glabrous skin on the underside of 
the hind paw. The injection site was close to the centre of the plantar region of the 
hind paw. On Day 14 post immunisation, 50 µl of fresh 10 mg/ml mBSA in 1% saline 
was injected subcutaneously into the plantar region of each hind paw, as described 
previously, using a 27-gauge needle and 50 µl gastight syringe (Hamilton Corp.). The 
volume of hind paws was measured immediately prior to lentiviral vectors injections, 
using a POCO 2T caliper (Kroeplin Längenmesstechnik). After mBSA injections in the 
paws, the thickness of the hind paws was measured every 24 hours for the following 
6 days. Animals were humanely terminated after the final assessment. 
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2.6 Statistical analysis 
 
 
 One-way analysis of variance (ANOVA) and a Tukey post-test was used to 
determine where significant differences lie when comparing the different groups. P 
values of less than 0.05 were considered significant. GraphPad Prism 5 software was 
used to perform statistical analyses (GraphPad Software, Inc. La Jolla, CA). 
 
 
  
 
 
  
 
Chapter III:              
Genetic construction and in vitro 
characterisation of the secretable 
PTD-fusion proteins 
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3.1 Introduction 
 
 
Secretable PTD-fusion proteins under the control of IL-2 secretion signal (ILss) 
from the commercially available pFUSE-mIgG2A Fc2 (IL2ss) vector (InvivoGen Corp., 
San Diego, CA) (Figure 3.1) to drive direct secretion were generated. The 11 amino 
acid long, TAT PTD derived from the HIV TAT protein (residues 47-57) was used 
initially. TAT PTD, which is rich in positively charged amino acids, could efficiently 
mediate entry into cells of heterologous proteins when chemically attached or 
genetically fused to these proteins (Fawell et al., 1994; Nagahara et al., 1998). 
Purified TAT-fusion proteins were also able to transduce cells in vivo when 
administered in animals (Schwarze et al., 1999).   
Barka et al. (2004) were able to generate cells lines that were able to secrete 
TAT-GFP, demonstrating the ability of ΤΑΤ PTD-fusion proteins to be secreted from 
mammalian cells. However,  a more recent study has revealed that positively charged 
PTDs inhibit secretion of PTD-fusion proteins from mammalian cells (Shaw et al., 
2008). As a result of this finding, different PTDs were also used in this study. The 
PTDs used, apart from TAT PTD (YGRKKRRQRRR), were TAT3 PTD 
(YARAAARQARA), MAntp4 PTD (GRQIAIWFQNRRMKWAAG) and PTD5 PTD 
(RRQRRTSKLMKR). TAT3 and MAntp4 PTDs were selected because they revealed 
the highest secretion levels in Shaw et al. (2008) study and PTD5 PTD because is 
another potent synthetic PTD that was derived from a peptide library (Mai et al., 
2001), and its secretion properties were tested, as this PTD was not studied by Shaw 
et al., (2008).  
The different protein cargos that were used to generate the secretable PTD-
fusion proteins were the immunoglobulin mIGg2A, the reporter protein eGFP, the NF-
κΒ inhibitors srΙκΒα and NBD, and the RAS binding domain Raf-1 (RBD) inhibitor. 
The immunoglobulin mIgG2A was derived from the original pFUSE-mIgG2A Fc2 
(IL2ss) vector and TAT-mIgG2A protein was generated in order to explore the 
secretion properties of a naturally secreted protein fused to TAT PTD. The TAT-eGFP 
protein was generated as a reporter TAT-fusion protein. The srIκΒα NF-κΒ inhibitor 
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was also fused to all of the four different PTDs used in this study and therefore TAT-
srIκΒα, TAT3-srIκΒα, MAntp4-srIκΒα and PTD5-srIκΒα fusion proteins were 
generated. srIκΒα is a S32A and S36A double mutant of IκBα, resistant to 
proteasome degradation and therefore is a potent inhibitor of NF-κB activity. Ιt has 
been shown that when srIκBα is expressed in human macrophages or primary RA 
synovial fibroblasts production of pro-inflammatory mediators was inhibited (Foxwell 
et al., 1998). Importantly, purified TAT-srIκBα was shown to inhibit NF-κB activity in 
cells in vitro and to diminish acute inflammation in a rat pleurisy model (Blackwell et 
al., 2004; Kabouridis et al., 2002). Specifically, systemic administration of TAT-srIκBα 
reduced the number of immune cells infiltrating the pleural cavity during the onset 
phase of the inflammatory process. Furthermore, inflammatory cells were shown to 
be more susceptible to apoptosis indicating a pro-survival role for this transcription 
factor in immune cells. The small synthetic NF-κΒ inhibitor NBD was also fused to the 
TAT3 PTD and the TAT3-NBD fusion protein was generated. The NBD peptide 
derives from the carboxyl-terminal segment of IKKα and IKKβ that interacts with the 
amino-terminal α-helical region of NEMO (IKKγ) for the formation of the IKK complex. 
Therefore, NBD is an NF-κB inhibitor that prevents the formation and activation of the 
IKK complex after its binding to NEMO regulatory protein (May et al., 2000). 
Interestingly, when NBD inhibitor was fused to the Antp-PTD could inhibit NF-κB 
transcriptional activity in vitro and in vivo. More specifically, administration of Antp-
NBD reduced phorbol 12-myristate 13-acetate (PMA) induced Ear oedema and 
immune cell infiltration in the zymosan induced peritonitis model in mice. Also, 
administration of Antp-NBD inhibited paw swelling in the Carrageenan paw oedema 
model and RANKL-induced osteoclastogenesis in the CIA model in mice (di Meglio et 
al., 2005; Jimi et al., 2004; May et al., 2000). The RBD inhibitor was also fused to the 
TAT PTD and the TAT-RBD PTD-fusion protein was generated. RBD is the minimal 
RAS-binding domain of RAF-1 kinase, which competitively inhibits the GTP bound 
form of RAS at the protein effector binding site (de Rooij and Bos, 1997). Therefore 
RBD inhibits the activation of RAS proteins and their downstream signaling. RBD is 
not a direct NF-κΒ inhibitor and used in this study only as a control TAT PTD-fusion 
inhibitor.  
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 The ability of the secretable PTD-fusion proteins to be secreted from 
mammalian cells was initially investigated by western blotting analysis of 
supernatants from transiently transfected 293T cells. In turn, the ability of the 
secreted PTD-fusion proteins to transduce other mammalian cells was studied by 
western blotting analysis and confocal microscopy of cells that were treated with the 
secreted PTD-fusion proteins.  
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3.2 Results 
 
 
3.2.1 Generation of the secretable TAT PTD-fusion proteins 
expression vectors 
 
 
Different polypeptides were initially subcloned into the commercially available 
pFUSE-mIgG2A Fc2 (IL2ss) vector (InvivoGen Corp.) (Figure 3.1), which contains the 
secretion signal from the IL-2 gene, in order to generate the secretable PTD-fusion 
proteins. 
 
3.2.1.1 IL-2ss-TAT-HA-srΙκΒα-V5 pFUSE expression vector 
 
Cloning of the human srIκΒα mutant gene into the prokaryotic expression 
vector pRSET-TAT-HA (a kind gift from S. Dowdy, UCSD, CA) has been described 
previously by Kabouridis et al. (2002). Using this construct as template, the TAT-HA-
srIκΒα-V5 region was amplified by PCR using the forward primer 5’-
TCGATATCGTACGGCCGCAAGAAACGC-3’ and the reverse primer 5’-
CTGCTAGCCGGATCAAGCTTCGA-3’. The PCR product was then recovered from 
the PCR reaction by ethanol precipitation, digested with EcoRV/NheI (underlined 
sites) and subcloned in frame into the corresponding sites of the commercial vector 
mIgG2A Fc2 pFUSE (IL2ss). This vector contains the 21 amino acid secretory signal 
from the IL-2 gene upstream of the Fc portion of the mouse IgG2A heavy chain. The 
final expression vector generated encodes IL2ss-TAT-HA-srIκΒα-V5 (Figure 3.2). 
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Figure 3.1: The restriction enzyme and genetic map of the commercial mIgG2A Fc2 
(IL2ss) pFUSE vector (Invivogen Corp.). mIgG2A Fc2 pFUSE plasmid contains the coding 
sequence of IL-2 signal sequence (ss), which encodes a 21 amino acid signal peptide that 
shares common characteristics with signal peptides of other secretory proteins. Immediately 
downstream the ss is the Fc portion of the mouse mIgG2A immunoglobulin, which is 
expressed under the control of hEF1-HTLV promoter. hEF1-HTLV promoter is a composite 
promoter comprising the Elongation Factor-1α (EF-1α) core promoter and the R segment of 
the U5 sequence (R-U5’) of the Human T-cell Leukemia Virus (HTLV) Type 1 Long Terminal 
Repeat. The EF-1α promoter exhibits strong activity and yields long lasting expression of a 
trangene in vivo. The R-U5’ is coupled to the EF-1α core promoter to enhance stability of 
RNA. The plasmid also contains a Zeocin resistance gene for selection in both mammalian 
cells and E. coli. The expression in mammalian cells is under the control of a composite 
promoter, which combines the human cytomegalovirus immediate-early gene 1 enhancer 
(CMV enh) and the core promoter of the human ferritin light chain (hFerL) gene and in 
bacterial cells is under the control of bacterial EM2KC promoter that enables constitutive 
expression. The origin of replication (ori) is derived from E. coli. The direction of 
gene/promoter transcription is indicated by the arrow shapes. 
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Figure 3.2: The restriction enzyme and genetic map of the IL2ss-TAT-HA-srIκΒα-V5 
pFUSE expression vector. The TAT-HA-srIκBa-V5 coding sequence is cloned immediately 
downstream the IL2ss sequence. TAT: coding sequence of TAT PTD. HA: coding sequence 
of HA epitope from the haemagglutinin of the human influenza virus. srIκΒα: coding 
sequence of super repressor IκΒ gene. V5: coding sequence of V5 epitope from the c-
terminal sequence of the p and v proteins of simian virus 5.  
 
 
3.2.1.2 IL2ss-TAT-HA-eGFP pFUSE expression vector 
 
To produce the IL2ss-TAT-HA-eGFP pFUSE expression vector, the srIκBα-V5 
segment (Figure 3.2) was excised using the internal KpnI/SphI sites (Kabouridis et 
al., 2002) and replaced with the eGFP (enhanced GFP) gene, which was amplified by 
PCR using as template the commercial vector pEGFP-N2 (BD Biosciences Clontech 
Inc., Palo Alto, CA) and primers 5’-ATTGGTACCGTGAGCAAGGGCGAGGAG-3’ 
(forward) and 5’-GCTGCATGCTTACTTGTACAGCTCGTC-3’ (reverse). The PCR 
product was then recovered from the PCR reaction by ethanol precipitation, digested 
with KpnI/SphI (underlined sites) and subcloned in frame into the corresponding sites 
of the IL2ss-TAT-HA-srIκΒα-V5 pFUSE expression vector. The final expression 
vector generated encodes IL2ss-TAT-HA-eGFP (Figure 3.3). 
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Figure 3.3: The restriction enzyme and genetic map of the IL2ss-TAT-HA-eGFP pFUSE 
expression vector. The TAT-HA-eGFP coding sequence is cloned immediately downstream 
the IL2ss sequence. 
 
 
3.2.1.3 IL2ss-TAT-HA-RBD pFUSE expression vector 
 
The RBD (Ras binding domain of RAf-1) gene was initially cloned into the 
prokaryotic expression vector pRSET-TAT-HA (a kind gift from Dr. N. Malik, London, 
UK). Using this expression vector as template the TAT-HA-RBD region was amplified 
by PCR using the forward primer 5’-TCGATATCGTACGGCCGCAAGAAACGC-3’ 
and the reverse primer 5’-CTGCTAGCCGGATCAAGCTTCGA-3’. The PCR product 
was then recovered from the PCR reaction by ethanol precipitation, digested with 
EcoRV/NheI (underlined sites) and subcloned in frame into the corresponding sites of 
the commercial vector mIgG2A Fc2 pFUSE (IL2ss) (Figure 3.1, InvivoGen Corp.). 
The final expression vector generated encodes IL2ss-TAT-HA-RBD (Figure 3.4). 
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Figure 3.4: The restriction enzyme and genetic map of the IL2ss-TAT-HA-RBD pFUSE 
expression vector. The TAT-HA-RBD coding sequence is cloned immediately downstream 
the IL2ss sequence. 
 
 
 
3.2.1.4 IL2ss-TAT-HA-mIgG2a pFUSE expression vector 
 
To produce the IL2ss-TAT-HA-mIgG2A pFUSE expression vector, the srIκBα-
V5 segment was excised using the internal KpnI/SphI sites (Figure 3.2) and replaced 
with the Fc portion of the mouse IgG2A heavy chain gene, which was amplified by 
PCR using as template the commercial vector mIgG2A Fc2 pFUSE (IL2ss) (Figure 
3.1, InvivoGen Corp.) and primers 5’-GAAGGTACCCCTCCACTCAAAGAGTGT-3’ 
(forward) and 5’-TTCGCATGCTCATTTACCCAGAGACCG-3’ (reverse). The PCR 
product was then recovered from the PCR reaction by ethanol precipitation, digested 
with KpnI/SphI (underlined sites) and subcloned in frame into the corresponding sites 
of the IL2ss-TAT-HA-srIκΒα-V5 pFUSE vector (Figure 3.2). The final expression 
vector generated encodes IL2ss-TAT-HA-IgG (Figure 3.5). 
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Figure 3.5: The restriction enzyme and genetic map of the IL2ss-TAT-HA-mIgG2A Fc 
pFUSE expression vector. The TAT-HA-mIgG2A coding sequence is cloned immediately 
downstream the IL2ss sequence.  
 
 
 
3.2.1.5 IL2ss-FLAG-PTD*-srΙκΒα-V5 pFUSE expression vectors 
(PTD* = TAT, or TAT3, or MAntp4, or PTD5) 
 
To produce the IL2ss-FLAG-PTD*-srΙκΒα-V5 pFUSE expression vectors the 
TAT-HA segment was excised using the internal EcoRV/Asp718I sites from the 
IL2ss-TAT-HA-srΙκΒα-V5 pFUSE expression vector (Figure 3.2). Complementary 
strands of oligonucleotides (Table 3.1) were phosphorylated, annealed and ligated. 
Ligated oligonucleotides then subcloned in frame into the corresponding sites of the 
IL2ss-TAT-HA-srIκΒα-V5 pFUSE expression vector.  
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Table 3.1: Sequences of oligonucleotides that were used for the generation of IL2ss-
FLAG-PTD-srΙκΒα-V5 pFUSE expression vectors. 
Fragment  Sense oligonucleotides Anti-sense oligonucleotides 
FLAG-TAT 1. 5’-ATCAGGTGGAGACTACAAAGACGAT 
GACGACAAGGGT-3’ 
2. 5’-GGATACGGCCGCAAGAAACGCCGC 
CAGCGCCGCCGCGGAG-3’ 
1. 5’-GTACCTCCGCGGCGGCGCTGGCGGCGTTTC 
TTGCGG-3’ 
2. 5’-CCGTATCCACCCTTGTCGTCATCGTCTTTG 
TAGTCTCCACCTGAT-3’ 
FLAG-TAT3 1. 5’-ATCAGGTGGAGACTACAAAGACGAT 
GACGACAAGGGT-3’ 
2. 5’-GGATATGCTCGTGCTGCTGCTCGT 
CAAGCTCGTGCTGGAG-3’ 
1. 5’-GTACCTCCAGCACGAGCTTGACGAGCAGCA 
GCACGA-3’ 
2. 5’-GCATATCCACCCTTGTCGTCATCGTCTTTG 
TAGTCTCCACCTGAT-3’ 
FLAG-MAntp4 1. 5’-ATCAGGTGGAGACTACAAAGACGAT 
GACGACAAGGGTGGAGGCCGTCAA-3’ 
2. 5’-ATTGCAATCTGGTTCCAAAATCGT 
CGCATGAAGTGGGCTGCTGGAGGCG 3’ 
1. 5’-GTACCGCCTCCAGCAGCCCACTTCATGCGA 
CGATTTTGGAACCAG-3’ 
2. 5’-ATTGCAATTTGACGGCCTCCACCCTTGTCG 
TCATCGTCTTTGTAGTCTCCACCTGAT-3’ 
FLAG-PTD5 1. 5’-ATCAGGTGGAGACTACAAAGACGAT 
GACGACAAGGGTGGA-3’ 
2. 5’-CGTCGCCAACGACGGACTTCTAAA 
CTGATGAAGAGGGGAG-3’ 
1. 5’-GTACCTCCCCTCTTCATCAGTTTAGAAGTC 
CGTCGT-3’ 
2. 5’-TGGCGACGTCCACCCTTGTCGTCATCGTCT 
TTGTAGTCTCCACCTGAT-3’ 
  
 
The final expression vectors generated encode IL2ss-FLAG-TAT3-srΙκΒα-V5, 
IL2ss-FLAG-MAntp4-srΙκΒα-V5, IL2ss-FLAG-PTD5-srΙκΒα-V5 and IL2ss-FLAG-TAT-
srΙκΒα-V5 (Figure 3.6).  
 
3.2.1.5 IL2ss-FLAG-TAT3-NBD pFUSE expression vector 
 
To produce the IL2ss-FLAG-TAT3-NBD pFUSE expression vector the srIκΒα-
V5 segment was excised using the internal Asp718I/NheI sites from the IL2ss-FLAG-
TAT3-srΙκΒα-V5 pFUSE expression vector (Figure 3.6). Complementary strands of 
oligonucleotides                                                                                   (sense: 5’-
GTACCACGGCCCTAGACTGGAGCTGGTTACAGACGGAATAGG-3’ and anti-
sense:  5’-CTAGCCTATTCCGTCTGTAACCAGCTCCAGTCTAGGGCCGTG 3’) were 
annealed and subcloned in frame into the corresponding sites of the IL2ss-FLAG-
TAT3-srΙκΒα-V5 pFUSE vector. The final expression vector generated encodes 
IL2ss-FLAG-TAT3-NBD (Figure 3.7). 
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Figure 3.6: The restriction enzyme and genetic map of the IL2ss-FLAG-PTD*-srIκΒα-V5 
pFUSE expression vector. The FLAG-PTD*-srIκBa-V5 coding sequence is cloned 
immediately downstream the IL2ss sequence. PTD*: coding sequence of TAT, or TAT3, or 
MAntp4, or PTD5 PTD. FLAG: FLAG epitope tag. 
 
 
 
Figure 3.7: The restriction enzyme and genetic map of the IL2ss-FLAG-TAT3-NBD 
pFUSE expression vector. The FLAG-TAT3-NBD coding sequence is cloned immediately 
downstream the IL2ss sequence.  
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3.2.1.5 IL2ss-FLAG-TAT3-NBD-V5 pFUSE expression vector 
 
To produce the IL2ss-FLAG-TAT3-NBD-V5 pFUSE expression vector the 
srIκΒα-V5 segment was excised using the internal Asp718I/NheI sites from the IL2ss-
FLAG-TAT3-srΙκΒα-V5 pFUSE expression vector (Figure 3.6). Complementary 
strands of oligonucleotides (Table 3.2) were phosphorylated, annealed and ligated, 
as described in materials and methods. Ligated oligonucleotides were then 
subcloned in frame into the corresponding sites of the IL2ss-FLAG-TAT3-srΙκΒα-V5 
pFUSE expression vector. The final expression vector generated encodes IL2ss-
FLAG-TAT3-NBD-V5 (Figure 3.8). 
 
Table 3.2: Sequences of oligonucleotides that were used for the production of IL2ss-
FLAG-TAT3-NBD-V5 pFUSE expression vector 
Fragment  Sense oligonucleotides Anti-sense oligonucleotides 
NBD-V5 1. 5’-GTACCACGGCCCTAGACTGGAG CTGGTTACAGACGGAAGGTGGA-3’   
 
2. 5’-GGTAAGCCTATCCCTAACCCTCTC CTCG 
GTCTCGATTCTACGTAGG-3 
1. 5’-CTAGCCTACGTAGAATCGAGACCGAGGAGAGG 
GTTAG-3’ 
 
2. 5’-GGATAGGCTTACCTCCACCTTCCGTCTGTAAC 
CAGCTCCAGTCTAGGGCCGTG-3’ 
 
 
 
Figure 3.8: The restriction enzyme and genetic map of the IL2ss-FLAG-TAT3-NBD-V5 
pFUSE expression vector. The FLAG-TAT3-NBD-V5 coding sequence is cloned 
immediately downstream the IL2ss sequence.  
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The correct construction of the secretable PTD-fusion proteins expression 
vectors was verified by DNA restriction enzyme or PCR analysis from single clone 
bacterial cultures (Figures 3.9 - 13) and confirmed by DNA sequencing. 
 
 
 
Figure 3.9: DNA restriction enzyme analysis of the IL2ss-TAT-HA-srIκΒα-V5 (A) and 
IL2ss-TAT-HA-eGFP pFUSE expression vectors (B). (A) IL2ss-TAT-HA-srIκΒα-V5 pFUSE 
plasmid was digested with EcoRV and NheI to release the TAT-HA-srIκΒα-V5 fragment 
(1193 bp). The remaining digested vector fragment is 3488 bp long. (B) IL2ss-TAT-HA-eGFP 
pFUSE plasmid was digested with KpnI and NheI to release the eGFP fragment (743 bp). 
The remaining digested vector fragment is 3590 bp long. (1) 1 Kb Plus DNA ladder, (2) 
Unrestricted DNA construct, (3) Restricted DNA construct. 
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Figure 3.10: DNA restriction enzyme analysis of the IL2ss-mIgG2A Fc (A) and IL2ss-
TAT-HA-mIgG2A Fc pFUSE expression vectors (B). (A) IL2ss-mIgG2A pFUSE plasmid 
was digested with EcoRV and NheI to release the mIgG2A fragment (704 bp). The remaining 
digested vector fragment is 3488 bp long. (B) IL2ss-TAT-HA-mIgG2A Fc pFUSE plasmid was 
digested with KpnI and NheI to release the mIgG2A fragment (710 bp). The remaining 
digested vector fragment is 3590 bp long. (1) 1 Kb Plus DNA ladder, (2) Unrestricted DNA 
construct, (3) Restricted DNA construct. 
 
 
 
 
Figure 3.11: DNA restriction enzyme analysis of the IL2ss-TAT-HA-RBD pFUSE 
expression vector. (A) IL2ss-TAT-HA-RBD pFUSE plasmid was digested with EcoRV and 
NheI to release the TAT-HA-RBD fragment (378 bp). The remaining digested vector fragment 
is 3488 bp long. (1) 1 Kb DNA ladder, (2) Unrestricted DNA construct, (3) Restricted DNA 
construct. 
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Figure 3.12: DNA restriction enzyme analysis of the IL2ss-FLAG-TAT-srIκBα-V5 pFUSE 
(A), IL2ss-FLAG-TAT3-srIκBα-V5 pFUSE (B), IL2ss-FLAG-MAntp4-srIκBα-V5 pFUSE (C) 
and IL2ss-FLAG-PTD5-srIκBα-V5 pFUSE expression vectors (D). (A) IL2ss-FLAG-TAT-
srIκBα-V5 pFUSE plasmid was digested with EcoRV and NheI to release the FLAG-TAT-
srIκBα-V5 fragment (1172 bp). The remaining digested vector fragment was 3488 bp long. 
(B) IL2ss-FLAG-TAT3-srIκBα-V5 pFUSE plasmid was digested with EcoRV and NheI to 
release the FLAG-TAT3-srIκBα-V5 fragment (1172 bp). The remaining digested vector 
fragment was 3488 bp long. (C) IL2ss-FLAG-MAntp4-srIκBα-V5 pFUSE plasmid was 
digested with EcoRV and NheI to release the FLAG-MAntp4-srIκBα-V5 fragment (1193 bp). 
The remaining digested vector fragment was 3488 bp long. (D) IL2ss-FLAG-PTD5-srIκBα-V5 
pFUSE plasmid was digested with EcoRV and NheI to release the FLAG-PTD5-srIκBα-V5 
fragment (1175 bp). The remaining digested vector fragment was 3488 bp long. (1) 1 kb plus 
DNA ladder, (2) unrestricted DNA construct, (3) restricted DNA construct. 
 
 
 
Figure 3.13: PCR analysis of the IL2ss-FLAG-TAT3-NBD-V5 pFUSE (A) and IL2ss-
FLAG-TAT3-NBD pFUSE expression vectors (B). The FLAG-TAT3-NBD-V5 (A) and 
FLAG-TAT3-NBD (B) regions were amplified by PCR. PCR reactions were performed with 5 
µl of bacterial cultures as DNA template and GoTaq DNA polymerase, as described in 
Material and Methods. (1) 100 bp plus DNA ladder, (2) Single positive clones of FLAG-TAT3-
NBD-V5 (A) / FLAG-TAT3-NBD (B), (3) Absence of plasmid DNA served as negative control.  
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3.2.2 Expression and secretion of the TAT PTD-fusion proteins 
 
 
All TAT PTD-fusion proteins incorporated the TAT PTD in their N-terminus 
end. The TAT PTD-fusion proteins generated were the TAT-srIκΒα, TAT-eGFP, TAT-
RBD and TAT-mIgG2A. A schematic presentation of these 4 chimeras, with 
incorporated HA and V5 tags for their immunodetection, is shown in Figure 3.14. The 
HA epitope (YPYDVPDYA) derives from the haemagglutinin of the human influenza 
virus and V5 epitope (GKPIPNPLLGLDST) is from the C-terminal sequence of the P 
and V proteins of Simian Virus 5. 
 
 
 
Figure 3.14: Schematic representation of the TAT PTD-fusion proteins engineered to 
be secreted from expressing cells. ss: secretion signal, TAT: TAT PTD, HA: HA epitope 
tag, V5: V5 epitope tag.  
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To assess the ability of the various TAT PTD-fusion proteins to be expressed 
and secreted by mammalian cells, 293T cells were transiently transfected with the 
expression constructs or with the original pFUSE vector as positive control. 
Mammalian expression and secretion of the following constructs; TAT-srIκΒα, TAT-
eGFP, TAT-RBD and TAT-mIgG2A was demonstrated by western blotting analysis 
using a monoclonal antibody against the HA tag of the construct (Figures 3.15). The 
TAT-srIκΒα fusion protein was detected as 50 kDa protein, the TAT-eGFP protein 
was detected as a 30 kDa, the TAT-RBD protein was detected as a 15 kDa and the 
TAT-mIgG2A protein was detected as a 30 kDa, as expected from the length of their 
amino acid sequence.  
 
 
 
Figure 3.15: TAT PTD inhibits protein secretion. Lysates (A) and serum-free supernatants 
(B) were collected 24 hours after transfection and analysed by western blotting analysis. 10 
µg of total cell lysate and 30 µl out of 5 ml of supernatant were run on SDS-PAGE under 
reducing conditions, transferred onto PVDF membrane and probed with anti-HA antibodies 
overnight. mIgG2A was detected by HRP-conjugated F(ab’)2 secondary antibodies. Cell 
lysates membrane was exposed for 3 seconds and supernatants membrane was exposed for 
30 seconds. Determination of actin expression levels served for equal loading control.  
 
 
(1) Mock  (4) TAT-eGFP 
(2) mIgG2A (5) TAT-srIκBα 
(3)TAT-mIgG2A (6) ΤΑΤ-RBD 
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TAT-eGFP was the only TAT PTD-fusion protein that could be detected in 
unconcentrated supernatants with anti-HA antibodies from transiently transfected 
293T cells. In contrast, TAT-srIκΒα, TAT-RBD and TAT-mIgG2A fusion proteins could 
not be detected. A substantial amount of the produced mIgG2A was detected in the 
supernatant compared to the much lower secreted TAT-eGFP proteins (Figures 
3.15). The fact that TAT-mIgG2A proteins could not be detected in unconcentrated 
supernatants revealed that TAT PTD has a significant affect on the secretion pathway 
of secretable forms of TAT PTD-fusion proteins.  
In order to investigate secretion of the TAT-srΙκBα inhibitor, supernatant from 
transiently transfected 293T cells was concentrated 50 times with Aquacide I. 
Concentrated supernatant was analysed by western blotting using a monoclonal 
antibody against the V5 tag of the fusion protein (Figure 3.16). Similarly, supernatant 
from transiently transfected 293T cells with the TAT-eGFP construct was 
concentrated 50 times and analysed by western blotting using anti-GFP antibodies 
(Figure 3.16). Multiple bands could be detected in cells lysates and supernatants of 
transiently transfected 293T cells with the TAT-eGFP or TAT-srΙκΒα constructs, 
suggesting that post-translational modifications occur during the production and 
secretion of TAT PTD-fusion proteins (Figures 3.15-16). These experiments showed 
that proteins fused with the TAT PTD can be secreted when placed under the control 
of an appropriate secretion signal, however secretion efficiency is considerably lower 
when compared to a naturally secreted protein, such as mIgG2A. 
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Figure 3.16: Expression and secretion of TAT-fusion proteins from transiently 
transfected 293T cells. Lysates and serum-free supernatants were collected 24 hours after 
transfection with the indicated constructs. Supernatants were concentrated 50 times with 
Aquacide I and analysed by western blotting analysis. Equivalent amounts of cell lysates (5 µl 
out of 1 ml) and supernatants (30 µl) were run on SDS-PAGE under reducing conditions and 
transferred onto PVDF membrane. mIgG2A was probed with HRP-conjugated F(ab’)2, TAT-
eGFP with anti-GFP and TAT-srIκΒa with anti-V5 antibodies. Both lysates and supernatants 
membranes were exposed for 5 minutes.  
 
 
3.2.3 Expression and secretion of the PTD-srIκΒα fusion proteins 
 
 
All polypeptides incorporated the PTD in their N-terminus of srΙκΒα and the 
FLAG tag (DYKDDDDK) was also incorporated immediately upstream of the PTD. 
The PTD-srIκΒα fusion proteins generated were the TAT-srIκΒα, TAT3-srIκΒα, 
ΜAntp4-srIκΒα and PTD5-srIκΒα. Incorporation of the FLAG epitope enabled 
immunodetection of the full length PTD-fusion proteins, in order to understand 
whether multiple bands observed in Figure 3.16 were the result of intracellular 
degradation. A schematic representation of the 4 different PTD-srIκΒα fusion proteins 
with incorporated tags is shown in Figure 3.17. 
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Figure 3.17: Schematic representation of the FLAG-PTD-srΙκΒα-V5 proteins engineered 
to be secreted from expressing cells. ss: secretion signal, PTD: protein transduction 
domain, FLAG: FLAG epitope tag, V5: V5 epitope tag.  
 
 
293T cells were transiently transfected with the expression constructs or with 
the original pFUSE vector as positive control, in order to assess the levels of 
secretion of the various PTD-srIκΒα proteins. Mammalian expression and secretion of 
the 4 different PTD-srIκΒα constructs was demonstrated by western blotting analysis 
using a monoclonal antibody against the FLAG tag of the construct (Figure 3.18). The 
PTD-srIκΒα fusion proteins were detected around 50 kDa proteins as expected from 
the length of their amino acid sequence. Different PTD-srIκΒα proteins could not be 
detected in unconcentrated supernatant from transiently transfected 293T cells by 
western blotting analysis. Therefore the use of less positively charged PTDs did not 
increase the secretion efficiency of the TAT-srΙκΒα inhibitor. Furthermore, western 
blotting analysis with anti-V5 antibodies of lysates from transiently transfected 293T 
cells revealed the detection of multiple bands, which indicates that intracellular 
processing occurred during the expression and secretion of the 4 different PTD-
srIκΒα fusion proteins (Figure 3.19). 
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Figure 3.18: Exchanging TAT for other PTDs does not improve srΙκΒα secretion. 
Lysates (I) and serum-free supernatants (II) were collected 24 hours after transfection and 
analysed by western blotting analysis. 10 µg of total cell lysate and 30 µl out of 5 ml of 
supernatant were run on SDS-PAGE under reducing conditions, transferred onto PVDF 
membrane and probed with anti-FLAG antibodies overnight. mIgG2A was detected by HRP-
conjugated F(ab’)2 secondary antibodies. Cell lysates and supernatants membranes were 
exposed for 10 seconds. Determination of actin expression levels served for equal loading 
control.  (A) TAT-srIκBα, (B) TAT3-srIκBα, (C) MAntp4-srIκBα, (D) PTD5-srIκBα.  
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Figure 3.19: Post-translational modifications occur to all four different PTD-srΙκΒα 
constructs. Lysates were collected 24 hours after transfection and analysed by western 
blotting analysis. 10 µl out of 1 ml of total cell lysate were run on SDS-PAGE under reducing 
conditions, transferred onto PVDF membrane and probed with anti-FLAG or anti-V5 
antibodies overnight. Lysates from untransfected cells used as negative control. Cell lysates 
membranes were exposed for 1 minute. (1) TAT3-srIκBα, (2) MAntp4-srIκBα, (3) PTD5-
srIκBα. (4) TAT-srIκBα, (5) Mock. 
 
 
 
3.2.4 Expression and secretion of the TAT3-NBD fusion proteins 
 
 
All polypeptides incorporated the TAT3 PTD in their N-terminus of NBD and 
the FLAG tag (DYKDDDDK) was also incorporated immediately upstream of TAT3. 
Two versions of the TAT3-NBD inhibitors were generated. One inhibitor that contains 
the V5 tag epitope at the C-terminus end and one that does not. The incorporation of 
tag epitopes would enable immunodetection of the TAT3-NBD and investigation of 
possible post-translational modifications. A schematic representation of the two 
different TAT3-NBD inhibitors with incorporated tags is shown in Figure 3.20.  
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Figure 3.20: Schematic representation of the TAT3-NBD proteins engineered to be 
secreted from expressing cells. ss: secretion signal, TAT3: TAT3 PTD, FLAG: FLAG 
epitope tag, V5: V5 epitope tag.  
 
 
Supernatants and cell lysates from transiently transfected 293T cells with the 
TAT3-NBD expression constructs were analysed by western blotting analysis in order 
to assess the secretion properties of the TAT3-NBD proteins. However, TAT3-NBD 
proteins could not be detected in both lysates and supernatants due to their small 
size (~ 4.5 KDa), even after using specific western blotting conditions for small 
peptides as described by Schagger (2006) and Duchesne and Fernig (2007).     
 
 
3.2.5 Cell transduction by secreted TAT PTD-fusion proteins  
 
 
Jurkat T-cells were incubated with concentrated supernatant from TAT-eGFP 
transfections, in order to test the ability of the secreted TAT PTD-fusion proteins to 
transduce un-manipulated mammalian cells. Incubations were carried out at 37o C for 
2 and 4 hours with a 50 x concentrated supernatant, or with a 10 x concentrated 
supernatant for 4 hours, or with supernatant from pFUSE vector-transfected cells as 
negative control. After incubation, cells were treated with trypsin to eliminate surface-
bound protein, lysed and analysed for the presence of internalised TAT-eGFP by 
western blotting. Two protein bands migrating above 25 kDa marker were detected 
on anti-GFP immunoblots (Figure 3.21, bottom panel), which correlated with the size 
of the TAT-eGFP bands detected in the concentrated supernatants (Figure 3.21, top 
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panel). The intensity of the 2 bands was significantly reduced in cells incubated with 
10 x concentrated supernatant. However, no time dependency for the entry of TAT-
eGFP was observed (Figure 3.21, bottom panel). Therefore, secreted TAT-eGFP can 
transduce cells and its levels are directly proportional to its concentration in the 
supernatant.  
 
 
 
 
Figure 3.21: TAT-eGFP can translocate into Jurkat T-cells. 2 x 106 Jurkat T-cells were 
cultured with 1 ml of concentrated supernatant from TAT-eGFP secreting transiently 
transfected 293T cell cultures for the times shown (top panel). mIgG2A containing 
supernatants were used as negative control. After incubation, cells were trypsinised to 
eliminate membrane-bound proteins and lysed in 100 µl of lysis buffer (bottom panel). 35 µl 
from the supernatants and the cell lysates were probed with anti-GFP antibodies. 
Concentrated supernatants exposed for 5 minutes and lysates overnight. Percentages at the 
bottom panel indicate the percentages of TAT-eGFP entry compared to the total amount of 
TAT-eGFP detected both in the concentrated supernatant and in cell lysate of transduced 
cells. 
 
 
 
 
 
 Page | 97  
 
 Chapter III   
Similarly, Jurkat cells were incubated with 50 x concentrated TAT-srIκΒα 
supernatant from transiently transfected 293T cells or with 5 µg/ml of TAT-srIκΒα 
purified from bacteria (Kabouridis et al., 2002) as positive control for the cell 
transduction. As mentioned above the secreted TAT-srIκΒα is a mixture of at least 3 
different species, while the purified TAT-srIκΒα which contains additional sequences 
at the N-terminus migrates at approximately 50 kDa on SDS-PAGE (Figure 3.22). 
The E. coli purified TAT-srIκΒα used was also denatured compared to 293T cell 
produced TAT-srIκΒα, which had its natural conformation. As expected, E. coli 
purified TAT-srIκΒα transduced cells, as shown by the presence of a 50 kDa band 
appearing in anti-V5 western blots of cell lysates. Similarly, anti-V5 blots of lysates 
from cells treated with concentrated supernatant from transfected 293T cells 
containing TAT-srIκΒα, but not control supernatant, revealed a reactive band 
migrating above 37 kDa marker (Figure 3.22). This band corresponds to the smaller 
of the species seen in supernatant from transfected cells and its size is closer to the 
theoretical size estimated according to the primary sequence of fusion protein. 
However, western blotting analysis with anti-FLAG antibodies demonstrated that the 
full length TAT-srΙκΒα inhibitor migrate just below 50 κDa marker (Figure 3.19). The 
nature of the multiple bands in the concentrated supernatant is unknown, however it 
is more possible that are products of protein degradation, as there are several furin 
cleavage sites at the TAT PTD sequence. Therefore, the finding that one band can 
only be detected in cell lysates could be explained as the result of intracellular 
degradation of the translocated TAT-srΙκΒα.  
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Figure 3.22: Cell transduction by secreted TAT-srIκBα. 2 x 106 Jurkat T-cells were 
incubated with 1 ml of 50 x concentrated supernatant containing TAT-srIκBα or with 1 ml of 5 
µg/ml E. coli purified TAT-srIκBα as positive control. mIgG2A containing supernatant was 
used as negative control. Following 4 hours of incubation at 37o C, cells were trypsinized to 
eliminate membrane-bound proteins and lysed in 100 µl of lysis buffer. 35 µl from the 
supernatants and cell lysates were run on SDS-PAGE under reducing conditions and 
transferred onto PVDF membrane and probed with anti-V5 antibodies. Both supernatants and 
lysates exposed for 1 hour. Percentages indicate the percentages of TAT-srΙκΒα entry 
compared to the total amount of TAT-srΙκΒα detected both in the concentrated supernatant 
and in cell lysate of transduced cells. 
 
 
3.2.6 Subcellular localisation of internalized TAT PTD-fusion 
proteins 
 
 
 Jurkat T-cells were incubated with supernatants containing concentrated TAT-
eGFP produced in transiently transfected 293T cells or purified TAT-eGFP produced 
in bacteria in order to investigate the subcellular location of TAT PTD-fusion proteins 
after cell transduction. Following incubation, cells were stained with anti-eGFP 
antibodies and analysed by confocal microscopy. Cells treated with supernatant from 
untransfected cells and stained with anti-GFP antibodies served as negative control. 
Figure 3.23 shows internalization of TAT PTD-fusion proteins in cells treated with 5 
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µg/ml E. coli purified TAT-eGFP or 50 x concentrated TAT-eGFP supernatants. Most 
of the protein was located in the cytoplasm and showed a punctuated staining 
pattern. TAT-eGFP also was visualized in Jurkat cells after treatement with 50 x 
concentrated TAT-eGFP supernatants without any immunostaining (Figure 3.24). 
This result excludes the possibility of TAT-eGFP transduction to be due to a fixation 
artefact. 
Similarly, Jurkat T-cells were incubated with supernatants containing 
concentrated TAT-srIκΒα produced in 293T cells or purified TAT-srIκΒα produced in 
bacteria. Following incubation and anti-V5 staining of treated Jurkat cells, internalised 
TAT-srIκΒα revealed a more punctuated staining pattern compared to TAT-eGFP, 
where most of the fluorescence was concentrated in structures located in one side of 
the cell rather than throughout of the cytoplasm. More specifically, TAT-srIκΒα was 
seen localised in a defined structure adjoining the nucleus (Figure 3.25).  
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Figure 3.23: Different intracellular distribution of translocated TAT-eGFP produced in 
E. coli or mammalian cells. 2 x 106 Jurkat T-cells were incubated with control supernatant 
from untransfected 293T cells, 1 ml of 5 µg/ml purified TAT-eGFP, or 1 ml of 50 x 
concentrated supernatant containing secreted TAT-eGFP for 4 hours at 37o C. Following 
incubation cells were washed, fixed, permeabilised, stained with anti-GFP antibodies and 
labeled with Alexa-488-conjugated anti-mouse antibodies. Background fluorescence was set 
by staining control supernatant-treated cells with anti-GFP antibodies. Two representative 
pictures are shown from each incubation. Bar = 5 µm. 
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Figure 3.24: Subcellular localisation of internalised TAT-eGFP proteins that were 
produced from mammalian cells. 2 x 106 Jurkat T-cells were incubated with control 
supernatant from untransfected 293T cells or 1 ml of 50 x concentrated supernatant 
containing secreted TAT-eGFP for 4 hours at 37o C. Following incubation cells were treated 
briefly with trypsin, washed and then immediately imaged by confocal microscopy. Two 
representative pictures are shown from each incubation. Bar = 5 µm. 
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Figure 3.25 Internalised TAT-srIκBα proteins localise to vesicular structures. 2 x 106 
Jurkat T-cells were incubated with control supernatant from untransfected 293T cells, 1 ml of 
5 µg/ml purified TAT-srIκBα or 1 ml of 50 x concentrated supernatant containing secreted 
TAT-srIκBα. Following incubation cells were washed, fixed, permeabilised, stained with anti-
V5 antibodies and labeled with Alexa-488-conjugated anti-mouse antibodies. Background 
fluorescence was set by staining control supernatant-treated cells with anti-V5 antibodies. 
Two representative pictures are shown from each incubation. Bar = 5 µm. 
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Double and triple staining of Jurkat T-cells after treatment with concentrated 
supernatant containing TAT PTD-fusion proteins was performed in order to obtain 
more information regarding the cellular structures to which internalised TAT PTD-
fusion proteins were localising and to gain information regarding the mechanism of 
entry of these proteins. Recent studies have shown that PTD-fusion proteins are 
internalised via caveolae/lipid raft-mediated endocytosis (Fittipaldi et al., 2003; Wadia 
et al., 2004). To assess whether the secretable TAT-srIκΒα inhibitor in our system 
uses lipid rafts to enter cells, Jurkat T-cells were treated with control or TAT-srIκΒα 
concentrated supernatant from transiently transfected 293T cells or purified TAT-
srIκΒα from bacteria and stained with anti-V5 antibodies and CTB, which binds to the 
lipid raft marker GMI. In Figure 3.26, the structures/vesicles to which most of the 
internalised TAT-srIκΒα was concentrated was also stained for the lipid raft marker 
GMI indicating co-localisation. In contrast, the pool of internalised TAT-srIκΒα that 
migrates into the nucleus in some treated cells (Figure 3.26) does not co-localise with 
CTB. 
Treated cells were also stained with an antibody to Giantin, a marker for Golgi, 
plus anti-GFP or anti-V5 respectively, in order to understand if the structure adjoining 
the nucleus to which a portion of the internalised TAT-eGFP and the majority of TAT-
srIκΒα localise in the Golgi apparatus. The DRAQ5TM DNA-binding dye was used to 
reveal the cell nucleus. As mentioned above, internalised TAT-eGFP was present in 
the cytoplasm and a portion of the protein localised to the Golgi as shown by its co-
localisation with anti-Giantin antibodies (Figure 3.27A). In the case of TAT-srIκΒα 
treated cells most of the internalised protein was concentrated in the Golgi apparatus, 
as shown by the merging of the anti-V5 and anti-Giantin images (Figure 3.27B). This 
confocal microscopy study revealed that lipid rafts play a role in the internalisation of 
TAT PTD-fusion proteins and that part of the internalised protein concentrates in the 
Golgi apparatus, though levels may vary depending on the nature of the transducing 
protein. 
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FIGURE 3.26: Co-localization of internalised TAT-srIκBα with a lipid raft marker. 2 x 106 
Jurkat T-cells were cultured for 4 hours with control supernatant, 1 ml of 5 µg/ml purified 
TAT-srIκBα, or 1 ml of 50 x concentrated supernatant containing secreted TAT-srIκBα. 
Following incubation cells were fixed, permeabilised and double stained with anti-v5/anti-
mouse-Alexa 488 (green) and CTB-Alexa-555 (red). Co-localization of green and red 
fluorescence is indicated by the development of yellow pseudo-colour merged images. Bar = 
10 µm. 
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Figure 3.27:  Localisation of internalised TAT PTD-fusion proteins to the Golgi 
apparatus. (A) Jurkat T-cells were were cultured for 4 hours with control supernatant, 1 ml of 
5 µg/ml purified TAT-eGFP or 50 x concentrated supernatant containing secreted TAT-eGFP 
and triple stained with anti-GFP (green), anti-Giantin (red) and DRAQ5TM nuclei staining 
(blue) to visualize internalised TAT-eGFP, Golgi and nucleus respectively. (B) Jurkat T-cells 
were cultured with control, 1 ml of 5 µg/ml purified TAT-srIκBα or 50 x concentrated 
supernatant containing secreted TAT-srIκBα and immunostained with anti-V5 (green) and 
anti-Giantin (red) antibodies and DRAQ5TM nuclei staining (blue). Development of yellow 
pseudo-colour indicates colocalization of TAT PTD-fusion protein with the Golgi marker 
Giantin. Bar = 10 µm. 
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3.3 Discussion 
 
 
The secretion signal from IL2 gene was initially employed for the generation of 
secretable PTD-fusion proteins. The different secretable PTD-fusion proteins 
generated are shown in Table 3.3. The inhibitors srΙκΒα, RBD, NBD, the reporter 
protein eGFP and the immunoglobulin mIgG2A were used as cargo proteins and four 
different PTDs (TAT, TAT3, MAntp4, PTD5) were tested. 
 
 
Table 3.3: Secretable PTD-fusion proteins under the control of IL2 secretion signal. 
IL2ss-TAT-HA-srΙκΒα-V5 
IL2ss-TAT-HA-eGFP 
IL2ss-TAT-HA-RBD 
IL2ss-TAT-HA-mIgG2A 
IL2ss-FLAG-TAT-srΙκΒα-V5 
IL2ss-FLAG-TAT3-srΙκΒα-V5 
IL2ss-FLAG-MAntp4-srΙκΒα-V5 
IL2ss-FLAG-PTD5-srΙκΒα-V5 
IL2ss-FLAG-TAT3-NBD 
IL2ss-FLAG-TAT3-NBD-V5 
 
  
This study has demonstrated that PTD-fusion proteins can be secreted from 
transiently secreted 293T cells, however their secretion efficiency is very low 
compared to mIgG2A immunoglobulin, which is a naturally secreted protein (Figures 
3.15 - 3.18). Similarly, other groups that have shown secretion of PTD-fusion 
proteins, have reported low levels of secretion (Barka et al., 2004; Flinterman et al., 
2009; Shaw et al., 2008). The only study that shows secretion of a PTD-fusion 
inhibitor is by Flinterman et al., (2009), where secretion of an anti-cancer protein 
apoptin was achieved by fusing the inhibitor with the PTD-eGFP molecule. However, 
here I show that secretion of TAT-srΙκΒα inhibitor is possible without the use of eGFP 
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as cargo protein (Figure 3.16). Clearly TAT PTD plays an important role in the 
secretion of the fusion protein, as fusion of TAT PTD to mIgG2A revealed its 
detrimental effect on the secretion of the immunoglobulin. One feature of the TAT 
PTD that could influence secretion efficiency is the presence of a furin cleavage site 
RX(K/R)R. Furin, a membrane bound serine protease located in the golgi could 
therefore cleave TAT at this site which would lead to removal of the secretion signal 
so preventing secretion of the molecule. This potential interference was also noted by 
Flinterman et al., (2009), so they engineered a synthetic PTD sequence TATκ-PTD 
devoid of a furin cleavage site. However, Shaw et al. (2008) showed that treating 
cells with a furin inhibitor did not increase secretion of a PTD-CRE molecule 
containing the furin cleavage site (Shaw et al., 2008). Comparison of the secretion 
levels in different TAT PTD-fusion proteins has revealed differences in secretion 
indicating that the protein cargo of the TAT PTD-fusion proteins plays also a role in 
the secretion. More specifically, TAT-eGFP appeared to be more efficiently secreted, 
as it was the only TAT PTD-fusion protein that could be detected in unconcentrated 
supernatants.  
In a recent relevant study, Shaw et al. (2008) found that less positively 
charged PTDs demonstrated higher levels of secretion, when fused to CRE 
recombinase. Here, the TAT PTD of TAT-srΙκΒα was also replaced in order to 
increase the secretion efficiently of the PTD-fusion NF-κΒ inhibitor. The TAT3 and 
MAntp4 less positively charged PTDs and PTD5 another positively charged PTD not 
studied before were used. The FLAG tag epitope was also incorporated immediately 
upstream the PTD in order to investigate possible degradation that may occur 
intracellularly, as anti-FLAG antibodies could only detect the full length inhibitors, 
which can explain the different species of proteins that were observed with anti-V5 
antibodies after western blotting analysis (Figure 3.19). TAT3-srΙκΒα, ΜAntp4-srΙκΒα 
and PTD5-srΙκΒα could not be detected in unconcentrated supernatants from 293T 
cells, therefore change of the TAT PTD did not increase the secretion levels of the 
PTD-fusion inhibitor. Interestingly, cell lysates probed with anti-FLAG antibodies 
revealed only one band, in contrast to the multiple bands observed in cell lysates 
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when probed with anti-V5 antibodies (Figure 3.19). This indicates that intracellular 
degradation occurs during the synthesis and secretion of PTD-srIκΒα inhibitors.  
Shaw et al., (2008) also tried to secrete the CRE recombinase by cloning the 
coding sequence of this protein immediately downstream the IgH secretion signal in 
the absence of any PTD, as a control for the secretable PTD-CRE fusion protein. 
Interestingly, they observed very low secretion levels of CRE recombinase alone. An 
explanation for this can be the fact that the CRE recombinase used had the SV40 
NLS sequence at the N-terminus. Therefore, although the protein is engineered to be 
secreted, the NLS signal can drive the protein into the nucleus, thus inhibiting its 
secretion. Similarly, the srIkBa inhibitor naturally contains a nuclear import sequence 
within the second ankyrin repeat (Sachdev et al., 1998; Turpin et al., 1999), which 
can contribute to the inefficient secretion of the PTD-srΙκΒα inhibitor. 
The NF-κΒ inhibitor NBD, which blocks the formation of IKK complex, was also 
employed in this study, in order to generate an efficiently secreted PTD-fusion 
inhibitor. NBD inhibitor was selected because is a small inhibitor and lacks any 
nuclear localisation sequence. NBD was only fused to the TAT3 PTD, because it is 
not a very positively charged PTD, showed highest levels of secretion in a similar 
study and demonstrated the strongest transduction efficiency when compared to 
other PTDs (Ho et al., 2001; Shaw et al., 2008). However, TAT3-NBD inhibitor could 
not be detected in both cell lysates and supernatants from transiently transfected 
293T cells by western blotting analysis due to its very small size (~ 4.5 KDa) and it is 
not known how efficiently this PTD-fusion protein is secreted.   
Jurkat T-cells were incubated with concentrated supernatant from transiently 
transfected 293T cells, containing TAT-srΙκΒα or TAT-eGFP fusion proteins in order 
to investigate the ability of the secreted PTD-fusion proteins from mammalian cells to 
transduce unmanipulated cells. Both western blotting and confocal microscopy 
analysis have revealed successful transduction of Jurkat cells by TAT-srΙκΒα and 
TAT-eGFP proteins. Therefore, PTD-fusion proteins that were produced and secreted 
from mammalian cells were able to transduce unmanipulated cells.  
An important question currently addressed by a number of groups is to 
understand how PTDs can enter cells. There is good evidence that cell surface 
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heparin sulphate proteoglycans play a role in the initial binding of a positively charged 
PTD to the cell surface (Console et al., 2003; Suzuki et al., 2002; Tyagi et al., 2001). 
Subsequently, entry of PTDs and their associated cargo into cells most likely occurs 
through energy-dependent endocytosis (Drin et al., 2003; Richard et al., 2003). Lipid 
raft and caveolae are reported to mediate, at least in part, endocytosis of PTDs 
(Fittipaldi et al., 2003; Wadia et al., 2004). Clathrin-mediated endocytosis has also 
been reported (Richard et al., 2005). What happens to the endocytosed material 
remains largely unknown. Internalised TAT-srIκBα has been previously shown to 
associate with endogenous NF-κB in transduced cells (Kabouridis et al., 2002). 
However, most likely only a portion of internalised TAT-srIκBα escapes from 
endocytic vesicles to find its target. Furthermore, different PTDs or PTD-fusion 
proteins may be targeted to different cell compartments. Therefore, generalizations 
should be avoided and endocytosis and subcellular localization of individual PTD-
fusion proteins should be assessed independently. 
In this study, by investigating cell entry of the secreted TAT-srΙκΒα and TAT-
eGFP, most of the internalised TAT-fusion proteins were found to concentrate in 
vesicular structures with the majority of TAT-srΙκΒα concentrating in a district area of 
the cell adjoining the nucleus (Figures 3.26 - 3.27). Confocal imaging of dually 
stained cells transduced with the secreted TAT-srΙκΒα showed colocalisation 
between GM1, a marker for lipid rafts, and internalised TAT-srΙκΒα (Figure 3.26). This 
result suggests that the secreted TAT-srΙκΒα uses a mechanism for cell entry similar 
to purified TAT PTD. It has also been reported that uptake of TAT PTD by HeLa cells 
involves the Golgi apparatus. More specifically, bodipy ceramide, a Golgi marker, was 
shown to partially colocalise with labelled TAT PTD (Fischer et al., 2004). The 
particular finding, in my study, that the secreted TAT-srΙκΒα concentrates in a distinct 
vesicular structure adjoining the nucleus led me to investigate if this structure 
overlaps with Golgi. Using Giantin, a specific antibody to visualise the Golgi, I found 
that there was substantial localisation of internalised TAT-srΙκΒα, and to a lesser 
degree of TAT-eGFP, to the Golgi apparatus (Figure 3.27). These results suggest 
that following their binding to the cell surface, secreted TAT-fusion proteins may use 
a retrograde mechanism of transport to the Golgi. The fate of internalised proteins 
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after the Golgi remains unknown and it could depend on the nature of the protein 
partner of TAT PTD. Here, some nuclear localisation of TAT-srΙκΒα has been 
observed (Figure 3.26, middle panel). It is also worth mentioning that TAT-eGFP 
internalisation without anti-GFP antibody immunostaining was also visualised, 
confirming that TAT-eGFP entry was not an imaging artefact (Figure 3.24).  
 
  
 
 
  
 
Chapter IV:                    
Genetic construction and in vitro 
characterisation of the secretable 
LAP-PTD-fusion proteins 
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4.1 Introduction 
 
 
PTD-fusion proteins were fused to the LAP peptide, which has secretion signal 
properties, via an MMP cleavage site in order to increase their ability to be secreted 
from expressing mammalian cells. The LAP peptide derives from TGFβ (Wakefield et 
al., 1990) and previous work in our laboratories has demonstrated latency of IFNβ 
when fused to LAP (Adams et al., 2003). Therefore, the advantage of this approach 
was that the LAP peptide would enable encapsulation of the PTD-fusion proteins and 
protect them from intracellular interactions and modifications, thus increased levels of 
secretion could be achieved. Additionally, the incorporation of the MMP cleavable site 
(Nagase and Fields, 1996; Peng et al., 1997; Ye et al., 1995), between the LAP 
peptide and the PTD-fusion protein would result in the release of the PTD-fusion 
inhibitor only at sites of the disease where levels of MMPs are high. Overexpression 
of MMPs has been observed at the inflammatory sites of rheumatic diseases, and 
more specifically MMP-1, MMP-3 and MMP-9 have an increased expression and 
activity in patients with rheumatoid arthritis (Martel-Pelletier et al., 2001; Tchetverikov 
et al., 2004). This overexpression of MMPs is mainly associated with cartilage 
degradation in arthritic diseases. The release of the PTD-fusion inhibitor only at sites 
of the disease, would in turn increase the safety of this gene therapy approach, as 
the LAP-PTD-fusion inhibitors would only be active at the sites of inflammation. The 
use of the LAP peptide secretion signal would also enabled the exploration of the 
effect the secretion signal could have had on the secretion of PTD-fusion inhibitors. 
Initially, the TAT-HA-RBD region was subcloned immediately downstream the LAP-
MMP region in the LAP-MMP pcDNA3 cloning vector (Figure 4.1). Similarly, 4 LAP-
MMP-FLAG-PTD-srΙΚΒα-V5 pcDNA3 constructs (PTD: TAT, or TAT3, or MAntp4, or 
PTD5); and LAP-MMP-FLAG-TAT3-NBD and LAP-MMP-FLAG-TAT3-NBD-V5 
pcDNA3 constructs were generated.  
The ability of the secretable LAP-PTD-fusion proteins to be secreted from 
mammalian cells was investigated by western blotting analysis of supernatants from 
transiently transfected 293T cells. 
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4.2 Results 
 
 
4.2.1 Generation of the secretable LAP-PTD-fusion proteins 
expression vectors 
 
 
4.2.1.1 LAP-MMP-TAT-HA-RBD pcDNA3 expression vector 
 
Cloning of the LAP-MMP fragment into the eukaryotic expression vector 
pcDNA3 (a kind gift from Dr. S. Vessillier, London, UK, Figure 4.1) has been 
described previously by Adams et al. (2003). Using the IL2ss-TAT-HA-RBD pFUSE 
expression vector as template (Figure 3.4), the TAT-HA-RBD region was amplified by 
PCR using the forward primer 5’-TAAGCGGCCGCCTACGGCCGCAAGAAACGC-3’ 
and the reverse primer 5’-CGCTCTAGACTACAGGAAATCTACTTGAAG-3’. The PCR 
product was then recovered from the PCR reaction by ethanol precipitation, digested 
with NotI/Xbal (underlined sites) and subcloned in frame into the corresponding sites 
of the LAP-MMP pcDNA3 expression vector (Adams et al., 2003). The final 
expression vector generated encodes LAP-MMP-TAT-HA-RBD (Figure 4.2).  
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Figure 4.1: The restriction enzyme and genetic map of the LAP-MMP pcDNA3 vector. 
LAP-MMP pcDNA3 plasmid contains the coding sequence of LAP peptide from TGFβ1. This 
sequence is followed by the coding sequence of a flexible linker (GGGGS), a MMP cleavage 
site (PLGLWA) and another flexible portion (GGGGSAAA) and the expression of the fusion 
protein is under the control of CMV enhancer and T7 promoter. The plasmid also contains an 
Ampicillin resistance gene for selection in E. coli and a Neomycin resistance gene for 
selection in mammalian cells under the control of Simian Virus 40 (SV40) promoter. The 
origin of replication (ori) is derived from SV40. The gene/promoter transcription direction is 
indicated by the arrow shapes. 
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Figure 4.2: The restriction enzyme and genetic map of the LAP-MMP-TAT-RBD pcDNA3 
vector. The TAT-HA-RBD coding sequence is cloned immediately downstream the LAP-
MMP sequence. 
 
 
4.2.1.2 LAP-MMP-FLAG-PTD*-srΙκΒα-V5 pcDNA3 expression vectors 
(PTD* = TAT, or TAT3, or MAntp4, or PTD5) 
 
Using the IL2ss-FLAG-PTD*-srΙκΒα-V5 pFUSE expression vectors (Figure 3.6) 
as template the FLAG-PTD*-srΙκΒα-V5 regions were amplified by PCR using the 
forward primer 5’-TAAGCGGCCGCCGGTGGAGACTACAAAGAC-3’ and the reverse 
primer 5’-CGCTCTAGATCAGGTGGAGTCCAATCCCAG-3’. The PCR products were 
then recovered from the PCR reaction by ethanol precipitation, digested with 
NotI/Xbal (underlined sites) and subcloned in frame into the corresponding sites of 
the LAP-MMP pcDNA3 expression vector (Figure 4.1). The final expression vectors 
generated encode LAP-MMP-FLAG-PTD*-srΙκΒα-V5 (Figure 4.3). 
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Figure 4.3: The restriction enzyme and genetic map of the LAP-MMP-FLAG-PTD*-
srIκΒα-V5 pcDNA3 vector. The FLAG-PTD*-srIκΒa-V5 coding sequence is cloned 
immediately downstream the LAP-MMP sequence. 
 
 
4.2.1.3 LAP-MMP-FLAG-TAT3-NBD pcDNA3 expression vector 
 
Using the IL2ss-FLAG-TAT3-NBD pFUSE expression vector as template 
(Figure 3.7) the FLAG-TAT3-NBD region was amplified by PCR using the forward 
primer 5’-TAAGCGGCCGCCGGTGGAGACTACAAAGAC-3’ and the reverse primer 
5’-CGCTCTAGATCATTCCGTCTGTAACCAGCT-3’. The PCR product was then 
recovered from the PCR reaction by ethanol precipitation, digested with NotI/Xbal 
(underlined sites) and subcloned in frame into the corresponding sites of the LAP-
MMP pcDNA3 expression vector (Figure 4.1). The final expression vector generated 
encodes LAP-MMP-FLAG-TAT3-NBD (Figure 4.4). 
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Figure 4.4: The restriction enzyme and genetic map of the LAP-MMP-FLAG-TAT3-NBD 
pcDNA3 vector. The FLAG-TAT3-NBD coding sequence is cloned immediately downstream 
the LAP-MMP sequence. 
 
 
4.2.1.4 LAP-MMP-FLAG-TAT3-NBD-V5 pcDNA3 expression vector 
 
Using the IL2ss-FLAG-TAT3-NBD-V5 pFUSE expression vector as template 
(Figure 3.8), the FLAG-TAT3-NBD-V5 region was amplified by PCR using the forward 
primer 5’-TAAGCGGCCGCCGGTGGAGACTACAAAGAC-3’ and the reverse primer 
5’-CGCTCTAGATCAGGTGGAGTCCAATCCCAG-3’. The PCR product was then 
recovered from the PCR reaction by ethanol precipitation, digested with NotI/Xbal 
(underlined sites) and subcloned in frame into the corresponding sites of the LAP-
MMP pcDNA3 expression vector (Figure 4.1). The final expression vector generated 
encodes LAP-MMP-FLAG-TAT3-NBD-V5 (Figure 4.5). 
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Figure 4.5: The restriction enzyme and genetic map of the LAP-MMP-FLAG-TAT3-NBD-
V5 pcDNA3 vector. The FLAG-TAT3-NBD-V5 coding sequence is cloned immediately 
downstream the LAP-MMP sequence. 
 
 
Correct construction of the secretable LAP-MMP-PTD-fusion proteins 
expression vectors was verified by DNA restriction enzyme or PCR analysis from 
single clone bacterial cultures (Figures 4.6 - 8) and confirmed by DNA sequencing. 
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Figure 4.6: DNA restriction enzyme analysis of the LAP-MMP-TAT-HA-RBD pcDNA3 
expression vector. LAP-MMP-TAT-HA-RBD pcDNA3 plasmid was digested with NotI and 
XbaI to release the TAT-HA-RBD fragment (353 bp). The remaining digested vector fragment 
was 6238 bp long. (1) 1 kb plus DNA ladder, (2) unrestricted DNA construct, (3) restricted 
DNA construct. 
 
 
 
Figure 4.7: PCR analysis of the LAP-MMP-FLAG-TAT-srIκBα-V5 pcDNA3 (A), LAP-MMP-
FLAG-TAT3-srIκBα-V5 pcDNA3 (B), LAP-MMP-FLAG-MAntp4-srIκBα-V5 pcDNA3 (C) 
and LAP-MMP-FLAG-PTD5-srIκBα-V5 pcDNA3 expression vectors (D). The LAP-MMP-
FLAG-PTD*-srIκΒα-V5 region was amplified by PCR. PCR reactions were performed with 5 
µl of bacterial cultures as DNA template and GoTaq DNA polymerase, as described in 
Material and Methods. (1) 1 kb plus DNA ladder, (2) Single positive clones of LAP-MMP-
FLAG-PTD*-srIκΒα-V5, (3) Absence of plasmid DNA served as negative control. PTD* = 
TAT, or TAT3, or MAntp4, or PTD5. 
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Figure 4.8: PCR analysis of the LAP-MMP-FLAG-TAT3-NBD pcDNA3 (A) and LAP-MMP-
FLAG-TAT3-NBD-V5 pcDNA3 expression vectors (B). The LAP-MMP-FLAG-TAT3-NBD 
(A) and LAP-MMP-FLAG-TAT3-NBD-V5 (B) regions were amplified by PCR. PCR reactions 
were performed with 5 µl of bacterial cultures as DNA template and GoTaq DNA polymerase, 
as described in Material and Methods. (1) 1 bp plus DNA ladder, (2) Single positive clones of 
LAP-MMP-FLAG-TAT3-NBD (A) / LAP-MMP-FLAG-TAT3-NBD-V5 (B), (3) Absence of 
plasmid DNA served as negative control.  
 
 
4.2.2 Expression and secretion of the LAP-MMP-PTD-fusion 
proteins  
 
 
All LAP-MMP-PTD-fusion proteins incorporated the LAP-MMP-PTD fragment 
in their N-terminus end. The LAP-MMP-PTD-fusion proteins generated were the LAP-
MMP-TAT-RBD, LAP-MMP-TAT-srIκΒα, LAP-MMP-TAT3-srIκΒα, LAP-MMP-MAntp4-
srIκΒα, LAP-MMP-PTD5-srIκΒα and two versions of LAP-MMP-TAT3-NBD (one with 
a V5 tag epitope and the other without). A schematic representation of LAP-MMP-
PTD-fusion proteins, with incorporated FLAG, HA or V5 tags for their 
immunodetection, that were generated is shown in Figure 4.9. 
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Figure 4.9: Schematic representation of the LAP-MMP-PTD-fusion proteins engineered 
to be secreted from expressing cells. LAP: Latency Associated Peptide from TGFβ1, 
ΜΜP: Matrix Metalloproteinase site, PTD: Protein Transduction Domain, TAT: TAT PTD, 
TAT3: TAT3 PTD, FLAG: FLAG epitope tag, HA: HA epitope from the haemagglutinin of the 
human influenza virus, V5: V5 epitope from the c-terminal sequence of the p and v proteins of 
simian virus 5. 
 
 
293T cells were transiently transfected with the expression constructs or with 
the original pFUSE vector as positive control, in order to assess the secretion levels 
of the various LAP-MMP-PTD-fusion proteins. Mammalian expression and secretion 
of the different constructs was demonstrated by western blotting analysis (Figures 
4.10 - 15). The LAP-MMP-PTD-srIκΒα fusion protein was detected as a 75 kDa 
protein, the LAP-MMP-TAT3-NBD protein as a 40 kDA and the LAP-MMP-TAT-RBD 
protein as a 50 kDa, as expected from the length of their amino acid sequence. 
Different LAP-MMP-PTD-srIκΒα proteins could not be detected in unconcentrated 
supernatant from transiently transfected 293T cells by western blotting analysis. 
Therefore the use of LAP did not increase the secretion efficiency of the PTD-srΙκΒα 
inhibitors. In contrast, LAP-MMP-TAT3-NBD and LAP-MMP-TAT-RBD inhibitors 
demonstrated high levels of secretion. This finding revealed that LAP peptide enables 
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the efficient secretion of small PTD-fusion molecules / inhibitors. Interestingly, the 
LAP-MMP-TAT3-NBD inhibitor was more efficiently secreted compared to the LAP-
MMP-TAT3-NBD-V5 inhibitor (Figure 4.15), suggesting that the presence of V5 had 
an inhibitory effect on the secretion of the inhibitor. Furthermore, western blotting 
analysis with anti-FLAG antibodies of lysates from transiently transfected 293T cells 
revealed the detection of multiple bands, which indicates intracellular processing that 
occurred during the expression and secretion process of the LAP-MMP-PTD-fusion 
proteins. Interestingly, the higher molecular weight bands, which represent 
glycosylated forms, are those that can be detected in supernatants (Figure 4.15). 
 
 
 
Figure 4.10: LAP-MMP-TAT-RBD is efficiently secreted from transiently transfected 
293T cells. Lysates (A) and serum-free supernatants (B) were collected 24 hours after 
transfection and analysed by western blotting analysis. 5 µl out of 1 ml of total cell lysate and 
30 µl out of 5 ml of supernatant were run on SDS-PAGE under reducing conditions, 
transferred onto PVDF membrane and probed with anti-HA antibodies overnight. mIgG2A 
was detected by HRP-conjugated F(ab’)2 secondary antibodies. Cell lysates and 
supernatants membranes were exposed for 3 minutes. (1) Mock, (2) mIgG2A, (3) LAP-MMP-
TAT-RBD.  
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Figure 4.11: LAP-MMP-TAT-srIκΒα is not detectable in supernatants from transiently 
transfected 293T cells, but LAP-MMP-TAT3-NBD is easily detectable. Lysates (A) and 
serum-free supernatants (B) were collected 24 hours after transfection and analysed by 
western blotting analysis. 10 µg of total cell lysate and 30 µl out of 5 ml of supernatant were 
run on SDS-PAGE under reducing conditions, transferred onto PVDF membrane and probed 
with anti-FLAG antibodies overnight. mIgG2A was detected by HRP-conjugated F(ab’)2 
secondary antibodies. Cell lysates and supernatants membranes were exposed for 10 
seconds. Determination of actin expression levels served for equal loading control.  
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Figure 4.12: LAP-MMP-TAT3-srIκΒα is not detectable in supernatants from transiently 
transfected 293T cells, but LAP-MMP-TAT3-NBD is easily detectable. Lysates (A) and 
serum-free supernatants (B) were collected 24 hours after transfection and analysed by 
western blotting analysis. 10 µg of total cell lysate and 30 µl out of 5 ml of supernatant were 
run on SDS-PAGE under reducing conditions, transferred onto PVDF membrane and probed 
with anti-FLAG antibodies overnight. mIgG2A was detected by HRP-conjugated F(ab’)2 
secondary antibodies. Cell lysates and supernatants membranes were exposed for 10 
seconds. Determination of actin expression levels served for equal loading control. 
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Figure 4.13: LAP-MMP-MAntp4-srIκΒα is not detectable in supernatants from 
transiently transfected 293T cells, but LAP-MMP-TAT3-NBD is easily detectable. 
Lysates (A) and serum-free supernatants (B) were collected 24 hours after transfection and 
analysed by western blotting analysis. 10 µg of total cell lysate and 30 µl out of 5 ml of 
supernatant were run on SDS-PAGE under reducing conditions, transferred onto PVDF 
membrane and probed with anti-FLAG antibodies overnight. mIgG2A was detected by HRP-
conjugated F(ab’)2 secondary antibodies. Cell lysates and supernatants membranes were 
exposed for 10 seconds. Determination of actin expression levels served for equal loading 
control. 
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Figure 4.14: LAP-MMP-PTD5-srIκΒα is not detectable in supernatants from transiently 
transfected 293T cells, but LAP-MMP-TAT3-NBD is easily detectable. Lysates (A) and 
serum-free supernatants (B) were collected 24 hours after transfection and analysed by 
western blotting analysis. 10 µg of total cell lysate and 30 µl out of 5 ml of supernatant were 
run on SDS-PAGE under reducing conditions, transferred onto PVDF membrane and probed 
with anti-FLAG antibodies overnight. mIgG2A was detected by HRP-conjugated F(ab’)2 
secondary antibodies. Cell lysates and supernatants membranes were exposed for 10 
seconds. Determination of actin expression levels served for equal loading control.  
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Figure 4.15: Expression and secretion of LAP-MMP-TAT3-NBD and LAP-MMP-TAT3-
NBD-V5 proteins from transiently transfected 293T cells. Lysates (A) and serum-free 
supernatants (B) were collected 24 hours after transfection and analysed by western blotting 
analysis. 5 µl out of 1 ml of total cell lysate and 30 µl out of 5 ml of supernatant were run on 
SDS-PAGE under reducing conditions, transferred onto PVDF membrane and probed with 
anti-FLAG antibodies overnight. Cell lysates and supernatants membranes were exposed for 
10 seconds. (1) Mock, (2) LAP-MMP-TAT3-NBD, (3) LAP-MMP-TAT3-NBD-V5.  
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4.3 Discussion 
 
 
PTD-fusion proteins were fused to the LAP peptide of TGFβ in order to be 
efficiently secreted from mammalian cells. Previous research in our laboratories, has 
demonstrated that the LAP domain of TGFβ when linked to IFNβ via an MMP site 
could shield the activity of the cytokine, increase its half life and the LAP domain was 
released in an MMP dependent manner to achieve latent activity of the cytokine 
(Adams et al., 2003; Vessillier et al., 2004). Similarly, in relation to a secretable PTD-
fusion protein, the LAP domain may shield the PTD-fusion protein and permit more 
efficient secretion.  
In this study, the LAP-MMP-TAT-RBD and LAP-MMP-TAT3-NBD inhibitors 
were secreted in high levels that were comparable to the secretion levels of the 
naturally secreted immunoglobulin mIgG2A. However, the PTD-srIκΒα could not be 
secreted efficiently when fused to the LAP peptide, which highlights the impact 
different cargoes can have on the secretion. Clearly, IκBα is not an endogenously 
secreted molecule that is naturally targeted to the cytoplasm and this endogenous 
targeting may override the secretion route to which the molecules were directed in 
this study. IkBα inhibitor also contains a nuclear import sequence within the second 
ankyrin repeat (Sachdev et al., 1998; Turpin et al., 1999), which can contribute to the 
inefficient secretion of the PTD-srΙκΒα inhibitor. Another explanation for the inefficient 
secretion of the LAP-PTD-srIκΒα inhibitors can be the size of the PTD-srΙκΒα 
proteins. PTD-srΙκΒα proteins have a molecular weight of ~ 50 kDa, which may result 
to the inability of LAP peptide to shield the fusion inhibitors. From this study, appears 
that PTD-fusion proteins that can be secreted successfully are small domains of 
larger proteins (RBD and NBD) that can be properly encapsulated by the LAP 
peptide. The PTD however does not appear to play a very important role to the 
secretion of LAP-PTD-fusion proteins, because TAT-RBD and TAT3-NBD were both 
secreted at levels comparable to the immunoglobulin mIgG2A, when fused to the LAP 
peptide. It is also worth noticing, that the LAP-MMP-TAT3-NBD could be more 
efficiently secreted compared to the LAP-MMP-TAT3-NBD-V5, which shows that the 
V5 epitope has a negative effect on its secretion (Figure 4.15). This finding was also 
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confirmed with anti-LAP western blotting analysis (data not included). All LAP-MMP-
PTD-srΙκΒα inhibitors had the V5 epitope fused in their C-terminus end, which again 
may explain partially their poor secretion levels. Western blotting analysis of cell 
lysates from cells expressing the LAP-PTD-fusion proteins revealed multiple bands, 
which may represent different glycosylation stages of the proteins or intracellular 
protein degradation.  
Flinterman et al, (2009) demonstrated efficient secretion of eGFP with the 
synthetic PTD TATκ and subsequent secretion of an anti-cancer protein apoptin was 
achieved by fusing it with the PTD-eGFP molecule. In this way the eGFP partner 
functions as a secretion carrier. The disadvantage of this strategy is that eGFP is a 
foreign protein that is immunogenic in vivo (Stripecke et al., 1999). Here in this study, 
the use of LAP peptide as secretion carrier can overcome this disadvantage, as it is 
not immunogenic in vivo (unpublished data).  
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5.1 Introduction 
 
 
Lentiviruses are a complex subclass of retroviruses that multiply slowly, and 
the most studied lentivirus is the HIV. Retroviruses are a class of enveloped viruses 
that contain a single stranded RNA molecule as a genome. The replication cycle of 
retroviruses initiate with the interaction of the the virus with the cell surface of the host 
cell. Following the cell infection, the viral RNA is reverse transcribed into double-
stranded cDNA, by viral reverse transcriptase. This double-stranded cDNA provirus in 
turn migrates into the nucleus and integrates into the host genome by viral intargrase. 
Once the cDNA has been integrated into the host genome, it becomes a permanent 
feature of the host genome and is termed a provirus. Transcription of the provirus by 
the host cell, results into the generation of new viral RNA and spliced RNA translated 
into viral proteins. In turn, viral proteins and full length RNA can assemble in order to 
from new virions that bud from the cell (Zhang and Godbey, 2006).  
The HIV-1 lentivirus genome consist of the gag, pol and env genes that can be 
found in all retroviruses and additional mRNA spliced variants genes such as tat, rev, 
nef, vpr, vpu and vif, which reflect a more complex replication cycle. The gag gene 
encodes for core proteins, the pol gene encodes for reverse transcriptase and 
integrase and env gene encodes for viral envelope proteins. tat encodes for TAT 
protein, which is a transcription transactivator, essential for HIV-1 replication (Feng 
and Holland, 1988). rev encodes for an RNA binding protein that binds to a complex 
secondary RNA structure known as rev-responsive element (RRE), which facilitates 
the export of the viral RNA from the nucleus to the cytoplasm (Malim et al., 1989). nef 
encodes for a protein that has multiple functions, including down regulation of CD4 
and Class I MHC, stimulation of HIV infectivity and disturbance of T-cell activation 
(Garcia and Miller, 1992; Miller et al., 1994; Schwartz et al., 1996). vpr encodes for a 
protein that facilitates the HIV infection in non-dividing cells (Heinzinger et al., 1994). 
vpu encodes for a protein that induces down-regulation of CD4 and enhances virus 
release into the cytoplasm after its attachment to the cell surface (Schubert et al., 
1996). vif encodes for a protein that is necessary for the HIV-1 replication in some cell 
lines (Strebel et al., 1987). At each end of the lentiviral genome are identical 
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sequences that are called long terminal repeats (LTRs), which include 
promoter/enhancer regions and sequences involved with the integration of cDNA to 
the host’s genome. Downstream from the 5’ LTR is the packaging signal ψ, which 
interacts with viral proteins in order for viral RNA to become encapsulated into virions. 
A short sequence (~10 bases), known as polypurine tract (PPT) is located between 
env and 3’ LTR and is responsible for the initiation of (+) strand synthesis during 
reverse transcription (Zhang and Godbey, 2006) (Figure 5.1). 
 
 
 
Figure 5.1: Schematic representation of proviral HIV-1 genome. LTR: long terminal 
repeats, PPT: polypurine tract, ψ: packaging signal, gag, pro, pol, vif, vpr, env, vpu, tat, rev, 
nef: genes – see text for details.  
 
 
The ability of lentiviruses to integrate in their host genome has been widely 
exploited for the generation of lentiviral vectors as vehicles to carry a foreign gene of 
interest into a target cell. Recombinant lentiviral vectors are derived from wild type 
lentiviruses and engineered by exchanging the viral genes with the gene of interest in 
the viral vector backbone. Lentiviral vectors are replication deficient, therefore all 
genes that are essential for the virus replication have been removed, however cis-
acting sequences essential for recognition by viral proteins are present. The trans-
acting viral genes (gag, pol and env) are typically provided by co-transfection with the 
vector transgene into packaging cell lines which work as factories for virion 
production. The recombinant viruses produced by the transfected cells are able to 
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integrate once but cannot propagate further, as they lack the necessary genes for 
assembly and replication (Zhang and Godbey, 2006). The tropism of a retrovirus is 
determined by its specific viral envelope, therefore exchanging the env gene in 
recombinant lentiviruses can affect their tropism. This approach is called 
pseudotyping and the vesicular stomatitis virus envelope glycoprotein (VSVG) is most 
commonly used as it is able to interact with the membrane lipid bilayer of most cell 
types in order to increase virus tropism. The 5’LTR region can also be replaced by a 
strong heterologous promoter, which is not dependent on Tat, therefore allowing 
removal of the regulatory tat gene (Dull et al., 1998). CMV and spleen focus forming 
virus (SFFV) promoters are also commonly used to achieve nonselective but broad-
spectrum expression (Demaison et al., 2002; Miyoshi et al., 1998). Transcriptional 
inactivation at the 5’LTR provirus can also be achieved by the removal of the TATA 
box and enhancer elements (U3 region) at the 3’LTR. Recombinant lentiviral vectors 
that contain such deletions are known as self-inactivating (SIN) vectors and potential 
transcription interference from the LTR with heterologous promoters such as CMV or 
SFFV as well as activation of downstream genes is avoided (Demaison et al., 2002; 
Miyoshi et al., 1998). The use of recombinant retroviral vectors as a means for 
genetically engineering target cells to achieve stable, long-term production of 
recombinant proteins has been widely studied in vitro and in vivo. More specifically, 
lentiviral vectors have been used to introduce expression of growth factors, 
transcription factors and other cell signaling modulating factors (reviewed in Zhang 
and Godbey, 2006). 
DTF cell lines for cell transplantation that were expressing LAP-PTD-fusion 
proteins were generated with the use of replication-deficient lentiviral vectors. In this 
study the lentiviral vector pHRSIN-CSGW was used for the generation of lentiviral 
vectors. The lentiviral vector pHRSIN-CSGW was originally described by Demaison 
et al. (2002) and is derived from the HIV I lentivirus and has been rendered self-
inactivating (SIN) by removal of the TATA box and enhancers in the 3’LTR U3 region. 
Additionally, a strong SFFV promoter has been inserted that drives efficient 
transgene expression, which is further enhanced by the mRNA-stabilising 
Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). Inclusion 
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of a central polypurine tract (cPPT) cis-acting sequence further improves transduction 
efficiency by facilitating nuclear entry of the pre-integrated virus. Pseudotyping with a 
VSVG encoding envelope vector enhances transduction and broadens cell tropism 
(Figure 5.2 - A).  
DTF expressing cells were generated after 6 rounds of infection, as described 
in Materials and Methods (Chapter II), in order to achieve high levels of expression. 
The different cell lines that were generated include LAP-MMP-TAT3-NBD expressing 
DTF cells for the inhibition of NF-κΒ signalling pathway, LAP-MMP-TAT3-eGFP and 
LAP-MMP expressing DTF cells, which served as negative controls. In addition, the 
MMP cleavage site of the LAP-MMP-TAT3-NBD and LAP-MMP-TAT3-eGFP in the 
lentiviral vectors was replaced with a glycine-serine linker (GGGGS) x 3, which also 
served as control for MMP cleavage in this study. Therefore, LAP-GS-TAT3-NBD and 
LAP-GS-TAT3-eGFP DTF cell lines were generated. The reason for replacing the 
MMP cleavage site with an uncleavable GS site, was to examine if the uncleaved 
LAP-GS-TAT3-NBD inhibitor could retain biological activity. 
The ability of the LAP-PTD-fusion proteins to be secreted from genetically 
engineered DTF cells was investigated by western blotting and ELISA binding assay 
analysis of cell supernatants. The ability of the LAP-PTD-fusion proteins to be 
cleaved by MMPs was also tested by treating DTF cell supernatants with exogenous 
MMP1.  
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5.2 Results 
 
 
5.2.1 Generation of the secretable LAP-PTD-fusion molecules 
lentiviral vectors 
 
 
5.2.1.1 LAP-MMP-FLAG-TAT3-NBD lentiviral vector 
 
To produce the LAP-MMP-FLAG-TAT3-NBD lentiviral vector, the TGFβ 
segment was excised using the internal NotI/SpeI sites from the lentiviral vector 
pHRSIN-CSGW LAP-MMP-TGFβ lentiviral vector (a kind gift from Dr. A. Rigby, 
London, UK, Figure 5.2 - B) and replaced with the FLAG-TAT3-NBD gene, which was 
excised using the internal NotI/Xbal sites from the LAP-MMP-FLAG-TAT3-NBD 
pcDNA3 expression vector (Figure 4.4) and ligated in frame into the corresponding 
sites of the LAP-MMP-TGFβ lentiviral vector. The final lentiviral vector generated 
encodes LAP-MMP-FLAG-TAT3-NBD (Figure 5.3 - A). 
 
5.2.1.2 LAP-GS-FLAG-TAT3-NBD lentiviral vector 
 
To produce the LAP-GS-FLAG-TAT3-NBD lentiviral vector, the MMP segment 
was excised using the internal Bsu36I/NotI sites from the LAP-MMP-FLAG-TAT3-
NBD lentiviral vector (Figure 5.3 - A) and replaced with the GS segment, which was 
excised using the internal Bsu36I/NotI sites from the LAP-GS-TGFβ pcDNA3 
expressing vector (a kind gift from Dr. A. Rigby, London, UK, Figure 5.3) and ligated 
in frame into the corresponding sites of the LAP-MMP-FLAG-TAT3-NBD lentiviral 
vector. The final lentiviral vector generated encodes LAP-GS-FLAG-TAT3-NBD 
(Figure 5.3 - B). 
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5.2.1.3 LAP-MMP-FLAG-TAT3-eGFP lentiviral vector 
 
By using the IL2ss-FLAG-TAT3-NBD pFUSE expression vector (Figure 3.7) as 
template the FLAG-TAT3 region was amplified by PCR using the forward primer 5’-
TCAGCGGCCGCCGGTGGAGACTACAAA-3’ and the reverse primer 5’-
TAGCATGCACCTCCAGCACGAGCTTG-3’. The PCR product was then recovered 
from the PCR reaction by ethanol precipitation and digested with NotI/SphI 
(underlined sites). By using the IL2ss-TAT-HA-eGFP pFUSE expression vector 
(Figure 3.3) as template, the eGFP gene was amplified by PCR using the forward 
primer 5’-TAAGCATGCGTGAGCAAGGGCGAGGAG-3’ and the reverse primer 5’-
GCGTCTAGATTACTTGTACAGCTCGTC-3’. The PCR product was then recovered 
from the PCR reaction by ethanol precipitation and digested with SphI/XbaI 
(underlined sites). The LAP-MMP-TGFβ lentiviral vector (Figure 5.2 - B) was digested 
with NotI and XbaI to remove the TGFβ gene, and the digested lentiviral vector co-
ligated with the FLAG-TAT3 region and eGFP gene. The final lentiviral vector 
generated encodes LAP-MMP-FLAG-TAT3-eGFP (Figure 5.3 - C). 
 
5.2.1.4 LAP-GS-FLAG-TAT3-eGFP lentiviral vector 
 
To produce the LAP-GS-FLAG-TAT3-eGFP lentiviral vector, the MMP 
segment was excised using the internal Bsu36I/NotI sites from the LAP-MMP-FLAG-
TAT3-eGFP lentiviral vector (Figure 5.3 - C) and replaced with the GS segment, 
which was excised using the internal Bsu36I/NotI sites from the LAP-GS-TGFβ 
pcDNA3 expressing vector (a kind gift from Dr. A. Rigby, London, UK, Figure 5.4) and 
ligated in frame into the corresponding sites of the LAP-MMP-FLAG-TAT3-eGFP 
lentiviral vector. The final lentiviral vector generated encodes LAP-GS-FLAG-TAT3-
eGFP (Figure 5.3 - D). 
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Figure 5.2: The restriction enzyme and genetic map of the viral DNA lentiviral vector 
constructs. The pHRSIN-CSGW lentiviral vector was derived from the HIV I lentivirus and 
has been rendered self-inactivating (SIN) by removal of the TATA box and enhancers in the 
3’LTR U3 region (3’LTRΔU3). Additionally, a strong spleen focus forming virus (SFFV) 
promoter has been inserted and drives efficient tansgene expression, which is further 
enhanced by the extra Woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE). Cis-acting elements include the ψ packaging sequence, the rev-responsive element 
(RRE) which interacts with the rev gene for RNA nuclear export and the central polypurine 
tract (cPPT) sequence which facilitates virus nuclear entry. Part of the gag gene remains 
(Δgag) as it overlaps with the ψ packaging sequence. (A) GFP pHRSIN-CSGW lentiviral 
vector, (B) LAP-MMP-TGFβ pHRSIN-CSGW lentiviral vector and (C) LAP-MMP pHRSIN-
CSGW lentiviral vector. 
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Figure 5.3: The restriction enzyme and genetic map of the viral DNA lentiviral vector 
constructs. The pHRSIN-CSGW lentiviral vector was used. (A) LAP-MMP-TAT3-NBD 
pHRSIN-CSGW lentiviral vector, (B) LAP-GS-TAT3-NBD pHRSIN-CSGW lentiviral vector, 
(C) LAP-MMP-TAT3-eGFP pHRSIN-CSGW lentiviral vector, (D) LAP-GS-TAT3-eGFP 
pHRSIN-CSGW lentiviral vector. 
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Figure 5.4: The restriction enzyme and genetic map of the LAP-GS-TGFβ pcDNA3 
vector. LAP-GS-TGFβ pcDNA3 plasmid contained the coding sequence of LAP peptide from 
TGFβ1. This sequence is followed by the coding sequence of a flexible linker 
(GGGGSGGGGSGGGGS) and immediately downstream the above sequences, the TGFβ 
coding sequence is cloned. 
 
 
 
Correct construction of the secretable LAP-PTD-fusion proteins viral DNA 
lentiviral vectors was verified by DNA restriction enzyme analysis (Figures 5.5 - 5.6) 
and confirmed by DNA sequencing. 
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Figure 5.5: DNA restriction enzyme analysis of the LAP-MMP-TAT3-NBD (A) and LAP-
GS-TAT3-NBD (B) pHRSIN-CSGW lentiviral vectors. (A) LAP-MMP-TAT3-NBD pHRSIN-
CSGW plasmid was digested with NotI and XhoI to release the FLAG-TAT3-NBD fragment 
and part of WPRE sequence (~ 800 bp). (B) LAP-GS-TAT3-NBD pHRSIN-CSGW plasmid 
was digested with Bsu36I and NotI to release part of the LAP sequence and the GS fragment 
(579 bp). (1) 1 kb plus DNA ladder, (2) unrestricted DNA construct, (3) restricted DNA 
construct. 
 
 
 
 
Figure 5.6: DNA restriction enzyme analysis of the LAP-MMP-TAT3-eGFP (A) and LAP-
GS-TAT3-eGFP (B) pHRSIN-CSGW lentiviral vectors. (A) LAP-MMP-TAT3-eGFP pHRSIN-
CSGW plasmid was digested with NotI and XhoI to release the FLAG-TAT3-eGFP fragment 
and part of WPRE sequence (~ 1300 bp). (B) LAP-GS-TAT3-eGFP pHRSIN-CSGW plasmid 
was digested with Bsu36I and NotI to release part of the LAP sequence and the GS fragment 
(579 bp). (1) 1 kb plus DNA ladder, (2) unrestricted DNA construct, (3) restricted DNA 
construct. 
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5.2.2 Expression and secretion of the LAP-PTD-fusion proteins from 
DTF cells 
 
 
5 different genetically engineered DTF cell lines expressing LAP-PTD-fusion 
proteins were generated. The different DTF cell lines were expressing LAP-MMP, or 
LAP-MMP-TAT3-NBD, or LAP-GS-TAT3-NBD, or LAP-MMP-TAT3-eGFP, or LAP-
GS-TAT3-eGFP. A schematic representation of LAP-PTD-fusion proteins, with the 
incorporated FLAG tag for their immunodetection, that were generated is shown in 
Figure 5.7. 
 
 
 
 
Figure 5.7: Schematic presentation of the LAP-PTD-fusion proteins that are expressed 
and secreted from genetically engineered DTF cell lines. LAP: Latency Associated 
Peptide from TGFβ1, ΜΜP: Matrix Metalloproteinase site, GS: (GGGGS) x 3 flexible linker, 
TAT3: TAT3 PTD, FLAG: FLAG epitope tag. 
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After each round of lentiviral infection, 1 x 106 of DTF cells were seeded on a 
10 cm tissue culture plate and cultured for 24 hours with serum-containing medium. 
After the initial 24 hours of cell culture, medium was replaced with serum-free 
medium and cells left to grow for 24 more hours. Serum-free medium from DTF cells 
was collected after 24 hour of cell culture and supernatants were analysed by 
western blotting analysis, in order to asses levels of secretion of the LAP-PTD-Fusion 
proteins. Monoclonal antibodies against the FLAG tag of the constructs or polyclonal 
antibodies against the LAP peptide were used for the western blotting analysis 
(Figures 5.8 – 10). The LAP-MMP-TAT3-NBD and LAP-GS-TAT3-NBD proteins were 
detected as 40 kDa proteins, the LAP-MMP-TAT3-eGFP and LAP-GS-TAT3-eGFP 
proteins were detected as 70 kDa and the LAP-MMP protein was detected as 40 kDa 
as expected from the length of their amino acid sequence. All constructs 
demonstrated high levels of secretion from DTF cells. As expected, increased 
number of infection rounds increased the levels of LAP proteins being expressed and 
secreted from the DTF cells. Interestingly, LAP-MMP-TAT3-NBD, LAP-GS-TAT3-
NBD, LAP-MMP-TAT3-eGFP and LAP-GS-TAT3-eGFP appeared to reach maximum 
levels of secretion after infection round 4 and levels of secretion reached plateau 
levels after infection 5 and 6. In contrast, LAP-MMP was the only protein that 
demonstrated steady increase of secretion after each round of infection. Furthermore, 
western blotting analysis with anti-LAP antibodies of supernatants from genetically 
engineered DTF cells revealed post-translational modifications as multiple bands 
were detected, representing different glycosylated forms (especially LAP proteins 
containing the GS domain which appeared to form strong complexes) or cleaved LAP 
proteins (Figures 5.8 - 10). 
 DTF cells expressing LAP-GS-TAT3-eGFP, or LAP-MMP-TAT3-eGFP after 
infection with the indicated lentiviruses were also visualised by fluorescence 
microscopy as an indirect means to assess transduction efficiency. Almost 100% of 
the cells were expressing the eGFP chimeras (Figure 5.11).      
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Figure 5.8: Increased secretion levels of LAP-MMP following multiple transduction 
cycles. DTF cells were infected with the LAP-MMP replication – deficient lentiviral vector. 
After an infection round, 1 x 106 cells were seeded on a 10 cm culture plate and cultured for 
24 hours with serum-containing medium. After the initial 24 hours of cell culture, medium was 
replaced with serum-free medium and cells left to grow for 24 more hours. Serum-free 
supernatants were collected after 24 hours of culture and analysed by western blotting 
analysis. 30 µl out of 5 ml of supernatant were run on SDS-PAGE under reducing conditions, 
transferred onto PVDF membrane and probed with anti-LAP antibodies overnight. Membrane 
was exposed for 15 seconds. (1) Mock, (2) DTF cells after infection round 1, (3) DTF cells 
after infection round 2, (4) DTF cells after infection round 3, (5) DTF cells after infection round 
4, (6) DTF cells after infection round 5, (7) DTF cells after infection round 6. 
 
 
 
 
 
 
 
 
 Page | 144  
 
 Chapter V 
 
 
Figure 5.9: Increased secretion levels of LAP-MMP-TAT3-NBD and LAP-GS-TAT3-NBD 
following multiple transduction cycles. DTF cells were infected with the LAP-MMP-TAT3-
NBD (A) or LAP-GS-TAT3-NBD (B) replication – deficient lentiviral vectors. After an infection 
round, 1 x 106 cells were seeded on a 10 cm culture plate and cultured for 24 hours with 
serum-containing medium. After the initial 24 hours of cell culture, medium was replaced with 
serum-free medium and cells left to grow for 24 more hours. Serum-free supernatants were 
collected after 24 hours of culture and analysed by western blotting analysis. 30 µl out of 5 ml 
of supernatant were run on SDS-PAGE under reducing conditions, transferred onto PVDF 
membrane and probed with anti-LAP (I) and anti-FLAG (II) antibodies overnight. Anti-LAP 
membrane (I) was exposed for 15 seconds and anti-FLAG membrane (I) was exposed for 3 
minutes. (1) Mock, (2) DTF cells after infection round 1, (3) DTF cells after infection round 2, 
(4) DTF cells after infection round 3, (5) DTF cells after infection round 4, (6) DTF cells after 
infection round 5, (7) DTF cells after infection round 6. 
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Figure 5.10: Increased secretion levels of LAP-MMP-TAT3-eGFP and LAP-GS-TAT3-
eGFP following multiple transduction cycles. DTF cells were infected with the LAP-MMP-
TAT3-eGFP (A) or LAP-GS-TAT3-eGFP (B) replication – deficient lentiviral vectors. After an 
infection round, 1 x 106 cells were seeded on a 10 cm culture plate and cultured for 24 hours 
with serum-containing medium. After the initial 24 hours of cell culture, medium was replaced 
with serum-free medium and cells left to grow for 24 more hours. Serum-free supernatants 
were collected after 24 hours of culture and analysed by western blotting analysis. 30 µl out 
of 5 ml of supernatant were run on SDS-PAGE under reducing conditions, transferred onto 
PVDF membrane and probed with anti-LAP (I) and anti-FLAG (II) antibodies overnight. Anti-
LAP membrane (I) was exposed for 1 minute and anti-FLAG membrane (II) was exposed for 
1 minute. (1) Mock, (2) DTF cells after infection round 1, (3) DTF cells after infection round 2, 
(4) DTF cells after infection round 3, (5) DTF cells after infection round 4, (6) DTF cells after 
infection round 5, (7) DTF cells after infection round 6.  
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Figure 5.11: DTF cells expressing LAP-MMP-TAT3-eGFP and LAP-GS-TAT3-eGFP show 
eGFP expression intracellularly. DTF cells were genetically engineered with the LAP-MMP-
TAT3-eGFP (A) or LAP-GS-TAT3-eGFP (B) replication – deficient lentiviral vector. Live DTF 
cells expressing LAP-MMP-TAT3-eGFP or LAP-GS-TAT3-eGFP were visualised under light 
microscopy (I) and fluorescence microscopy (II). (x 400 magnification). 
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Similarly, 1 million cells from each different DTF cell line that was generated 
after round 6 of infection with the lentiviral vectors, expressing either, LAP-MMP, or 
LAP-MMP-TAT3-NBD, or LAP-GS-TAT3-NBD, or LAP-MMP-TAT3-eGFP, or LAP-
GS-TAT3-eGFP, were seeded on 10 cm culture plate and cultured in serum 
containing medium for 24 hours. In turn, medium was replaced with 5 ml of serum-
free medium and cells left to grow for 24 hours. After 24 hours, 5 ml of supernatants 
were collected and cells were covered with 1 ml of TE buffer and lysed by 5 repeated 
cycles of freezing and thawing. Cell lysates and supernatants were analysed by 
ELISA, using anti-LAP antibodies, in order to calculate the concentration of 
expressed and secreted LAP proteins (Figure 5.12). Further analysis of the ELISA 
data revealed that the percentage of LAP proteins that are secreted is as follows: 
LAP-MMP – 89%, LAP-MMP-TAT3-NBD – 84%, LAP-GS-TAT3-NBD – 64%, LAP-
MMP-TAT3-eGFP – 84% and LAP-GS-TAT3-eGFP – 82% (Table 5.1). Therefore, 
most of the LAP-PTD-fusion proteins that were produced by DTF cells could be 
detected in cell supernatants, which indicated that LAP-PTD-Fusion proteins could be 
efficiently secreted from genetically engineered DTF cells. 
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Figure 5.12: Direct ELISA of LAP-PTD-fusion proteins confirms high levels of secretion 
from genetically engineered DTF cells. 1 x 106 cells from each different DTF cell line that 
was generated after round 6 of infection with lentiviruses were seeded on 10 cm culture plate 
and cultured in serum containing medium for 24 hours. Medium was replaced with 5 ml of 
serum-free medium and cells left to grow for 24 hours. Serum-free supernatants were 
collected after 24 hours of culture and cells were covered with TE buffer and subsequently 
lysed by 5 repeated freezing and thawing cycles. Cells lysates (A) and supernatants (B) were 
analysed by anti-LAP direct Elisa binding assay and concentrations of LAP-proteins were 
calculated. Protein levels are expressed in µg/ml. (C) Different dilutions of lap peptide 
detected by anti-lap direct ELISA. Protein levels are expressed in optical density arbitrary 
units (A.U.) at 450 nm. 
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Table 5.1: Expression and secretion levels of LAP-PTD-fusion proteins from 
genetically engineered DTF cells. 
 Protein amount 
in cell lysates 
(µg/ml) 
Protein amount 
in supernatants 
(µg/ 5 ml) 
Total protein 
amount 
expressed (µg) 
% of protein 
amount 
secreted 
LAP-MMP 0.5328 4.4695 5.0023 89% 
LAP-MMP-TAT3-NBD 0.463 2.0885 2.5515 84% 
LAP-GS-TAT3-NBD 1.1060 1.9875 3.0935 64% 
LAP-MMP-TAT3-eGFP 2.1052 10.7875 12.8927 84% 
LAP-GS-TAT3-eGFP 2.4087  10.8307 13.2394 82% 
 
293T cells were also transiently transfected with the different PTD-fusion 
eGFP expression constructs or with the pFUSE vector as positive control, in order to 
explore whether the LAP peptide had any beneficial effect on the secretion of the 
PTD-fusion eGFP proteins. Mammalian expression and secretion of the different 
constructs was demonstrated by western blotting analysis using a monoclonal 
antibody against GFP (Figure 5.13). The LAP-MMP-TAT3-eGFP and LAP-GS-TAT3-
eGFP fusion proteins were detected as 75 kDa proteins, the TAT-eGFP and mIgG2A 
proteins were detected as 30 kDa, as expected from the length of their amino acid 
sequence. All PTD-fusion eGFP proteins could be detected in unconcentrated 
supernatant from transiently transfected 293T cells and high levels of secretion were 
demonstrated by western blotting analysis. The LAP-MMP-TAT3-eGFP, LAP-GS-
TAT3-eGFP and TAT-eGFP proteins were also detected in similar levels. Therefore, 
the use of LAP peptide did not increase the secretion efficiency of the PTD-fusion 
eGFP protein significantly. Furthermore, the western blotting analysis with anti-eGFP 
antibodies revealed multiple bands in both lysates and supernatants from transiently 
transfected 293T cells, which indicates post-translational modifications of the fusion 
proteins (Figure 5.13). 
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Figure 5.13: Expression and secretion of TAT-eGFP, LAP-GS-TAT3-eGFP and LAP-
MMP-TAT3-eGFP proteins from transiently transfected 293T cells. Lysates (A) and 
serum-free supernatants (B) were collected 24 hours after transfection and analysed by 
western blotting analysis. 10 µg of total cell lysate and 30 µl out of 5 ml of supernatant were 
run on SDS-PAGE under reducing conditions, transferred onto PVDF membrane and probed 
with anti-GFP antibodies overnight. mIgG2A was detected by HRP-conjugated F(ab’)2 
secondary antibodies. Cell lysates and supernatants membranes were exposed for 15 
seconds. Determination of actin expression levels served for equal loading. (1) Mock, (2) 
LAP-GS-TAT3-eGFP (3) LAP-MMP-TAT3-eGFP, (4) TAT-eGFP. 
 
 
 
5.2.3 MMP cleavage of secreted LAP-PTD-fusion proteins 
 
 Supernatants from DTF cells expressing LAP-PTD-fusion proteins were 
incubated with the MMP-1 catalytic domain (human, recombinant) at 37o C overnight, 
in order to asses MMP cleavage of the LAP proteins that were generated. 
Supernatants after MMP treatment were analysed by western blotting analysis 
(Figures 5.14 - 5.15). LAP-MMP-PTD-fusion proteins could efficiently be cleaved by 
the MMP1 catalytic domain, where in contrast LAP-GS-PTD-fusion proteins revealed 
resistance to the MMP1 catalytic domain cleavage. However, LAP-GS-PTD-fusion 
proteins could be cleaved when treated with high concentrations of the MMP1 
catalytic domain (Figure 5.15).    
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Figure 5.14: Cleavage of LAP-GS-TAT3-eGFP and LAP-MMP-TAT3-eGFP secreted 
proteins by recombinant MMP1 catalytic domain. Serum-free supernatants from 
syngeneic DTF cells expressing LAP-MMP, or LAP-GS-TAT3-eGFP, or LAP-MMP-TAT3-
eGFP were incubated at 37o C with 1 µg/ml of recombinant MMP1 catalytic domain. Samples 
were run on SDS-PAGE under reducing conditions, transferred onto PVDF membrane and 
probed with anti-LAP antibodies overnight. (1) Mock / (-) MMP1, (2) Mock / (+) MMP1, (3) 
LAP-MMP / (-) MMP1, (4) LAP-MMP / (+) MMP, (5) LAP-GS-TAT3-eGFP / (-) MMP1, (6) 
LAP-GS-TAT3-eGFP / (+) MMP1, (7) LAP-MMP-TAT3-eGFP / (-) MMP1, (8) LAP-MMP-
TAT3-eGFP / (+) MMP1. 
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Figure 5.15: Cleavage of LAP-GS-TAT3-NBD and LAP-MMP-TAT3-NBD secreted 
proteins by recombinant MMP1 catalytic domain. Serum-free supernatants from 
syngeneic DTF cells expressing LAP-MMP, or LAP-GS-TAT3-NBD, or LAP-MMP-TAT3-NBD 
were incubated at 37o C with 2 µg/ml of recombinant MMP1 catalytic domain. Samples were 
run on SDS-PAGE under reducing conditions, transferred onto PVDF membrane and probed 
with anti-LAP antibodies overnight. (1) Mock / (-) MMP1, (2) Mock / (+) MMP1, (3) LAP-MMP 
/ (-) MMP1, (4) LAP-MMP / (+) MMP, (5) LAP-GS-TAT3-NBD / (-) MMP1, (6) LAP-GS-TAT3-
NBD / (+) MMP1, (7) LAP-MMP-TAT3-NBD / (-) MMP1, (8) LAP-MMP-TAT3-NBD / (+) 
MMP1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page | 153  
 
 Chapter V 
5.3 Discussion 
 
 
 Only the TAT3 PTD was used for the generation of LAP-PTD-fusion proteins to 
be secreted from DTF cells. There are a number of different reasons for switching to 
TAT3 PTD. This synthetic PTD is one of the most potent PTDs in terms of 
transducing cells (Ho et al., 2001); is less sensitive to furin cleavage and is thought to 
target molecules to the cytoplasm, which would the preferred site for delivery of an 
NF-κB inhibitor (Chauhan et al., 2007). TAT3 was also shown in a previous study to 
be the most efficiently secreted PTD when fused to CRE recombinase (Shaw et al., 
2008). The NBD inhibitor was also the only ΝF-κΒ inhibitor used, as it was the only 
ΝF-κΒ inhibitor that demonstrated high secretion levels (see Chapter IV). The eGFP 
protein was also used for the generation of a reporter LAP-TAT3-fusion protein.  
 Visualisation by fluorescence microscopy of DTF cells expressing LAP-MMP-
TAT3-eGFP or LAP-GS-TAT3-eGFP revealed efficient transduction by the lentiviral 
vectors, as almost 100% of the cells were expressing the eGFP constructs (Figure 
5.12). Following western blotting and ELISA binding assay analysis also revealed 
high levels of secretion of LAP-TAT3-fusion proteins. Shaw et. al. (2008) 
demonstrated that up to 0.04% of total PTD-CRE protein was secreted when tested in 
2 different cell lines. In comparison to this study, here the secretion levels observed 
were in excess of 80% and compares to the levels achieved with naturally secreted 
proteins devoid of a PTD (Table 5.1). 
 Treatment of LAP-TAT3-fusion proteins with exogenous MMP1, revealed that 
the constructs containing the GS domain are resistant to MMP1 cleavage, whereas 
constructs containing the MMP1 cleavage site were efficiently cleaved. However, 
increased concentrations of MMP1 could cleave the LAP-GS-TAT3-NBD constructs. 
An explanation for this can be the fact that LAP peptide is prone to cleavage by 
MMPs (Maeda et al., 2002).    
 
  
 
 
  
 
Chapter VI:              
Biological activity of LAP-PTD-fusion 
NF-κB inhibitors in vitro 
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6.1 Introduction 
 
 
The inhibitory properties of the secreted PTD-fusion NF-κΒ inhibitors were 
determined by directly measuring transcriptional activity of NF-κΒ in 57A HeLa cells in 
vitro. 57A HeLa cells are permanently transfected with a reporter vector where the 
luciferase gene is under the control of a NF-κB regulated promoter (Rodriguez et al., 
1999). Reduction in luciferase activity in IL-1β-stimulated 57A HeLa lysates, when 
treated with the secreted PTD-fusion inhibitors therefore would indicate inhibition of 
NF-κB.  
Initially, NF-κΒ transcriptional activity was measured in 57A HeLa cells that 
were treated with supernatants from cells secreting PTD-fusion proteins. 
Subsequently, NF-κΒ transcriptional activity was measured in 57A HeLa cells that 
were co-cultured with DTF cells expressing the secretable PTD-Fusion proteins.  
Endogenous levels of MMPs secreted by the cells used in the in vitro cell 
based assays were determined by gelatine zymography (see Chapter II). Gelatin 
zymography is mainly used for the detection of MMP9 and MMP2, however other 
MMPs such as MMP1, MMP8 and MMP13 can also be detected, but this technique is 
not sensitive for these enzymes because gelatine is not their preferential substrate 
(Snoek-van Beurden and Von den Hoff, 2005). 
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6.2 Results  
 
 
6.2.1 Treatment of 57A HeLa cells with supernatants containing the 
secreted LAP-PTD-fusion NF-κB inhibitor NBD can inhibit NF-κB 
transcriptional activity  
 
 
Initially, 57A HeLa cells were treated with the commercially available Antp-
NBD PTD-fusion NF-κΒ inhibitor for 2 hours, followed by IL-1β stimulation for an 
additional 4 hours in order to assess NF-κΒ inhibition and validate this cell based 
assay. Antp-NBD inhibited NF-κΒ in a dose dependent manner (Figure 6.1 - A). In the 
experiment shown in Figure 6.1, the presence of 50 µM Antp-NBD in the culture 
medium resulted in ~ 50% inhibition and NF-κΒ transcriptional activity was completely 
abolished with 100 μΜ of Antp-NBD. It also appeared that the control peptide, which 
was used as a negative control, increased the NF-κΒ activity again in a dose 
dependent manner. However, this increase in NF-κB activity was not due to the 
presence of the control peptide, but due to DMSO which was present in the peptides 
storage solution. This was confirmed by incubation of 57A HeLa cells with three 
different concentrations of DMSO (Figure 6.1 - B). This finding also suggests that 
Antp-NBD could be a more potent inhibitor if it was clear of DMSO.         
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Figure 6.1: Inhibition of IL-1β-induced NF-κΒ activation by Antp-NBD. (A) 57A HeLa 
cells were preincubated for 2 hours with the indicated concentrations of purified Control or 
Antp-NBD peptides. Cells were stimulated with 10 ng/ml IL-1β for 4 hours and luciferase 
activity in cell lysates was determined. (B) 57A HeLa cells were preincubated for 2 hours with 
the indicated concentrations of DMSO. Cells were stimulated with 10 ng/ml IL-1β for 4 hours 
and luciferase activity in cell lysates was determined. The histograms represent mean relative 
light units (in arbitrary units) ± SEM of triplicate cell cultures (n = 3, * = p ≤ 0.05, *** = p ≤ 
0.001, 1 way ANOVA followed by Tukey’s Multiple Comparison Test). 
 
 
 
Subsequently, 57A HeLa cells were treated with supernatants from transiently 
transfected 293T cells, in order to assess the ability of the secreted inhibitors to inhibit 
NF-κB transcriptional activity in vitro. Similarly, 57A HeLa cells were treated with 
supernatants containing the secreted inhibitors for 2 hours, followed by IL-1β 
stimulation for an additional 4 hours. Luciferase activity in cell lysates was 
determined, as a direct measurement of NF-κΒ activity. In two different experiments 
shown in Figures 6.2 - 6.3, the presence of the secreted LAP-MMP-TAT3-NBD in the 
culture medium resulted in ~ 50% - 60% inhibition of NF-κΒ activity. Furthermore 
addition of exogenous MMP1 did not significantly increase the levels of inhibition. 
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Figure 6.2: Inhibition of IL-1β-induced NF-κΒ activation by secreted LAP-MMP-TAT3-
NBD from 293T cells. 57A HeLa cells were preincubated for 2 hours with 100 µl of the 
indicated supernatants from transiently transfected 293T cells. In group (B) MMP1 (1 µg/ml) 
was also added to the 293T supernatant for the 2 hour pretreatment phase. Cells were 
stimulated with IL-1β (10 ng/ml) for 4 hours and luciferase activity in cell lysates was 
determined. The histograms represent mean relative light units ± SEM of triplicate cell 
cultures (n = 3, * = p ≤ 0.05, *** = p ≤ 0.001, 1 way ANOVA followed by Tukey’s Multiple 
Comparison Test). 
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Figure 6.3: Inhibition of IL-1β-induced NF-κΒ activation by secreted LAP-MMP-TAT3-
NBD from 293T cells. 57A HeLa cells were preincubated for 2 hours with 100 µl of the 
indicated supernatants from transiently transfected 293T cells. Cells were stimulated with IL-
1β (10 ng/ml) for 4 hours and luciferase activity in cell lysates was determined. The 
histograms represent mean relative light units ± SEM of triplicate cell cultures (n = 3, *** = p ≤ 
0.001, 1 way ANOVA followed by Tukey’s Multiple Comparison Test). 
 
 
 
Supernatants containing the secreted PTD-fusion inhibitors were also 
concentrated with Vivaspin concentrators in order to increase the inhibitors 
concentration. Concentrated supernatants, in turn, were used to treat 57A HeLa cells, 
as described above in an attempt to achieve higher levels of NF-κΒ inhibition. In the 
experiment shown in Figure 6.4, treatment of 57A HeLa cells with 20 times 
concentrated supernatant containing the LAP-MMP-TAT3-NBD inhibitor resulted in ~ 
50% inhibition of NF-κΒ activity and higher  levels of inhibition could not be achieved 
when compared to experiments where unconcentrated supernatants were used.  It 
was also found that cells that were treated with concentrated supernatants, 
consistently resulted in lower levels luciferase activity. This finding suggests that the 
concentration of supernatants resulted in the concentration of factors present in the 
supernatants of transiently transfectd 293T cells that affected NF-κΒ signalling. 
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Figure 6.4: Inhibition of IL-1β-induced NF-κΒ activation by secreted LAP-MMP-TAT3-
NBD from 293T cells. 57A HeLa cells were preincubated for 2 hours with 40 µl of the 
indicated concentrated supernatants from transiently transfected 293T cells. Cells were 
stimulated with IL-1β (10 ng/ml) for 4 hours and luciferase activity in cell lysates was 
determined. Supernatant concentrations were 20 times (A), 10 times (B), 5 times (C) and 2.5 
times (D). The histograms represent mean relative light units ± SEM of triplicate cell cultures 
(n = 3, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, 1 way ANOVA followed by Tukey’s Multiple 
Comparison Test). 
 
 
 
 
 
 
 Page | 161  
 
 Chapter VI 
57A HeLa cells were also treated with 20 times concentrated supernatants 
from transiently transfected 293T cells containing the secreted LAP-MMP-TAT3-NBD 
inhibitor in the presence of exogenous MMP1, in order to achieve higher levels of NF-
κΒ inhibition. Theoretically, the presence of MMP1 would cleave the latent form of 
TAT3-NBD inhibitor and subsequently increase the concentration of the active NF-κΒ 
inhibitor. However, as shown in Figure 6.5 MMP1 resulted in strong inhibition of 
luciferase activity in the cells treated with LAP-MMP containing supernatants, which 
were used as negative control. This finding demonstrated that MMP1 interfered with 
this in vitro assay and no clear conclusions could be made. The TAPI1 inhibitor, 
which is an MMP inhibitor, was also used in 57A HeLa cells that were treated with 
MMP1 in order to test if the MMP1 effect on the assay could be reversed. However, 
the presence of 500 µM of TAPI1 inhibitor were unable to reverse any MMP1 activity 
and higher inhibition of luciferase activity was observed when compared to cells that 
were only treated with IL-1β (Figure 6.5). 
Subsequently, supernatants from DTF cells (infected 6 times) expressing the 
secretable LAP-MMP-TAT3-NBD inhibitor were used in the same in vitro luciferase 
activity assay. Similarly, 57A HeLa cells treated with supernatants containing the 
secreted inhibitor for 2 hours, followed by IL-1β stimulation for an additional 4 hours. 
Luciferase activity in cell lysates was determined, as a direct measurement of NF-κΒ 
activity. In the experiment shown in Figure 6.6, the presence of the secreted LAP-
MMP-TAT3-NBD in the culture medium resulted in ~ 20% inhibition of NF-κΒ activity.  
The inhibition of NF-κΒ activity by supernatants from DTF cells was significantly lower 
compared to the inhibition of NF-κΒ activity with supernatants from 293T cells. This 
can be explained by the higher levels of the LAP-MMP-TAT3-NBD inhibitor that was 
present in supernatants from transiently transfected 293T cells (Figure 6.7).    
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Figure 6.5: Inhibition of IL-1β-induced NF-κΒ activation by secreted LAP-MMP-TAT3-
NBD from 293T cells. (A) 57A HeLa cells were preincubated for 2 hours with 40 µl of the 
indicated 20 times concentrated supernatants from transiently transfected 293T cells. Cells 
were stimulated with 10 ng/ml IL-1β for 4 hours and luciferase activity in cell lysates was 
determined. (B) 57A HeLa cells were preincubated for 2 hours with 40 µl of the indicated 20 
times concentrated supernatants from transiently transfected 293T cells. Cells were 
stimulated with IL-1β (10 ng/ml) in the presence of 1 µg/ml recombinant MMP1 catalytic 
domain for 4 hours and luciferase activity in cell lysates was determined. (C) 57A HeLa cells 
were preincubated for 2 hours with 40 µl of the indicated 20 times concentrated supernatants 
from transiently transfected 293T cells. Cells were stimulated with IL-1β (10 ng/ml) in the 
presence of 1 μg/ml recombinant MMP1 catalytic domain and ΤΑPI1 (500 μΜ) for 4 hours 
and luciferase activity in cell lysates was determined. The histograms represent mean relative 
light units ± SEM of triplicate cell cultures (n = 3, *** = p ≤ 0.001, 1 way ANOVA followed by 
Tukey’s Multiple Comparison Test). 
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Figure 6.6: Inhibition of IL-1β-induced NF-κΒ activation by secreted LAP-MMP-TAT3-
NBD from DTF cells. 57A HeLa cells were preincubated for 2 hours with 100 µl of the 
indicated supernatants from 1 x 106 DTF cells after infection round 6. Cells were stimulated 
with 10 ng/ml IL-1β for 4 hours and luciferase activity in cell lysates was determined. The 
histograms represent mean relative light units ± SEM of triplicate cell cultures (n = 3, * = p ≤ 
0.05, 1 way ANOVA followed by Tukey’s Multiple Comparison Test). 
 
 
 
Figure 6.7:  Transiently transfected 293T cells can secrete more LAP-MMP-TAT3-NBD 
than DTF transduced cells. DTF cells were infected with the LAP-MMP-TAT3-NBD lentiviral 
vector. After infection round 6, 1 x 106 cells were seeded on a 10 cm culture plate and 
cultured for 24 hours with serum-containing medium. After the initial 24 hours of cell culture, 
medium was replaced with serum-free medium and cells left to grow for 24 more hours. 
Serum-free supernatants were collected after 24 hours of cell culture. 1 x 106 293T cells were 
transiently transfected with the LAP-MMP-TAT3-NBD pcDNA3 vector and serum free 
medium was collected 24 hours post transfection. Serum free supernatants were analysed by 
western blotting analysis. 30 µl out of 5 ml of supernatant were run on SDS-PAGE under 
reducing conditions, transferred onto PVDF membrane and probed with anti-FLAG antibodies 
overnight. Membrane was exposed for 3 minutes. (1) Mock, (2) DTF cells after infection 
round 6, (3) transiently transfected 293T cells. 
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6.2.2 Co-culture of 57A HeLa cells with DTF cells expressing the 
secretable LAP-PTD-fusion NF-κB inhibitor NBD can inhibit NF-κB 
transcriptional activity  
 
 
 57A HeLa cells were also co-cultured with DTF cells expressing the secretable 
NF-κΒ PTD-fusion inhibitors in order to assess NF-κB inhibition in vitro. 4 x 104 or 8 x 
104 57A HeLa cells were seeded in the same 96 culture well plate with 4 x 104 of 
genetically engineered DTF cells and left to grow together overnight in the presence 
or not of MMP1. Next day, cells were stimulated with IL-1β for 4 hours and luciferase 
activity in live cells was determined. In the experiment shown in Figures 6.8 – 6.9, co-
culture of 57A HeLa cells with DTF cells secreting LAP-GS-TAT3-NBD, or LAP-MMP-
TAT3-NBD resulted in reduction of luciferase activity only when cells were not treated 
with MMP1. MMP1 treatment resulted in overall reduction of luciferase activity, 
including strong inhibition of luciferase activity in 57A HeLa cells that were co-cultured 
with DTF cells secreting LAP-MMP, LAP-GS-TAT3-eGFP, or LAP-MMP-TAT3-eGFP. 
This finding, which was also observed in the experiments where 57A HeLa cells were 
treated with supernatants containing the PTD-fusion inhibitors in the presence of 
MMP1, confirmed that MMP1 was affecting NF-κΒ transcriptional activity. Therefore, 
the presence of MMP1 was interfering with this in vitro assay and no clear 
conclusions could be made when MMP1 was used. This experiment also revealed 
that the secretable NF-κΒ inhibitors from DTF cells could demonstrate NF-κΒ 
inhibition; however the levels of inhibition were approximately ~ 10% - 20% when 8 x 
104 57A HeLa cells were co-cultured with 4 x 104 DTF cells (Figure 6.8 - A and Figure 
6.9 - B). 
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Figure 6.8: Co-cultured DTF cells expressing LAP-PTD-fusion NF-κΒ inhibitors affect 
IL-1β-induced luciferase expression in 57A HeLa cells. Images of 96 well co-cultures of 
57A HeLa cells with the indicated DTF cell lines. 57A HeLa cells were co-cultured overnight 
in the presence (B) or absence (A) of MMP1. Next day cells were stimulated with IL-1β (10 
ng/ml) for 4 hours and luciferase activity in live cells was determined. Luciferase images were 
overlaid on the 96 well photograph, and emission of light was quantified as photons per 
steradian per square centimeter using living image® software version 2.5.50.1. Plates were 
exposed for 30 seconds after 5 minutes of initial incubation of the cells with luciferin K+ salt. 
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Figure 6.9: Inhibition of IL-1β induced NF-κΒ activation by secreted LAP-GS-TAT3-NBD 
and LAP-MMP-TAT3-NBD from DTF cells. 4 x 104 (A, C) or 8 x 104 (B, D) 57A HeLa cells 
57A HeLa cells were co-cultured with 4 x 104 of the indicated DTF cell lines overnight in the 
presence (C, D) or not (A, B) of MMP1. Next day cells were stimulated with 10 ng/ml IL-1β for 
4 hours and luciferase activity in live cells was determined. The histograms represent mean 
relative light units ± SEM of triplicate cell cultures (n = 3, * = p ≤ 0.05, 1 way ANOVA followed 
by Tukey’s Multiple Comparison Test). 
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6.2.3 Gelatin zymography in 293T, 57A HeLa and DTF cells 
 
 
In all the in vitro studies that were performed with 57A HeLa cells, the secreted 
LAP-MMP-TAT3-NBD and LAP-GS-TAT3-NBD inhibitors demonstrated NF-κΒ 
inhibitory activity without the use of exogenous MMPs. This finding suggests that the 
inhibitors could penetrate the cells without the need of MMP cleavage, or 
endogenous levels of MMP were sufficient to cleave the latent TAT3-NBD inhibitors, 
which in turn were free to exert their functions. The levels of endogenous MMPs that 
were present in the supernatants from transiently transfected 293T, DTF and 57A 
HeLa cells were determined by gelatin zymography. In the experiment shown in 
Figure 6.10, all supernatants demonstrated MMP2 activity and supernatants from 
DTF cells revealed highest levels of active MMP2 (Figure 6.10 - 4). There was also 
no difference between the levels of MMP2 activity in unstimulated (Figure 6.10 - 5) 
and stimulated (Figure 6.10 - 6) 57A HeLa cells with IL-1β. Therefore, stimulation with 
IL-1β did not upregulate the secretion of MMP2 in 57A HeLa cells. MMP9 activity was 
not detected in any of the supernatants that were used. However, the supernatants 
that were used in this experiment were unconcentrated and small amounts of MMP9, 
if present, could not be detected. Gelatin zymography does not provide information 
about other members of the MMP family proteins, apart from those described above, 
and therefore it is not known if other MMPs are present in the supernatants from 
transiently transfected 293T, DTF and 57A HeLa cells.     
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Figure 6.10: Gelatin zymography of MMP in supernatants from transiently transfected 
293T, DTF and 57A HeLa cells. Serum free supernatants from 1 x 106 293T cells that were 
transiently transfected with the LAP-MMP-TAT3-NBD pcDNA3 vector, 1 x 106 of LAP-MMP-
TAT3-NBD DTF cells and 1 x 106 of 57A HeLa cells were collected and analysed by gelatine 
zymography. Serum free supernatants from 1 x 106 57A HeLa cells that were stimulated with  
IL-1β (10 ng/ml) for 4 hours were also analysed. 20 µl out of 5 ml of supernatant were run on 
α gelatine containing gel under reducing non denaturating conditions. Arrows indicate pro 
and active forms of MMP 2. (1) Blank (2) Supernatant from transiently transfected 293T cells 
with the LAP-MMP-TAT3-NBD pcDNA3 vector, (3) Supernatant from LAP-MMP-TAT3-NBD 
DTF cells, (4) Supernatant from unstimulated 57A HeLa cells, (5) Supernatant from 57A 
HeLa cells after 4 hours stimulation with IL-1β. 
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6.3 Discussion 
 
 
 The LAP-MMP-TAT3-NBD inhibitor showed inhibition of NF-κB in the absence 
of exogenous MMP1 enzyme, and there was no additional activity observed when 
MMP1 was added to the in vitro assays. It was anticipated that the LAP-MMP-TAT3-
NBD inhibitor would have been inactive, because LAP would prevent interaction of 
the TAT3 domain with the cell surface or interaction of the NBD domain with the IKK 
complex. Similarly the LAP-GS-TAT3-NBD inhibitor, where the MMP sequence was 
replaced with a GS linker which was not sensitive to MMP cleavage, demonstrated 
NF-κB inhibitory activity in the co-culture biological assay. This data indicates that the 
LAP-TAT3-NBD displays activity as an intact molecule or as the TAT3-NBD 
component alone when cleaved with endogenous MMPs. Previous observations 
showing latency of IFNβ (Adams et al., 2003) and other molecules when linked to the 
LAP domain have had sites of action that are extracellular and in these constructs the 
LAP domain dimerises to have latent activity. In this study, the monomeric forms of 
LAP-PTD-fusion constructs were also detected in supernatants from expressing DTF 
cells after western blotting analysis in non-denaturing conditions (data not included). 
Therefore, in vitro activity of the LAP-PTD-fusion inhibitors can be due to the 
monomeric, non-latent active forms of the inhibitors that are present in the 
supernatants. The reducing conditions inside cells may prevent dimer formation and 
so preclude latency of the LAP-TAT3-NBD molecule. Although the LAP domain does 
not inhibit activity of the NBD peptide, it can be assumed that the half life of the 
peptide will be increased through stabilisation of the molecule. 
 The addition of exogenous MMP1 appeared to interfere with the biological 
assays, as NF-κΒ inhibition was observed in all samples when MMP1 was added. An 
explanation for this is that MMP1 can also cleave non-matrix substrates such as IL-
1β, antichymotrypsin, antitrypsin, insulin-growth factor binding protein (IGFBP)-3, 
IGFBP-5, L-selectin, ovostatin, TNF-α, and stromal cell-derived factor-1. MMP1 can 
also cleave and activate pro-MMP2 and cell-surface receptors, such as protease-
activator receptors, which in turn can alter cell signalling (Schonbeck et al., 1998; 
McCawley and Matrisian, 2001; Boire et al., 2005; Pardo and Selman, 2005;). Gelatin 
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zymography revealed expression of pro-MMP2 and MMP2 from 57A HeLa, DTF and 
293T cells, therefore addition of MMP1 can increase the levels of active MMP2, which 
can also target non-matrix proteins such as IL-1β, ΤΝFα and FGF-R1(McCawley and 
Matrisian, 2001). Thus, the addition of exogenous MMP1 can lead to the cleavage 
and neutralisation of IL-1β, which in turn results to decreased levels of NF-κΒ activity. 
 An interesting finding was that the supernatants from 293T cells containing the 
LAP-MMP-TAT3-NBD demonstrated stronger NF-κΒ inhibition when compared to 
supernatants from DTF cells. This can be explained by the higher concentration of 
the inhibitor that is present in the supernatants from 293T cells. In agreement to this 
finding, the purified Antp-NBD inhibitor also demonstrated NF-κΒ inhibition in a dose 
dependent manner. This data suggest that certain levels of the inhibitor must be 
present in the microenviroment in order for NF-κΒ inhibition to be achieved, which 
represents one of the major challenges in this study for the successful inhibition of 
NF-κΒ in a biological system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
Chapter VII:                 
Biological activity of LAP-PTD-fusion 
NF-κB inhibitors in vivo 
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7.1 Introduction 
  
 
The in vivo NF-κB inhibitory properties of the secreted LAP-PTD-fusion 
inhibitors were tested in three different acute inflammation animal models, the 
Carrageenan-induced paw oedema model, the mBSA Antigen-Induced Arthritis 
model and the Air-Pouch inflammation model. 
 
7.1.1 Carrageenan-induced paw oedema 
 
 
 Carrageenan-induced paw oedema is an acute, nonimmune and highly 
reproducible inflammation model that is based on the injection of λ-carrageenan, a 
polysaccharide composed of galactose-related monomers repeats, into the animals’ 
paws. Following injections of λ-carrageenan, inflammation develops that is 
characterised by oedema, hyperalgesia, and erythema. Proinflammatory agents, such 
as bradykinin, histamine, tachykinins, complement, reactive oxygen and nitrogen 
species are responsible for the inflammation induction. The proinflammatory agents 
are generated in situ at the site of injection or by infiltrating cells, such as neutrophils 
(Winyard and Willoughby, 2003).  
 In this study, DTF cells expressing the secretable LAP-TAT3-fusion proteins 
were transplanted into the paws of Swiss mice. After 48 hours of cell transplantation, 
λ-carrageenan was injected into the paws and the inflammatory response was 
quantified by the increase in paw swelling (oedema). 
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7.1.2 mBSA Antigen Induced Arthritis model 
 
 
 mBSA Antigen-Induced-Arthritis model is a T-cell-driven acute inflammation 
model. This model is based on methylated BSA (mBSA) injections into the paws of 
previously immunised animals. It is a simpler model compared to autoimmune 
polyarthritis models, as inflammation is only induced to the injected joint and severity 
can be controlled with the dose of locally injected antigen (van den Berg et al., 2007).      
In this study, lentiviral vectors encoding the secretable LAP-TAT3-fusion 
proteins were injected into the paws of Balb/c mice. After 72 hours of lentiviral vectors 
injections, mBSA was injected into the paws and the inflammatory response was 
quantified by the increase in paw swelling (oedema). 
 
7.1.3 Air-Pouch inflammation model 
 
 
 The Air-Pouch inflammation model is an acute inflammation model for the 
study of cytokine- or chemokine-induced leukocyte recruitment. It is a simplified 
version of more complex immune reactions induced by agents such as carrageenan 
or zymosan, and exploits the ability of cytokines (such as IL-1, TNF) and chemokines 
[such as IL-8, monocyte chemoattractant protein-1 (MCP-1)] to recruit immune cells 
into the inflammation site. Therefore, this model is mainly used for the identification 
and characterisation of selective antagonists to cytokine and chemokine receptors 
(Winyard and Willoughby, 2003). 
 In this study, DTF cells expressing the secretable LAP-TAT3-fusion proteins 
were transplanted into the air pouch that was formed in the back of the neck of Swiss 
mice. After 72 hours of cell transplantation, IL-1β was injected into the air pouch and 
4 hours later the pouch was washed and cell accumulation was quantified by 
differential counting and analysed by FACS analysis. 
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7.2 Results 
 
 
7.2.1 Reduced paw swelling in animals treated with engineered DTF 
cells secreting the LAP-MMP-TAT3-NBD NF-κΒ inhibitor in the 
Carrageenan-induced paw oedema model 
 
 
2 million genetically engineered DTF cells that were producing the secretable 
LAP-TAT3-fusion NF-κΒ inhibitors were transplanted in the hind paws of Swiss mice. 
In the experiment shown in Figure 7.1, acute inflammation was induced with 25 µl of 
1% λ-carrageenan and animals that were transplanted with the DTF cells expressing 
the secretable LAP-MMP-TAT3-NBD demonstrated significantly lower swelling of 
their hind paws, when compared to animals that were transplanted with non 
genetically engineered DTF or DTF cells expressing LAP-MMP. Animals that were 
not transplated with DTF cells showed milder paw swelling when compared with the 
other groups. For the LAP-MMP DTF and LAP-MMP-TAT3-NBD DTF groups the paw 
swelling peaked 24 hours (Day 3) after carrageenan injection followed by continuous 
reduction in the next 5 days of monitoring. For the DTF group, the swelling of the 
paws peaked 96 hours (Day 6) after carrageenan injection. For the group where no 
cells were transplated the paw swelling peaked 48 hours (Day 4) after carrageenan 
injection. The monitoring of the animals’ weights also showed a physiological 
increase, which demonstrated good overall health of the animals (Figure 7.2). 
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Figure 7.1: Therapeutic effect of the secretable LAP-MMP-TAT3-NBD NF-κΒ inhibitor 
after transplantation of genetically engineered DTF cells in the λ-carrageenan induced 
paw oedema. DTF cells (2 x 106) or PBS were injected in both hind paws of Swiss mice on 
Day 0. On Day 2 (48 hours post cell transplantation), 25 μl of 1% λ-carrageenan were 
injected in the hind paws and their thickness measured daily. Symbols illustrate significant 
differences of the LAP-MMP-TAT3-NBD DTF group from the DTF group, *** = p ≤ 0.001 and 
from the LAP-MMP DTF group, ▪ = p ≤ 0.05, ▪▪ = ≤ 0.01. Values represent the mean and SEM 
(n = 10). Statistics were performed using 1 way ANOVA followed by Tukey’s Multiple 
Comparison Test. 
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Figure 7.2: Animal weights after transplantation of genetically engineered DTF cells in 
the λ-carrageenan induced paw oedema. DTF cells (2 x 106) or PBS were injected in both 
hind paws of Swiss mice on Day 0. On Day 2 (48 hours post cell transplantation), 25 µl of 1% 
λ-carrageenan were injected in the hind paws and animal weights measured daily. Values 
represent the mean and SEM (n = 5). 
 
 
 
In a second experiment, 2 million of genetically engineered DTF cells 
producing the secretable LAP-TAT3-fusion NF-κΒ inhibitors were transplanted in the 
hind paws of Swiss mice and acute inflammation was induced with 50 μl of 1% λ-
carrageenan. Animals that were transplanted with the DTF cells expressing the 
secretable LAP-MMP-TAT3-NBD demonstrated significantly lower thickness of their 
hind paws, when compared to the negative controls (Figure 7.3). As negative controls 
non genetically engineered DTF, LAP-MMP DTF, LAP-GS-TAT3-NBD DTF cells or 
PBS were injected. For the LAP-MMP DTF and LAP-GS-TAT3-NBD DTF groups the 
paw swelling peaked at 72 hours (Day 5) after carrageenan injection followed by 
continuous reduction for the next 4 days that the animals were monitored. For the 
DTF group, the swelling of the paws continued raising up to 120 hours (Day 7) after 
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carrageenan injection and for the LAP-MMP-TAT3-NBD DTF group it peaked 96 
hours (Day 6). Interestingly, the LAP-GS-TAT3-NBD DTF group showed milder paw 
swelling after the LAP-MMP-TAT3-NBD DTF group, followed by the LAP-MMP DTF 
and unmanipulatd DTF groups. For the group that no cells were transplated the paw 
swelling peaked 72 hours (Day 5) after carrageenan injection and again animals 
demonstrated overall milder paw swelling when compared to the groups where DTF 
cells were transplanted. There was also observed a physiological increase of the 
animals’ weights, which demonstrated good overall health of the animals (Figure 7.4). 
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Figure 7.3: Therapeutic effect of the secretable LAP-MMP-TAT3-NBD NF-κΒ inhibitor 
after transplantation of genetically engineered DTF cells in the λ-carrageenan induced 
paw oedema. DTF cells (2 x 106) or PBS were injected in both hind paws of Swiss mice on 
Day 0. On Day 2 (48 hours post cell transplantation), 50 μl of 1% λ-carrageenan were 
injected in the hind paws and their thickness measured daily. Symbols illustrate significant 
differences of the LAP-MMP-TAT3-NBD DTF group from the DTF group, ** = p ≤ 0.01, *** = p 
≤ 0.001, from the LAP-GS-TAT3-NBD DTF group, ▪ = p ≤ 0.05, and from the LAP-MMP DTF 
group, x = p ≤ 0.05. Values represent the mean and SEM (n = 10). Statistics were performed 
using 1 way ANOVA followed by Tukey’s Multiple Comparison Test. 
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Figure 7.4: Animal weights after transplantation of genetically engineered DTF cells in 
the λ-carrageenan induced paw oedema. DTF cells (2 x 106) or PBS were injected in both 
hind paws of Swiss mice on Day 0. On Day 2 (48 hours post cell transplantation), 50 µl of 1% 
λ-carrageenan were injected in the hind paws and animal weights measured daily. Values 
represent the mean and SEM (n = 5). 
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7.2.2 Reduced paw swelling in animals treated with lentiviral vectors 
encoding the secretable LAP-MMP-TAT3-NF-κΒ inhibitor in the 
mBSA antigen-induced arthritis model 
 
 
The mBSA Antigen-Induced Arthritis model was also used for the study of the 
anti-inflammatory effects of the secretable LAP-TAT3-NBD inhibitor. In the 
experiment shown in Figure 7.5, 1.5 x 106 TU of the LAP-MMP, LAP-MMP-TAT3-
eGFP, LAP-MMP-TAT3-NBD lentiviral vectors in a volume of 20 µl or 20µl of DMEM 
culture medium were injected in the hind paws of Balb/c mice. 72 hour post-injection 
of the lentiviral vectors, acute inflammation was induced with 50 µl of mBSA. Animals 
that were injected with the LAP-MMP-TAT3-NBD lentiviral vector demonstrated 
significantly lower thickness of their hind paws, when compared to the animals that 
were injected with LAP-MMP or LAP-MMP-TAT3-eGFP lentiviral vectors (Figure 7.5). 
In all groups injected with lentiviral vectors, paw swelling peaked at 24 hours (Day 15) 
after mBSA injection followed by continuous reduction for the next 5 days the animals 
were monitored. Paw swelling in animals that were not injected with a lentiviral vector 
peaked 48 hours post-mBSA injection and was milder when compared to the other 
groups. However, after day Day 16 post-immunasation unteated animals 
demonstrated similar paw swelling to LAP-MMP-TAT3-NBD treated animals. Also no 
major changes in the animals’ weights were observed, which demonstrated good 
overall health of the animals (Figure 7.6). Pictures of representative paws 48 hours 
post mBSA injection is shown in Figure 7.7. 
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Figure 7.5: Treatment with the replication-deficient lentiviral vector encoding LAP-
MMP-TAT3-NBD and effect of the secretable LAP-MMP-TAT3-NBD NF-κΒ inhibitor on 
mBSA Antigen-Induced Arthritis model. BALB/c mice were immunised by subcutaneous 
injection of 0.5 ml mBSA in complete Freund’s adjuvant at Day 0. On day 11, 1.5 x 106 TU of 
the LAP-MMP, LAP-MMP-TAT3-eGFP, LAP-MMP-TAT3-NBD lentiviral vectors in a volume of 
20 µl or 20 µl of DMEM culture medium were injected in both hind paws. 72 hours post 
lentiviral vector injection (Day 14), 50 µl of mBSA were injected in the hind paws and their 
thickness was measured using POCO 2T caliper daily. Values represent the mean and SEM 
(n = 5, * = p ≤ 0.05 and ** = p ≤ 0.01 when LAP-MMP-TAT3-NBD group is compared to LAP-
MMP group, ▪ = p ≤ 0.05, ▪▪ = p ≤ 0.01 and ▪▪▪ = p ≤ 0.001 when LAP-MMP-TAT3-NBD group 
is compared to LAP-MMP-TAT3-eGFP group. 1 way ANOVA followed by Tukey’s Multiple 
Comparison Test). 
 
 
 
 
 
 
 Page | 182  
 
 Chapter VII 
 
 
Figure 7.6: Animal weights after treatment with the replication-deficient lentiviral 
vectors on mBSA Antigen-Induced Arthritis model. Balb/c mice were immunised by 
subcutaneous injection of 0.5 ml mBSA in complete Freund’s adjuvant at Day 0. On day 11, 
1.5 x 106 TU of the LAP-MMP, LAP-MMP-TAT3-eGFP, LAP-MMP-TAT3-NBD lentiviral 
vectors in a volume of 20 µl or 20 µl of DMEM culture medium were injected in both hind 
paws. 72 hours post lentiviral vector injection (Day 14), 50 µl of mBSA were injected in the 
hind paws and animal weights were measured daily. Values represent the mean and SEM (n 
= 5). 
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Figure 7.7: Photographs of representative hind paws after treatment with the 
replication-deficient lentiviral vectors on mBSA Antigen-Induced Arthritis model. 
BALB/c mice were immunised by subcutaneous injection of 0.5 ml mBSA in complete 
Freund’s adjuvant at Day 0. On day 11, 1.5 x 106 TU of the LAP-MMP, LAP-MMP-TAT3-
eGFP, LAP-MMP-TAT3-NBD lentiviral vectors or 20 µl of DMEM culture medium in a volume 
of 20 µl were injected in both hind paws. 72 hours post lentiviral vector injection (Day 14), 50 
µl of mBSA were injected in the hind paws. Pictures were taken 48 hours post mBSA 
injection. (A) LAP-MMP, (B) LAP-MMP-TAT3-eGFP, (C) LAP-MMP-TAT3-NBD and (D) No 
treatment. 
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7.2.3 Treatment with engineered DTF cells secreting the LAP-MMP-
TAT3-NBD NF-κΒ inhibitor in the Air-Pouch inflammation model did 
not inhibit cell infiltration 
 
 
The Air-Pouch inflammation model was also used for the study of the anti-
inflammatory effects of the secretable LAP-TAT3-NBD inhibitor. 2 million genetically 
engineered DTF cells were transplanted into the air pouch of Swiss mice, that was 
formed in the back, and 72 hours later acute inflammation was induced with IL-1β (20 
ng). After 4 hours of IL-1β stimulation, air pouches were washed and cell infiltration 
was quantified by differential counting and analysed by FACS analysis. Cells that 
migrate into the air pouch are predominantly GR1+ and Figure 7.9, shows a 
representative example of FACS analysis with PE-conjugated GR1 antibodies from 
sample collected from the air pouch. The ability of PE-conjugated GR1 antibodies to 
bind to DTF cells was also examined and no DTF cell specificity was detected (Figure 
7.8). Together total cell count calculated by differential counting and the percentage 
of GR1+ cells calculated by FACS analysis can approximately determine the immune 
cells that migrated into the air pouch. In the experiment shown in Figure 7.10, animals 
that were transplanted with DTF cells expressing the secretable LAP-MMP-TAT3-
NBD did not inhibit the infiltration of GR1+ cells when compared to the controls. As 
controls unmanipulated DTF, LAP-MMP DTF cells or PBS were injected into the air 
pouches. The monitoring of the animals’ weights also showed a physiological 
increase, which demonstrated good overall health of the animals (Figure 7.11). 
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Figure 7.8: PE-conjugated GR1 antibodies do not bind to DTF cells. DTF cells were 
probed with isotype control antibodies or PE-conjugated GR1 antibodies. After staining 
binding antibodies were detected by FACS analysis and DTF cells were gated on live 
populations. Dot Blots representation show DTF staining with isotype control antibody (A), 
PE-conjugated GR1 antibody (B). 
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Figure 7.9: Identification of GR1+ leucocytes by FACS analysis. A representative 
example of all cells harvested from a 4 hour IL-1β stimulated air pouch FACS analysis. PE-
conjugated GR1 antibodies were used to identify a specific GR1+ population of granulocytes 
that migrated into the air pouch. After staining, binding antibodies were detected by FACS 
analysis and GR1+ cells were gated on live populations. Dot Blots and histograms show 
GR1+ cells staining with isotype control antibody (A and C), PE-conjugated GR1 antibody (B 
and D). Neutrophils are characterised by high GR1+ binding (circle). A percentage of the total 
population can be derived and compared with total cell counts to derive total GR1+ cells 
within a given cell suspension.  
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Figure 7.10: Lack of therapeutic effect of the secretable LAP-MMP-TAT3-NBD NF-κΒ 
inhibitor after transplantation of genetically engineered DTF cells in IL-1β-induced air 
pouch. DTF cells (2 x 106) or PBS were injected into the air pouch of Swiss mice on Day 4. 
On Day 7 (72 hours post cell transplantation), 20 ng of IL-1β were injected into the air pouch 
and 4 hours later the air pouch was washed and cell infiltration was quantified by differential 
counting and analysed by FACS analysis. (A) Total GR1+ cells per air pouch, (B) Total high 
GR1+ cells per air pouch, (C) Percentage of GR1+ cells per air pouch, (D) Percentage of high 
GR1+ cells per air pouch. Values represent the mean and SEM (n = 5), p ≥ 0.05, 1 way 
ANOVA followed by Tukey’s Multiple Comparison Test. 
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Figure 7.11: Animal weights after transplantation of genetically engineered DTF cells in 
IL-1β-induced air pouch. Air pouch was formed on Day 0. DTF cells (2 x 106) or PBS were 
injected into the air pouch of Swiss mice on Day 4. On Day 7 (72 hours post cell 
transplantation), 20 ng of IL-1β were injected into the air pouch and 4 hours later the air 
pouch was washed and cell infiltration was quantified by differential counting and analysed by 
FACS analysis. Animal weights were measured daily. Values represent the mean and SEM 
(n = 5). 
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As there were no effects on cell recruitment observed with the transplantation 
of 2 million of LAP-MMP-TAT3-NBD DTF cells the number of cells transplanted was 
increased in a repeated experiment. This time 10 million of genetically engineered 
DTF cells were transplanted into the air pouch of Swiss mice, and similarly to the 
previous experiment, after 72 hours of cell transplantation acute inflammation was 
induced with IL-1β (20 ng). After 4 hours of IL-1β stimulation, air pouches were 
washed and cell infiltration was quantified by differential counting and analysed by 
FACS analysis. Animals that were transplanted with DTF cells expressing the 
secretable LAP-MMP-TAT3-NBD did not demonstrate a significant difference in 
infiltration of GR1+ cells when compared to the negative controls, however as it can 
be seen in Figure 7.12 there was a tendency for significantly reduced percentage of 
high GR1+ cells in the LAP-MMP-TAT3-NBD DTF group. As negative controls 
unmanipulated DTF, LAP-MMP DTF, LAP-GS-TAT3-NBD cells or PBS were injected. 
Good overall health of the animals was also observed from the physiological increase 
of animals’ weights (Figure 7.13). 
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Figure 7.12: Lack of therapeutic effect of the secretable LAP-TAT3-NBD NF-κΒ inhibitor 
after transplantation of genetically engineered DTF cells in IL-1β-induced air pouch. 
DTF cells (1 x 107) or PBS were injected into the air pouch of Swiss mice on Day 4. On Day 7 
(72 hours post cell transplantation), 20 ng of IL-1β were injected into the air pouch and 4 
hours later the air pouch was washed and cell infiltration was quantified by differential 
counting and analysed by FACS analysis. (A) Total GR1+ cells per air pouch, (B) Total high 
GR1+ cells per air pouch, (C) Percentage of GR1+ cells per air pouch, (D) Percentage of high 
GR1+ cells per air pouch. Values represent the mean and SEM (n = 5), p ≥ 0.05, 1 way 
ANOVA followed by Tukey’s Multiple Comparison Test. 
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Figure 7.13: Animal weights after transplantation of genetically engineered DTF cells in 
IL-1β-induced air pouch. Air pouch was formed on Day 0. DTF cells (10 x 106) or PBS were 
injected into the air pouch of Swiss mice on Day 4. On Day 7 (72 hours post cell 
transplantation), 20 ng of IL-1β were injected into the air pouch and 4 hours later the air 
pouch was washed and cell infiltration was quantified by differential counting and analysed by 
FACS analysis. Animal weights were measured daily. Values represent the mean and SEM 
(n = 5). 
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7.3 Discussion 
 
 
 The LAP-MMP-TAT3-NBD molecule with the MMP cleavage site displays anti-
inflammatory activity in the carrageenan and mBSA Antigen-Induced Arthritis models 
when delivered locally from transplanted cells or from injected lentivirus and 
compared to other LAP-fusion proteins. However, LAP-MMP-TAT3-NBD did not 
demonstrate strong enough anti-inflammatory properties in order to completely 
abolise inflammatory responses and in all experiments untreated animals showed 
milder paw swelling when compared to the other groups. An explanation for this could 
be that the transplatantion of allogenic DTF cells to Swiss mice and injections of 
lentiviruses to Balb/c mice few days prior the induction of inflammation by λ-
caraggenan or mBSA possibly had induced initial inflammatory responces and 
therefore, animals were primed for stronger inflammatory reactions.  
 The equivalent LAP-TAT3-NBD molecule with the GS linkage was not as 
effective as the LAP-MMP-TAT3-NBD when tested in the carrageenan model whilst 
both showed inhibition of NF-κΒ in vitro. This may reflect the fact that in the smaller 
cleaved TAT3-NBD molecule (4.5 kDa) achieves better distribution in the inflamed 
paw compared with the GS molecule which remains attached to the LAP domain (41 
kDa), or the levels of MMPs in the inflamed paws are not sufficient for the cleavage of 
the less sensitive to MMPs LAP-GS-TAT3-NBD construct, which results in less 
availability of the TAT3-NBD. Interestingly, the LAP-MMP treated group appears to 
demonstrate milder paw swelling after the LAP-MMP-TAT3-NBD and LAP-GS-TAT3-
NBD groups, which suggest that LAP peptide may have an anti-inflammatory effect 
on its own. Ali et al., (2008) have reported that LAP peptide alone can block in vivo 
inflammation in a murine model of the delayed-type hypersensitivity response 
(DTHR). The purified inhibitor Antp-NBD, which can be compared to the TAT3-NBD 
that is released from the secreted LAP-fusion proteins, has been shown to inhibit 
inflammation in the carrageenan and CIA model by specifically blocking the NF-κΒ 
signalling pathway (di Meglio et al., 2005; Jimi et al., 2004). In these studies, high 
concentration of the purified inhibitor was administered and in the CIA model the 
purified inhibitor was administered on a daily basis. Here in this study, producing cells 
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can not secrete comparable amounts of the inhibitor, however it appears that 
secretion of the inhibitor in the environment were inflammation occurs is efficient in 
order to demonstrate anti-inflammatory results. A major limitation of this approach is 
the amount of the inhibitor secreted into the joint microenvironment, and from the 
above it can be concluded that increased bio- availability of the secreted LAP-MMP-
TAT3-NBD can demonstrate stronger anti-inflammatory results. Interestingly, the 
LAP-MMP-TAT3-NBD had no effect on cell recruitment in the Air-Pouch acute 
inflammation model. However, when 10 million of DTF cells were transplanted, there 
was a tendency for a lower percentage of neutrophil recruitment (Figure 7.12). The 
secreted inhibitor in the air pouch is distributed in a much larger inflamed tissue and 
levels of the inhibitor may not be sufficient to demonstrate anti-inflammatory effects. 
Again this finding can support the importance of efficient levels of the inhibitor that 
need to be secreted in order to exert its actions.  
 
 
  
 
 
  
 
Chapter VIII:        
General discussion 
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8.1 General discussion 
 
 
Our better understanding of the molecular mechanisms that are involved in the 
development of RA has revolutionised RA patients’ treatment, over the past two 
decades. The early use of NSAIDs was followed by the development of DMARDs and 
introduction of glucocorticoid regiments. The real breakthrough, however, came with 
the introduction of biological agents, which in general demonstrate rapid and strong 
improvements on the disease symptoms. Today, clinicians have on their arsenal a 
wide range of NSAIDs, DMARDs, glucocorticoids and biological agents with distinct 
mechanisms of action and new better strategies for the treatment of RA. However, a 
number of patients does not respond to these therapies and many are associated 
with toxicities and adverse effects, destructive process cannot be halted in all patients 
and a ‘cure’ still remains an elusive goal. Therefore, new more efficient and cost 
effective therapeutic approaches need to be developed (van Vollenhoven, 2009). 
 Promising therapeutic strategies that could provide solutions to the unmet 
needs in RA therapy could derive from gene therapy approaches. Indeed, gene 
therapies directed toward the treatment of RA continues to be a very active research 
areas (Evans et al., 2009). Recent preclinical studies have demonstrated that 
adenoviral gene delivery of adiponectin (Ebina et al., 2009) and soluble VEGF 
receptor 1 (sFlt-1) (Afuwape et al., 2003) reduced disease severity in CIA mice. 
Khoury et al., (2008) also suppressed disease development in CIA mice after 
administrating anti-IL-1, anti-IL-6 and anti-IL-18 siRNA based lipoplexes. Delivery of 
mesenchymal stem cells (MSC) that were engineered with retroviruses to over-
express IL-10 ameliorated the disease characteristics in CIA mice (Choi et al., 2008). 
Gene silencing of B-cell activating factor (BAFF), which is an important factor for B-
cell maturation and proliferation, using lentiviral vectors that express small hairpin 
RNA for BAFF also attenuated the severity and disease progression in CIA mice (Lai 
Kwan Lam et al., 2008). In clinical studies, blockage of IL-1 and TNF with intra-
articular expression of IL-1Ra and TNFR:Fc respectively, using ex vivo and in vivo 
approaches has shown that patients are responsive to these therapies (Evans et al., 
2009).  
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Long term gene expression is required for a successful gene therapy treatment 
of RA, as RA is a chronic inflammatory disease. Studies by Sandalon et al. (2007), 
have shown persistent high expression of soluble TNF receptor (sTNFR) for over a 
year when sTNFR cDNA was delivered in rats with AAV vectors. Long term 
expression of human IL-1Ra in rats when delivered with lentiviral or AAV vectors was 
also reported by Gouze et. al., (2007). These studies therefore make clear that long 
term expression can be achieved in animal models of disease and ongoing research 
on the development of less immunogenic vectors with increased transduction 
efficiency will enable more effective delivery and expression of therapeutic genes 
(Evans et al., 2009). 
Safety is another limitation of gene therapy. However, enhanced safety of this 
therapeutic approach can be achieved with the use of adenoviral based vectors that 
do not integrate into the host’s genome and with the use of inducible promoters. 
Regulation of gene expression has been achieved with the use of NF-κB responsive 
elements (Adriaansen et al., 2007; Khoury et al., 2007), cyclooxygenase-2 promoter 
(Rachakonda et al., 2008), a hybrid IL-1 enhancer/ IL-6 proximal promoter (Geurts et 
al., 2007) and Dox dependent promoter (Gould et al., 2007). Initial clinical trials on 
gene therapy of RA have also reported no drug-related adverse events, with the 
exception of the death of a young woman after the second AAV2 vector injection of 
into her right knee joint (Evans et al., 2009). 
Another important concern that determines the outcome of an RA gene 
therapy approach is the gene that is delivered. As mentioned above, previous studies 
have explored a wide range of different genes that target signalling pathways that are 
involved in the development of RA. These include TNF, IL-1, IL-18, ΝF-κΒ inhibitors, 
IL-4, IL-10, IL-13 anti-inflammatory cytokines and immunomodulatory genes such as 
BAFF and CTLA-4 (Chernajovsky et al., 2004; Evans et al., 2009). Here in this study, 
the focus was on NF-κΒ signalling, as aberrant NF-κΒ activity has been linked to the 
development of chronic inflammatory and autoimmune diseases, such as RA (Ghosh 
and Hayden, 2008; Karin et al., 2004). The NF-κΒ transcription factor regulates the 
expression of many genes that are involved in inflammation, innate and adaptive 
immunity, cell growth, survival and proliferation. NF-κΒ signalling has a central role in 
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inflammatory responses (Barnes and Karin, 1997; Simmonds and Foxwell, 2008) and 
its upregulation has been shown in the paws of transgenic animals that have the 
luciferase gene under the control of NF-κΒ during the development of arthritis 
(Carlsen et al., 2002). NF-κΒ is generally considered as a master regulator for the 
development and perpetuation of RA and therefore is an attractive target for the 
development of effective therapeutic approaches (Tak and Firestein, 2001). NF-κB, 
however, is involved in the regulation of a wide range of cellular responses and a 
major limitation for targeting the NF-κΒ signalling pathway is the possible disruption of 
physiological functions and wide spread cytotoxicity.  
In order to provide localised inhibition of NF-κΒ in this study, the PTD 
technology was employed. This technology is based on PTDs, which are small 
peptides that have the ability to translocate into cells. When PTD peptides are fused 
chemically or genetically to different cargos they maintain their ability to translocate 
into cells. Over the past 10 years, many research groups have fused different PTDs 
(Table 1.3) with a wide range of different cargos and demonstrated successful and 
efficient transduction. Several groups also have shown that cargos fused to PTDs can 
exert biological activity in vitro and in vivo once translocated into the cells. This 
finding is the most interesting part of this technology, because PTDs can provide an 
alternative way for delivering therapeutics into cells to target signalling pathways 
intracellularly (Chauhan et al., 2007; Kabouridis, 2003; Tilstra et al., 2007). 
Several studies have shown successful inhibition of the ΝF-κB signalling 
pathway and more specifically the canonical NF-κB pathway with PTD-fusion ΝF-κΒ 
inhibitors in vitro and in vivo.  Horng et al., (2001) achieved inhibition of TLR4-induced 
NF-κΒ activation by fusion of the Antp PTD with a peptide directed against TIR 
domain-containing adaptor protein (TIRAP) in a murine monocytic cell line and 
primary dendritic cells. Antp-TIRAP could also inhibit LPS-induced innate responses 
in the lungs of mice (Jeyaseelan et al., 2005). Similarly, Loiarro et al., (2005) 
demonstrated inhibition of TLR / IL-1-induced NF-κΒ activity with a peptide that 
targets the TIR domain of MyD88 adaptor protein when fused to Antp PTD in HeLa 
and HEK293 cells. Also inhibition of MyD88 homodimerization in vivo, resulted in 
decreased serum levels of IL-6 in mice injected intraperitoneally with IL-1 (Loiarro et 
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al., 2007). Targeting of TRAF6, which is a RANK-1 receptor signalling intermediate 
with a peptide inhibitor fused to MTS PTD, demonstrated inhibition of RANK-1 ligand-
induced NF-κΒ activation in macrophages, but not of RANK-2 (Ye et al., 2002). A 
peptide termed NP50, which contains the NLS sequence from p50 showed inhibition 
of NF-κΒ in a wide range of cells, including fibroblast, monocytes and vascular 
endothelial cells, when fused to MTS PTD (Lin et al., 1995). The p50 NLS interacts 
with a nuclear transport localization complex, which facilitates the entry of 
transcription factors into the nucleus and inhibits NF-κΒ by leaving the transcription 
factor in the cytoplasm (Torgerson et al., 1998). The NLS sequences from SV40 and 
c-myc have also been fused to the MTS PTD and both inhibitors demonstrated 
inhibition of NF-κΒ (Fujihara et al., 2000). The srIκΒa inhibitor, which blocks nuclear 
translocation of NF-κΒ, when fused to TAT PTD has shown successful inhibition of IL-
1- and TNF-induced NF-κΒ activation in HeLa, Jurkat and A456 cells (Fujihara et al., 
2005; Kabouridis et al., 2002). TAT-srIκΒα administration also blocked cell infiltration 
and induced cell apoptosis in the rat pleurisy acute inflammation model (Blackwell et 
al., 2004). One of the most widely studied PTD-fusion NF-κB inhibitors is the NBD 
inhibitor, which has been fused to a wide range of PTDs, such as Antp, TAT, PTD5 
and used in a wide range of in vitro and in vivo models. NBD inhibitor targets the 
NEMO kinase and blocks the formation and subsequent activation of the IKK 
complex. Previous studies have demonstrated in vitro inhibition of NF-κΒ in HeLa 
cells (May et al., 2000), in endothelial cells (Paria et al., 2003), pancreatic acinar cells 
(Ramnath and Bhatia, 2006), neutrophils after LPS stimulation (Choi et al., 2003), T-
cells after TCR activation (Qi and Sun, 2004; Yang et al., 2006), B-cells after BCR 
activation, where increased B-cell apoptosis was observed (Tian et al., 2005) and 
DCs, where reduced expression levels of IL-6, IL-12 and TNF were observed (Tas et 
al., 2005). Previous studies have also shown the ability of NBD to inhibit NF-κΒ in 
vivo in acute and chronic inflammation models. NBD inhibitor has been tested in 
acute inflammation models, such as the PMA-induced ear oedema (May et al., 2000), 
carrageenan paw eoedema (di Meglio et al., 2005), cerulean-induced acute 
pancreatitis (Ethridge et al., 2002) and Respiratory Syncytial Virus (RSV)-induced 
acute inflammation in the lungs (Haeberle et al., 2004), where it could inhibit NF-κΒ 
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and demonstrate anti-inflammatory properties. Recent reports have also 
demonstrated the ability of NBD to exert biological activity in chronic inflammation 
models, such as the CIA model (Dai et al., 2004; Jimi et al., 2004), experimental 
allergic encephalomyelitis (EAE) model of multiple sclerosis (Dasgupta et al., 2004) 
and mdx mouse model of Duchenne muscular dystrophy (DMD) (Acharyya et al., 
2007), where NBD treated animals demonstrated reduced inflammation and 
ameliorated symptoms of the disease. Interestingly, studies in the CIA model 
revealed that animals treated with the PTD-NBD inhibitor demonstrated milder paw 
swelling, reduced lymphocyte infiltration and octeoclastogenesis (Dai et al., 2004; 
Jimi et al., 2004). It is clear therefore that PTD-fusion NF-κΒ inhibitors can inhibit NF-
κΒ activity in vitro and in vivo; demonstrate anti-inflammatory properties and protect 
against the development of the disease in inflammation models. 
Here in this study, a novel therapeutic approach was investigated for the the 
treatment of arthritis. This approach is based on the production and secretion of a 
PTD-fusion NF-κΒ inhibitor from genetically engineered cells at the sites of 
inflammation, which in turn will translocate into adjacent cells and inhibit NF-κΒ. 
Initially, this study focused on the development of PTD-fusion inhibitors that are 
efficiently secreted from mammalian cells. Preliminary data showed that secretable 
forms of TAT PTD-fusion proteins are poorly secreted (Chapter III) and in agreement 
with this study, similar studies have demonstrated low levels of secretion of TAT 
PTD-fusion proteins from mammalian cells (Barka et al., 2004; Flinterman et al., 
2009; Shaw et al., 2008). The detrimental effect of TAT PTD to the secretion of a 
protein was clearly shown when TAT fused to the mIgG2A, which resulted in 
complete inhibition of secretion of this naturally secreted protein. A small increase on 
the secretion levels of TAT PTD-fusion proteins has been shown in previous studies 
when some arginine residues were replaced with alanine residues on the TAT PTD 
sequence, resulting in less positively charged PTDs with fewer furin cleavage sites 
(Flinterman et al., 2009; Shaw et al., 2008). These two groups suggested that 
positively charged PTDs that contain furin cleavage sites, such as TAT PTD have a 
negative impact on the secretion of TAT-fusion proteins. It could also be 
hypothesised that TAT-fusion proteins can escape from the secretory vesicles during 
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the secretion process or can immediately translocate back into the secretory cells 
after their secretion, since TAT-fusion proteins have the ability to penetrate cell 
membranes.  
In order to increase the efficiency of PTD-fusion molecules to be secreted form 
mammalian cells, the LAP peptide of TGFβ was used for the generation of LAP-PTD-
fusion proteins. A latent form of IFNβ could be achieved when the LAP peptide was 
fused to the cytokine via an MMP cleavage site, as LAP-fusion proteins have the 
ability to dimerise (Figure 1.5) (Adams et al., 2003; Vessillier et al., 2004). Similarly, 
fusion of LAP peptide to a PTD-fusion protein can theoretically result in a latent form 
of the PTD-fusion protein. Such a latent structure therefore could shield and protect 
from any intracellular interactions of the PTD-fusion protein and result in its efficient 
secretion. In this study, LAP-TAT3-eGFP, LAP-TAT-RBD and LAP-TAT3-NBD were 
very efficiently secreted and in levels comparable to naturally secreted proteins. 
However, the LAP-TAT3-srΙκΒα was not secreted. This finding clearly showed the 
importance of the cargo polypeptide on the ability of the fusion protein to be secreted. 
It maybe that cargo polypeptides that have a small molecular weight can be efficiently 
secreted when fused to the LAP peptide, as the molecules that were secreted well 
had molecular weights less than 30 kDa, whereas srΙκBα is a 50 kDa protein. 
Interestingly, the type of PTD does not to play a very important role, as both TAT-
RBD and TAT3-NBD were secreted at levels comparable to mIgG2A, when fused to 
the LAP. 
The secreted LAP-TAT3-NBD NF-κΒ inhibitors demonstrated inhibition of NF-
κΒ in 57A HeLa cells after IL-1β stimulation. NF-κΒ inhibition was observed after 
incubation of 57A HeLa cells with supernatants containing the inhibitor or co-culture 
with DTF cells expressing the inhibitor, in the absence of exogenous MMP1. 
Interestingly, the non-cleavable LAP-GS-TAT3-NBD inhibitor also inhibited NF-κΒ 
signalling in 57A ΗeLa cells when co-cultured with the expressing DTF cells. This 
finding, suggests that the LAP-TAT3-NBD inhibitor can exert its actions as an intact 
protein without the need of LAP peptide cleavage. In supernatants from over 
expressing DTF cells, both monomeric and dimerised forms of the LAP-TAT3-NBD 
inhibitors could be detected after western blotting analysis in non-reducing conditions, 
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but it is not known if both forms can translocate into the cells or it is just the 
monomeric form that can translocate and exert its function. 
The secreted LAP-MMP-TAT3-NBD inhibitor demonstrated anti-inflammatory 
activity in the carrageenan and mBSA Antigen-Induced Arthritis in vivo. Both acute 
inflammation models were affected when LAP-MMP-TAT3-NBD was delivered from 
transplanted genetically engineered cells or from injected lentivirus. More specifically, 
animals treated to express the LAP-MMP-TAT3-NBD inhibitor showed milder paw 
swelling, when compared to animals treated to express control LAP-fusion proteins. 
Similarly, other investigators have demonstrated milder paw swelling in the 
carrageenan and CIA models of arthritis in animals that were treated with the PTD-
NBD inhibitor (Dai et al., 2004; di Meglio et al., 2005; Jimi et al., 2004).  
This study demonstrates a feasible way of generating a cell translocating NF-
κΒ inhibitor that is efficiently secreted from mammalian cells and demonstrates in 
vitro and in vivo activity. This technology can be applied for the development of a 
novel therapeutic and gene therapy approach for the treatment of RA. The gene 
therapy strategy that is described in this study can overcome many of the limitations 
that exist in present gene therapy approaches. Unwanted toxicity will be avoided, 
because the LAP-MMP-TAT3-NBD inhibitor will be produced and exert its action only 
at the sites of inflammation, as it will translocate into cells that are in close proximity 
to the producing cells. The latent form of the inhibitor will also increase the safety of 
this approach, because active TAT3-NBD inhibitors will be released only at the sites 
of inflammation where MMPs are high. Previous work in our laboratories has 
demonstrated increased half life of LAP-fusion proteins (Adams et al., 2003; Vessillier 
et al., 2004), therefore it can be hypothesised that half life of the TAT3-NBD inhibitor 
will be increased through stabilization of the molecule with the LAP peptide. Lentiviral 
vectors in general demonstrate low levels of immunogenicity (Chernajovsky et al., 
2004). In addition, lower levels of immunogenicity can be achieved with an ex vivo 
gene therapy approach, where syngeneic cells are transplanted. Additionally, a major 
advantage of inhibiting NF-κΒ signalling with the NBD inhibitor is that only the 
canonical pathway is inhibited and non-canonical pathway is unaffected. This permits 
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basal activity of NF-κΒ which is crucial, because complete inhibition of NF-κΒ can 
lead to undesired apoptosis and non-specific toxicity (May et al., 2000).   
 In conclusion, this study presents a novel strategy for the development of a 
safer and more efficient gene therapy approach for the treatment of RA. 
 
8.2 Future work 
 
 
8.2.1 In vitro studies 
 
 
 Further aspects of the LAP-PTD-fusion proteins still need to be explored in 
order to better understand their properties. The ability of LAP-PTD-fusion proteins to 
transduce mammalian cells can be demonstrated by western blotting analysis, FACS 
analysis or confocal microscopy of cells that were treated with the secreted fusion 
proteins. It is not clear yet if the whole LAP-PTD-fusion molecules can translocate 
into the cells or only the cleaved PTD-fusion product.  
 Specific inhibition of NF-κΒ with the LAP-TAT3-NBD inhibitors can also be 
demonstrated directly, by electrophoretic mobility shift assay (EMSA), which can 
measure the ability of NF-κΒ to bind to DNA, or by measuring levels of mRNA with 
reverse-transcriptase (RT) PCR of genes that are upregulated by NF-κΒ, such as 
COX-2 and TNF-α (di Meglio et al., 2005). 
 LAP-TAT3-NBD inhibitor can also be optimised by complete removal of the 
incorporated tags and potency could theoretically be increased with the addition of 
extra NBD sequences via an MMP cleavage sites to the inhibitor. The NBD inhibitor is 
a small ~ 4 kDa peptide and this study demonstrated that fusion of proteins with 
molecular weight of ~ 30 kDa, such as eGFP can be efficiently secreted when fused 
to the LAP. Therefore an inhibitor with the form of LAP-MMP-TAT3-(NBD)4 could be 
generated with possible enhanced inhibitory effects.    
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8.2.2 In vivo studies  
 
 
 In this study, acute inflammation models were used for the investigation of 
anti-inflammatory activity of the LAP-MMP-TAT3-NBD inhibitor, by directly measuring 
the swelling of the paws. Similar, experiments could also be repeated in order to 
show that the ability of LAP-MMP-TAT3-NBD to demonstrate activity is due to NF-κΒ 
inhibition. This can be shown by collecting and analysing tissues from the paws after 
the induction of acute inflammation with EMSA and RT-PCR, as described above. 
 The ability of LAP-TAT3-NBD to demonstrate in vivo activity also needs to be 
investigated in a chronic inflammatory model, such as CIA model. In this experiment 
however, genetically engineered DTF fibroblasts need to be transplated in DBA/1 
mice in order to avoid immunogenic reactions and achieve long term expression and 
secretion of the inhibitor. Similarly, in the CIA model paw swelling and tissue analysis 
can demonstrate the ability of the inhibitor to exert long term effect. Jimi et. al., (2004) 
have demonstrated that specific inhibition of NF-κΒ in the CIA model protects from 
bone destruction. Therefore, histological analyses of the paws from the animals 
expressing the secretable LAP-MMP-TAT3-NBD can also demonstrate inhibition of 
bone destruction.     
 
8.3.3 General studies 
 
  
 This study presented a novel approach for the delivery of a PTD-fusion 
inhibitor that is produced from genetically engineered cells. More specifically, the NF-
κΒ signalling pathway was targeted because of its central role in the regulation of 
inflammatory and immune responses (Barnes and Karin, 1997; Simmonds and 
Foxwell, 2008).  However, NF-κΒ regulates physiological processes such as survival 
and proliferation; and recent reports have highlighted the importance of NF-κΒ in the 
resolution of inflammation and tissue repair (Ghosh and Hayden, 2008). A major 
consideration in this study was the induction of cell death to the expressing cells due 
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to NF-κB inhibition. However, no increased cell death was observed in DTF cells 
when compared to TNFR double KO DTF cells that were expressing the LAP-MMP-
TAT3-NBD inhibitor after IL-1 or TNFα stimulation (data not included). It would also 
be interesting cell if death in DTF cells expressing the LAP-MMP-TAT3-srIκΒα 
inhibitor was evaluated, as this inhibitor is mainly retained inside the cells and it would 
be expected NF-κΒ inhibition to be stronger if released to the cytoplasm.  
The activation and termination of NF-κΒ activity, however, is way beyond the 
simplified known canonical and non canonical signalling pathways. Recent studies 
reveal new regulators of NF-κΒ and bring a better insight in the mechanism that 
control NF-κΒ. It is also becoming clearer that the ability of NF-κΒ to regulate such a 
wide range of different cellular responses is due to the complexity of this signalling 
pathway (Ghosh and Hayden, 2008). Interestingly, Hong et al., (2001), Ye et al., 
(2002) and Loiarro et al., (2005) could achieve selective inhibition of NF-κΒ after 
specific receptor activation by targeting adaptor proteins. Similar approaches can 
lead to a more selective NF-κΒ inhibition, which in turn can result in the development 
of safer inhibitors. There is no study up to date that demonstrates the effects of 
inhibiting the non-cononical NF-κΒ pathway only. It is expected, however, that 
research groups will develop such inhibitors and explore their potential in 
inflammatory diseases (Orange and May, 2008).   
Inflammatory responses can also be regulated by targeting signal transduction 
molecules other than NF-κΒ. The p38 mitogen-activated protein kinase (MAPK) for 
example is a kinase that regulates mediators of inflammation such as cytokines, 
chemokines, COX-2 and nitric oxide synthase. A widely used inhibitor for MAPK is 
the SB20358, which directly binds to the MAPK (Dinarello, 2010). Tyrosine kinases 
such as the Janus kinases (Jak), which are involved in the proliferation and 
differentiation of leucocytes is another promising target. RA patients that were treated 
with the CP-690550 Jak inhibitor demonstrated reduction in inflammation markers 
and improved quality of life (Dinarello, 2010). Inhibition of speen tyrosine kinase 
(Syk), which regulates the expression of Fc-γ receptors in B-cells  in the CIA model 
reduced bone erosion, pannus formation and synovitis (Weinblatt et al., 2008). 
Peroxisome proliferator-activator receptor (PPAR) agonists also demonstrate anti-
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inflammatory properties. PPAR orphan receptors regulate the expression of several 
proinflammatory cytokines, chemokines and cells adhesion molecules. There are 
several endogenous PPAR agonists, such as prostacyclin; and synthetic ligands for 
PPARγ, such as rosiglitazone, pioglitazone and troglitazone (Dasu et al., 2009; 
Dinarello, 2010). It is clear therefore that inflammatory responses can be regulated by 
targeting a wide range of signal transduction molecules. It is also understood that the 
development of novel inhibitors for the control of inflammation is a very active 
research area. The NBD inhibitor used in this study can be replaced with other 
inhibitors that specifically target intracellular signalling pathways. Consequently, the 
development of different LAP-MMP-TAT3-fusion inhibitors can in turn be tested in 
vitro and in vivo.  
Ongoing research, therefore, with the development of more signal specific 
peptide inhibitors and the use of the technology that was described in this study can 
lead to the development of more effective and safer therapeutic approaches for the 
treatment of RA.                
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Appendices 
 
The whole sequences from the engineered constructs generated are 
shown. One letter code translation is also shown and * indicates termination of 
transcription.  
 
A1. IL2ss-TAT-HA-srIkBa-V5  
 
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA  
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I 
 
TCG TAC GGC CGC AAG AAA CGC CGC CAG CGC CGC CGC GGT GGA TCC ACC ATG TCC GGC TAT CCA   
S   Y   G   R   K   K   R   R   Q   R   R   R   G   G   S   T   M   S   G   Y   P    
   
TAT GAC GTC CCA GAC TAT GCT GGC TCC ATG GCC GGT ACC GAG CTC GGA TCC ATG TTC CAG GCG 
Y   D   V   P   D   Y   A   G   S   M   A   G   T   E   L   G   S   M   F   Q   A 
 
GCC GAG CGC CCC CAG GAG TGG GCC ATG GAG GGC CCC CGC GAC TGG CTG AAG AAG GAG CGG CTA 
A   E   R   P   Q   E   W   A   M   E   G   P   R   D   W   L   K   K   E   R   L    
 
CTG GAC GAC CGC CAC GAC GCC GGC CTG GAC GCC ATG AAA GAC GAG GAG TAC GAG CAG ATG GTC 
L   D   D   R   H   D   A   G   L   D   A   M   K   D   E   E   Y   E   Q   M   V    
   
AAG GAG CTG CAG GAG ATC CGC CTC GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CCC TGG AAG  
K   E   L   Q   E   I   R   L   E   P   Q   E   V   P   R   G   S   E   P   W   K    
 
CAG CAG CTC ACC GAG GAC GGG GAC TCG TTC CTG CAC TTG GCC ATC ATC CAT GAA GAA AAG GCA 
Q   Q   L   T   E   D   G   D   S   F   L   H   L   A   I   I   H   E   E   K   A    
   
CTG ACC ATG GAA GTG ATC CGC CAG GTG AAG GGA GAC CTG GCC TTC CTC AAC TTC CAG AAC AAC 
L   T   M   E   V   I   R   Q   V   K   G   D   L   A   F   L   N   F   Q   N   N    
   
CTG CAG CAG ACT CCA CTC CAC TTG GCT GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GCA CTT  
L   Q   Q   T   P   L   H   L   A   V   I   T   N   Q   P   E   I   A   E   A   L    
 
CTG GGA GCT GGC TGT GAT CCT GAG CTC CGA GAC TTT CGA GGA AAT ACC CCC CTA CAC CTT GCC 
L   G   A   G   C   D   P   E   L   R   D   F   R   G   N   T   P   L   H   L   A    
   
TGT GAG CAG GGC TGC CTG GCC AGC GTG GGA GTC CTG ACT CAG TCC TGC ACC ACC CCG CAC CTC  
C   E   Q   G   C   L   A   S   V   G   V   L   T   Q   S   C   T   T   P   H   L    
 
CAC TCC ATC CTG AAG GCT ACC AAC TAC AAT GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CAC 
H   S   I   L   K   A   T   N   Y   N   G   H   T   C   L   H   L   A   S   I   H    
   
GGC TAC CTG GGC ATC GTG GAG CTT TTG GTG TCC TTG GGT GCT GAT GTC AAT GCT CAG GAG CCC 
G   Y   L   G   I   V   E   L   L   V   S   L   G   A   D   V   N   A   Q   E   P    
   
TGT AAT GGC CGG ACT GCC CTT CAC CTC GCA GTG GAC CTG CAA AAT CCT GAC CTG GTG TCA CTC  
C   N   G   R   T   A   L   H   L   A   V   D   L   Q   N   P   D   L   V   S   L    
 
CTG TTG AAG TGT GGG GCT GAT GTC AAC AGA GTT ACC TAC CAG GGC TAT TCT CCC TAC CAG CTC   
L   L   K   C   G   A   D   V   N   R   V   T   Y   Q   G   Y   S   P   Y   Q   L    
 
ACC TGG GGC CGC CCA AGC ACC CGG ATA CAG CAG CAG CTG GGC CAG CTG ACA CTA GAA ACC CTT  
T   W   G   R   P   S   T   R   I   Q   Q   Q   L   G   Q   L   T   L   E   T   L    
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CAG ATG CTG CCA GAG AGT GAG GAT GAG GAG AGC TAT GAC ACA GAG TCA GAG TTC ACG GAG TTC  
Q   M   L   P   E   S   E   D   E   E   S   Y   D   T   E   S   E   F   T   E   F    
 
ACA GAG GAC GAG CTG CCC TAT GAT GAC TGT GTG TTT GGA GGC CAG CGT CTG ACG TTA GGA ATT 
T   E   D   E   L   P   Y   D   D   C   V   F   G   G   Q   R   L   T   L   G   I    
 
CCA GGA AAG CCG ATC CCA AAC CCT TTG CTG GGA TTG GAC TCC ACC TGA  
P   G   K   P   I   P   N   P   L   L   G   L   D   S   T   *    
 
 
 
A2. IL2ss-TAT-HA-eGFP 
   
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA  
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I    
 
TCG TAC GGC CGC AAG AAA CGC CGC CAG CGC CGC CGC GGT GGA TCC ACC ATG TCC GGC TAT CCA 
S   Y   G   R   K   K   R   R   Q   R   R   R   G   G   S   T   M   S   G   Y   P    
   
TAT GAC GTC CCA GAC TAT GCT GGC TCC ATG GCC GGT ACC GTG AGC AAG GGC GAG GAG CTG TTC 
Y   D   V   P   D   Y   A   G   S   M   A   G   T   V   S   K   G   E   E   L   F 
 
ACC GGG GTG GTG CCC ATC CTG GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG 
T   G   V   V   P   I   L   V   E   L   D   G   D   V   N   G   H   K   F   S   V    
   
TCC GGC GAG GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC  
S   G   E   G   E   G   D   A   T   Y   G   K   L   T   L   K   F   I   C   T   T    
   
GGC AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC  
G   K   L   P   V   P   W   P   T   L   V   T   T   L   T   Y   G   V   Q   C   F       
 
AGC CGC TAC CCC GAC CAC ATG AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC 
S   R   Y   P   D   H   M   K   Q   H   D   F   F   K   S   A   M   P   E   G   Y 
  
GTC CAG GAG CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG   
V   Q   E   R   T   I   F   F   K   D   D   G   N   Y   K   T   R   A   E   V   K 
   
TTC GAG GGC GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC 
F   E   G   D   T   L   V   N   R   I   E   L   K   G   I   D   F   K   E   D   G    
 
AAC ATC CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC 
N   I   L   G   H   K   L   E   Y   N   Y   N   S   H   N   V   Y   I   M   A   D    
   
AAG CAG AAG AAC GGC ATC AAG GTG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG  
K   Q   K   N   G   I   K   V   N   F   K   I   R   H   N   I   E   D   G   S   V    
 
CAG CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC 
Q   L   A   D   H   Y   Q   Q   N   T   P   I   G   D   G   P   V   L   L   P   D 
   
AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT CAC ATG 
N   H   Y   L   S   T   Q   S   A   L   S   K   D   P   N   E   K   R   D   H   M    
 
GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG TAA  
V   L   L   E   F   V   T   A   A   G   I   T   L   G   M   D   E   L   Y   K   *       
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A3. IL2ss-TAT-HA-RBD 
   
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA 
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I 
 
TCG TAC GGC CGC AAG AAA CGC CGC CAG CGC CGC CGC GGT GGA TCC ACC ATG TCC GGC TAT CCA 
S   Y   G   R   K   K   R   R   Q   R   R   R   G   G   S   T   M   S   G   Y   P 
   
TAT GAC GTC CCA GAC TAT GCT GGC TCC ATG GCC GGT ACC CCT TCT AAG ACA AGC AAC ACT ATC 
Y   D   V   P   D   Y   A   G   S   M   A   G   T   P   S   K   T   S   N   T   I 
 
CGT GTT TTC TTG CCG AAC AAG CAA AGA ACA GTG GTC AAT GTG CGA AAT GGA ATG AGC TTG CAT 
R   V   F   L   P   N   K   Q   R   T   V   V   N   V   R   N   G   M   S   L   H 
 
GAC TGC CTT ATG AAA GCA CTC AAG GTG AGG GGC CTG CAA CCA GAG TGC TGT GCA GTG TTC AGA  
D   C   L   M   K   A   L   K   V   R   G   L   Q   P   E   C   C   A   V   F   R   
   
CTT CTC CAC GAA CAC AAA GGT AAA AAA GCA CGC TTA GAT TGG AAT ACT GAT GCT GCG TCT TTG 
L   L   H   E   H   K   G   K   K   A   R   L   D   W   N   T   D   A   A   S   L 
 
ATT GGA GAA GAA CTT CAA GTA GAT TTC CTG TGA 
I   G   E   E   L   Q   V   D   F   L   * 
 
 
 
A4. IL2ss-TAT-HA-mIgG2A 
 
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA  
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I      
 
TCG TAC GGC CGC AAG AAA CGC CGC CAG CGC CGC CGC GGT GGA TCC ACC ATG TCC GGC TAT CCA 
S   Y   G   R   K   K   R   R   Q   R   R   R   G   G   S   T   M   S   G   Y   P    
   
TAT GAC GTC CCA GAC TAT GCT GGC TCC ATG GCC GGT ACC CCT CCA CTC AAA GAG TGT CCC CCA  
Y   D   V   P   D   Y   A   G   S   M   A   G   T   P   P   L   K   E   C   P   P    
 
TGC GCA GCT CCA GAC CTC TTG GGT GGA CCA TCC GTC TTC ATC TTC CCT CCA AAG ATC AAG GAT 
C   A   A   P   D   L   L   G   G   P   S   V   F   I   F   P   P   K   I   K   D      
 
GTA CTC ATG ATC TCC CTG AGC CCC ATG GTC ACA TGT GTG GTG GTG GAT GTG AGC GAG GAT GAC 
V   L   M   I   S   L   S   P   M   V   T   C   V   V   V   D   V   S   E   D   D    
   
CCA GAC GTC CAG ATC AGC TGG TTT GTG AAC AAC GTG GAA GTA CAC ACA GCT CAG ACA CAA ACC 
P   D   V   Q   I   S   W   F   V   N   N   V   E   V   H   T   A   Q   T   Q   T   
 
CAT AGA GAG GAT TAC AAC AGT ACT CTC CGG GTG GTC AGT GCC CTC CCC ATC CAG CAC CAG GAC 
H   R   E   D   Y   N   S   T   L   R   V   V   S   A   L   P   I   Q   H   Q   D    
 
TGG ATG AGT GGC AAG GAG TTC AAA TGC AAG GTC AAC AAC AGA GCC CTC CCA TCC CCC ATC GAG 
W   M   S   G   K   E   F   K   C   K   V   N   N   R   A   L   P   S   P   I   E 
   
AAA ACC ATC TCA AAA CCC AGA GGG CCA GTA AGA GCT CCA CAG GTA TAT GTC TTG CCT CCA CCA 
K   T   I   S   K   P   R   G   P   V   R   A   P   Q   V   Y   V   L   P   P   P    
 
GCA GAA GAG ATG ACT AAG AAA GAG TTC AGT CTG ACC TGC ATG ATC ACA GGC TTC TTA CCT GCC 
A   E   E   M   T   K   K   E   F   S   L   T   C   M   I   T   G   F   L   P   A      
 
GAA ATT GCT GTG GAC TGG ACC AGC AAT GGG CGT ACA GAG CAA AAC TAC AAG AAC ACC GCA ACA  
E   I   A   V   D   W   T   S   N   G   R   T   E   Q   N   Y   K   N   T   A   T 
 
GTC CTG GAC TCT GAT GGT TCT TAC TTC ATG TAC AGC AAG CTC AGA GTA CAA AAG AGC ACT TGG 
V   L   D   S   D   G   S   Y   F   M   Y   S   K   L   R   V   Q   K   S   T   W    
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GAA AGA GGA AGT CTT TTC GCC TGC TCA GTG GTC CAC GAG GGT CTG CAC AAT CAC CTT ACG ACT 
E   R   G   S   L   F   A   C   S   V   V   H   E   G   L   H   N   H   L   T   T    
   
AAG ACC ATC TCC CGG TCT CTG GGT AAA TGA 
K   T   I   S   R   S   L   G   K   *    
 
 
 
A5. IL2ss-FLAG-TAT-srΙκΒα-V5 
   
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA 
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I 
 
TCA GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAC GGC CGC AAG AAA CGC CGC CAG 
S   G   G   D   Y   K   D   D   D   D   K   G   G   Y   G   R   K   K   R   R   Q 
   
CGC CGC CGC GGA GGT ACC GAG CTC GGA TCC ATG TTC CAG GCG GCC GAG CGC CCC CAG GAG TGG 
R   R   R   G   G   T   E   L   G   S   M   F   Q   A   A   E   R   P   Q   E   W    
 
GCC ATG GAG GGC CCC CGC GAC TGG CTG AAG AAG GAG CGG CTA CTG GAC GAC CGC CAC GAC GCC 
A   M   E   G   P   R   D   W   L   K   K   E   R   L   L   D   D   R   H   D   A    
 
GGC CTG GAC GCC ATG AAA GAC GAG GAG TAC GAG CAG ATG GTC AAG GAG CTG CAG GAG ATC CGC 
G   L   D   A   M   K   D   E   E   Y   E   Q   M   V   K   E   L   Q   E   I   R    
   
CTC GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CCC TGG AAG CAG CAG CTC ACC GAG GAC GGG 
L   E   P   Q   E   V   P   R   G   S   E   P   W   K   Q   Q   L   T   E   D   G    
 
GAC TCG TTC CTG CAC TTG GCC ATC ATC CAT GAA GAA AAG GCA CTG ACC ATG GAA GTG ATC CGC 
D   S   F   L   H   L   A   I   I   H   E   E   K   A   L   T   M   E   V   I   R    
   
CAG GTG AAG GGA GAC CTG GCC TTC CTC AAC TTC CAG AAC AAC CTG CAG CAG ACT CCA CTC CAC 
Q   V   K   G   D   L   A   F   L   N   F   Q   N   N   L   Q   Q   T   P   L   H    
   
TTG GCT GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GCA CTT CTG GGA GCT GGC TGT GAT CCT 
L   A   V   I   T   N   Q   P   E   I   A   E   A   L   L   G   A   G   C   D   P    
 
GAG CTC CGA GAC TTT CGA GGA AAT ACC CCC CTA CAC CTT GCC TGT GAG CAG GGC TGC CTG GCC 
E   L   R   D   F   R   G   N   T   P   L   H   L   A   C   E   Q   G   C   L   A    
   
AGC GTG GGA GTC CTG ACT CAG TCC TGC ACC ACC CCG CAC CTC CAC TCC ATC CTG AAG GCT ACC 
S   V   G   V   L   T   Q   S   C   T   T   P   H   L   H   S   I   L   K   A   T    
 
AAC TAC AAT GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CAC GGC TAC CTG GGC ATC GTG GAG 
N   Y   N   G   H   T   C   L   H   L   A   S   I   H   G   Y   L   G   I   V   E    
   
CTT TTG GTG TCC TTG GGT GCT GAT GTC AAT GCT CAG GAG CCC TGT AAT GGC CGG ACT GCC CTT 
L   L   V   S   L   G   A   D   V   N   A   Q   E   P   C   N   G   R   T   A   L    
   
CAC CTC GCA GTG GAC CTG CAA AAT CCT GAC CTG GTG TCA CTC CTG TTG AAG TGT GGG GCT GAT 
H   L   A   V   D   L   Q   N   P   D   L   V   S   L   L   L   K   C   G   A   D    
 
GTC AAC AGA GTT ACC TAC CAG GGC TAT TCT CCC TAC CAG CTC ACC TGG GGC CGC CCA AGC ACC  
V   N   R   V   T   Y   Q   G   Y   S   P   Y   Q   L   T   W   G   R   P   S   T    
 
CGG ATA CAG CAG CAG CTG GGC CAG CTG ACA CTA GAA ACC CTT CAG ATG CTG CCA GAG AGT GAG 
R   I   Q   Q   Q   L   G   Q   L   T   L   E   T   L   Q   M   L   P   E   S   E    
 
GAT GAG GAG AGC TAT GAC ACA GAG TCA GAG TTC ACG GAG TTC ACA GAG GAC GAG CTG CCC TAT 
D   E   E   S   Y   D   T   E   S   E   F   T   E   F   T   E   D   E   L   P   Y    
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GAT GAC TGT GTG TTT GGA GGC CAG CGT CTG ACG TTA GGA ATT CCA GGA AAG CCG ATC CCA AAC 
D   D   C   V   F   G   G   Q   R   L   T   L   G   I   P   G   K   P   I   P   N    
 
CCT TTG CTG GGA TTG GAC TCC ACC TGA  
P   L   L   G   L   D   S   T   *    
 
 
 
A6. IL2ss-FLAG-TAT3-srΙκΒα-V5 
   
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA 
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I 
 
TCA GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAT GCT CGT GCT GCT GCT CGT CAA  
S   G   G   D   Y   K   D   D   D   D   K   G   G   Y   A   R   A   A   A   R   Q 
   
GCT CGT GCT GGA GGT ACC GAG CTC GGA TCC ATG TTC CAG GCG GCC GAG CGC CCC CAG GAG TGG 
A   R   A   G   G   T   E   L   G   S   M   F   Q   A   A   E   R   P   Q   E   W    
 
GCC ATG GAG GGC CCC CGC GAC TGG CTG AAG AAG GAG CGG CTA CTG GAC GAC CGC CAC GAC GCC 
A   M   E   G   P   R   D   W   L   K   K   E   R   L   L   D   D   R   H   D   A    
 
GGC CTG GAC GCC ATG AAA GAC GAG GAG TAC GAG CAG ATG GTC AAG GAG CTG CAG GAG ATC CGC 
G   L   D   A   M   K   D   E   E   Y   E   Q   M   V   K   E   L   Q   E   I   R    
   
CTC GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CCC TGG AAG CAG CAG CTC ACC GAG GAC GGG 
L   E   P   Q   E   V   P   R   G   S   E   P   W   K   Q   Q   L   T   E   D   G    
 
GAC TCG TTC CTG CAC TTG GCC ATC ATC CAT GAA GAA AAG GCA CTG ACC ATG GAA GTG ATC CGC 
D   S   F   L   H   L   A   I   I   H   E   E   K   A   L   T   M   E   V   I   R    
   
CAG GTG AAG GGA GAC CTG GCC TTC CTC AAC TTC CAG AAC AAC CTG CAG CAG ACT CCA CTC CAC 
Q   V   K   G   D   L   A   F   L   N   F   Q   N   N   L   Q   Q   T   P   L   H    
   
TTG GCT GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GCA CTT CTG GGA GCT GGC TGT GAT CCT 
L   A   V   I   T   N   Q   P   E   I   A   E   A   L   L   G   A   G   C   D   P    
 
GAG CTC CGA GAC TTT CGA GGA AAT ACC CCC CTA CAC CTT GCC TGT GAG CAG GGC TGC CTG GCC 
E   L   R   D   F   R   G   N   T   P   L   H   L   A   C   E   Q   G   C   L   A    
   
AGC GTG GGA GTC CTG ACT CAG TCC TGC ACC ACC CCG CAC CTC CAC TCC ATC CTG AAG GCT ACC 
S   V   G   V   L   T   Q   S   C   T   T   P   H   L   H   S   I   L   K   A   T    
 
AAC TAC AAT GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CAC GGC TAC CTG GGC ATC GTG GAG 
N   Y   N   G   H   T   C   L   H   L   A   S   I   H   G   Y   L   G   I   V   E    
   
CTT TTG GTG TCC TTG GGT GCT GAT GTC AAT GCT CAG GAG CCC TGT AAT GGC CGG ACT GCC CTT 
L   L   V   S   L   G   A   D   V   N   A   Q   E   P   C   N   G   R   T   A   L    
   
CAC CTC GCA GTG GAC CTG CAA AAT CCT GAC CTG GTG TCA CTC CTG TTG AAG TGT GGG GCT GAT 
H   L   A   V   D   L   Q   N   P   D   L   V   S   L   L   L   K   C   G   A   D    
 
GTC AAC AGA GTT ACC TAC CAG GGC TAT TCT CCC TAC CAG CTC ACC TGG GGC CGC CCA AGC ACC  
V   N   R   V   T   Y   Q   G   Y   S   P   Y   Q   L   T   W   G   R   P   S   T    
 
CGG ATA CAG CAG CAG CTG GGC CAG CTG ACA CTA GAA ACC CTT CAG ATG CTG CCA GAG AGT GAG 
R   I   Q   Q   Q   L   G   Q   L   T   L   E   T   L   Q   M   L   P   E   S   E    
 
GAT GAG GAG AGC TAT GAC ACA GAG TCA GAG TTC ACG GAG TTC ACA GAG GAC GAG CTG CCC TAT 
D   E   E   S   Y   D   T   E   S   E   F   T   E   F   T   E   D   E   L   P   Y    
 
GAT GAC TGT GTG TTT GGA GGC CAG CGT CTG ACG TTA GGA ATT CCA GGA AAG CCG ATC CCA AAC 
D   D   C   V   F   G   G   Q   R   L   T   L   G   I   P   G   K   P   I   P   N    
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CCT TTG CTG GGA TTG GAC TCC ACC TGA  
P   L   L   G   L   D   S   T   *    
 
 
 
A7. IL2ss-FLAG-MAntp4-srΙκΒα-V5 
 
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA  
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I          
 
TCA GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA GGC CGT CAA ATT GCA ATC TGG TTC 
S   G   G   D   Y   K   D   D   D   D   K   G   G   G   R   Q   I   A   I   W   F    
 
CAA AAT CGT CGC ATG AAG TGG GCT GCT GGA GGC GGT ACC GAG CTC GGA TCC ATG TTC CAG GCG  
Q   N   R   R   M   K   W   A   A   G   G   G   T   E   L   G   S   M   F   Q   A    
 
GCC GAG CGC CCC CAG GAG TGG GCC ATG GAG GGC CCC CGC GAC TGG CTG AAG AAG GAG CGG CTA 
A   E   R   P   Q   E   W   A   M   E   G   P   R   D   W   L   K   K   E   R   L    
 
CTG GAC GAC CGC CAC GAC GCC GGC CTG GAC GCC ATG AAA GAC GAG GAG TAC GAG CAG ATG GTC 
L   D   D   R   H   D   A   G   L   D   A   M   K   D   E   E   Y   E   Q   M   V    
 
AAG GAG CTG CAG GAG ATC CGC CTC GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CCC TGG AAG 
K   E   L   Q   E   I   R   L   E   P   Q   E   V   P   R   G   S   E   P   W   K    
   
CAG CAG CTC ACC GAG GAC GGG GAC TCG TTC CTG CAC TTG GCC ATC ATC CAT GAA GAA AAG GCA 
Q   Q   L   T   E   D   G   D   S   F   L   H   L   A   I   I   H   E   E   K   A    
 
CTG ACC ATG GAA GTG ATC CGC CAG GTG AAG GGA GAC CTG GCC TTC CTC AAC TTC CAG AAC AAC 
L   T   M   E   V   I   R   Q   V   K   G   D   L   A   F   L   N   F   Q   N   N   
   
CTG CAG CAG ACT CCA CTC CAC TTG GCT GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GCA CTT 
L   Q   Q   T   P   L   H   L   A   V   I   T   N   Q   P   E   I   A   E   A   L    
   
CTG GGA GCT GGC TGT GAT CCT GAG CTC CGA GAC TTT CGA GGA AAT ACC CCC CTA CAC CTT GCC 
L   G   A   G   C   D   P   E   L   R   D   F   R   G   N   T   P   L   H   L   A    
 
TGT GAG CAG GGC TGC CTG GCC AGC GTG GGA GTC CTG ACT CAG TCC TGC ACC ACC CCG CAC CTC 
C   E   Q   G   C   L   A   S   V   G   V   L   T   Q   S   C   T   T   P   H   L    
   
CAC TCC ATC CTG AAG GCT ACC AAC TAC AAT GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CAC 
H   S   I   L   K   A   T   N   Y   N   G   H   T   C   L   H   L   A   S   I   H    
 
GGC TAC CTG GGC ATC GTG GAG CTT TTG GTG TCC TTG GGT GCT GAT GTC AAT GCT CAG GAG CCC 
G   Y   L   G   I   V   E   L   L   V   S   L   G   A   D   V   N   A   Q   E   P   
   
TGT AAT GGC CGG ACT GCC CTT CAC CTC GCA GTG GAC CTG CAA AAT CCT GAC CTG GTG TCA CTC 
C   N   G   R   T   A   L   H   L   A   V   D   L   Q   N   P   D   L   V   S   L    
   
CTG TTG AAG TGT GGG GCT GAT GTC AAC AGA GTT ACC TAC CAG GGC TAT TCT CCC TAC CAG CTC 
L   L   K   C   G   A   D   V   N   R   V   T   Y   Q   G   Y   S   P   Y   Q   L    
 
ACC TGG GGC CGC CCA AGC ACC CGG ATA CAG CAG CAG CTG GGC CAG CTG ACA CTA GAA ACC CTT 
T   W   G   R   P   S   T   R   I   Q   Q   Q   L   G   Q   L   T   L   E   T   L    
 
CAG ATG CTG CCA GAG AGT GAG GAT GAG GAG AGC TAT GAC ACA GAG TCA GAG TTC ACG GAG TTC 
Q   M   L   P   E   S   E   D   E   E   S   Y   D   T   E   S   E   F   T   E   F   
   
ACA GAG GAC GAG CTG CCC TAT GAT GAC TGT GTG TTT GGA GGC CAG CGT CTG ACG TTA GGA ATT 
T   E   D   E   L   P   Y   D   D   C   V   F   G   G   Q   R   L   T   L   G   I    
 
 
 Page | 238  
 
 Appendices 
CCA GGA AAG CCG ATC CCA AAC CCT TTG CTG GGA TTG GAC TCC ACC TGA 
P   G   K   P   I   P   N   P   L   L   G   L   D   S   T   * 
 
 
 
A8. IL2ss-FLAG-PTD5-srΙκΒα-V5 
 
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA  
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I    
 
TCA GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA CGT CGC CAA CGA CGG ACT TCT AAA  
S   G   G   D   Y   K   D   D   D   D   K   G   G   R   R   Q   R   R   T   S   K    
 
CTG ATG AAG AGG GGA GGT ACC GAG CTC GGA TCC ATG TTC CAG GCG GCC GAG CGC CCC CAG GAG  
L   M   K   R   G   G   T   E   L   G   S   M   F   Q   A   A   E   R   P   Q   E    
 
TGG GCC ATG GAG GGC CCC CGC GAC TGG CTG AAG AAG GAG CGG CTA CTG GAC GAC CGC CAC GAC 
W   A   M   E   G   P   R   D   W   L   K   K   E   R   L   L   D   D   R   H   D    
 
GCC GGC CTG GAC GCC ATG AAA GAC GAG GAG TAC GAG CAG ATG GTC AAG GAG CTG CAG GAG ATC 
A   G   L   D   A   M   K   D   E   E   Y   E   Q   M   V   K   E   L   Q   E   I    
 
CGC CTC GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CCC TGG AAG CAG CAG CTC ACC GAG GAC 
R   L   E   P   Q   E   V   P   R   G   S   E   P   W   K   Q   Q   L   T   E   D    
   
GGG GAC TCG TTC CTG CAC TTG GCC ATC ATC CAT GAA GAA AAG GCA CTG ACC ATG GAA GTG ATC 
G   D   S   F   L   H   L   A   I   I   H   E   E   K   A   L   T   M   E   V   I    
 
CGC CAG GTG AAG GGA GAC CTG GCC TTC CTC AAC TTC CAG AAC AAC CTG CAG CAG ACT CCA CTC 
R   Q   V   K   G   D   L   A   F   L   N   F   Q   N   N   L   Q   Q   T   P   L    
   
CAC TTG GCT GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GCA CTT CTG GGA GCT GGC TGT GAT 
H   L   A   V   I   T   N   Q   P   E   I   A   E   A   L   L   G   A   G   C   D    
   
CCT GAG CTC CGA GAC TTT CGA GGA AAT ACC CCC CTA CAC CTT GCC TGT GAG CAG GGC TGC CTG 
P   E   L   R   D   F   R   G   N   T   P   L   H   L   A   C   E   Q   G   C   L 
 
GCC AGC GTG GGA GTC CTG ACT CAG TCC TGC ACC ACC CCG CAC CTC CAC TCC ATC CTG AAG GCT 
A   S   V   G   V   L   T   Q   S   C   T   T   P   H   L   H   S   I   L   K   A    
   
ACC AAC TAC AAT GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CAC GGC TAC CTG GGC ATC GTG 
T   N   Y   N   G   H   T   C   L   H   L   A   S   I   H   G   Y   L   G   I   V    
 
GAG CTT TTG GTG TCC TTG GGT GCT GAT GTC AAT GCT CAG GAG CCC TGT AAT GGC CGG ACT GCC 
E   L   L   V   S   L   G   A   D   V   N   A   Q   E   P   C   N   G   R   T   A    
   
CTT CAC CTC GCA GTG GAC CTG CAA AAT CCT GAC CTG GTG TCA CTC CTG TTG AAG TGT GGG GCT 
L   H   L   A   V   D   L   Q   N   P   D   L   V   S   L   L   L   K   C   G   A 
   
GAT GTC AAC AGA GTT ACC TAC CAG GGC TAT TCT CCC TAC CAG CTC ACC TGG GGC CGC CCA AGC 
D   V   N   R   V   T   Y   Q   G   Y   S   P   Y   Q   L   T   W   G   R   P   S 
 
ACC CGG ATA CAG CAG CAG CTG GGC CAG CTG ACA CTA GAA ACC CTT CAG ATG CTG CCA GAG AGT 
T   R   I   Q   Q   Q   L   G   Q   L   T   L   E   T   L   Q   M   L   P   E   S    
 
GAG GAT GAG GAG AGC TAT GAC ACA GAG TCA GAG TTC ACG GAG TTC ACA GAG GAC GAG CTG CCC 
E   D   E   E   S   Y   D   T   E   S   E   F   T   E   F   T   E   D   E   L   P  
   
TAT GAT GAC TGT GTG TTT GGA GGC CAG CGT CTG ACG TTA GGA ATT CCA GGA AAG CCG ATC CCA 
Y   D   D   C   V   F   G   G   Q   R   L   T   L   G   I   P   G   K   P   I   P    
 
AAC CCT TTG CTG GGA TTG GAC TCC ACC TGA  
N   P   L   L   G   L   D   S   T   *    
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A9. IL2ss-FLAG-TAT3-NBD 
 
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA 
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I      
 
TCA GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAT GCT CGT GCT GCT GCT CGT CAA 
S   G   G   D   Y   K   D   D   D   D   K   G   G   Y   A   R   A   A   A   R   Q    
   
GCT CGT GCT GGA GGT ACC ACG GCC CTA GAC TGG AGC TGG TTA CAG ACG GAA TGA  
A   R   A   G   G   T   T   A   L   D   W   S   W   L   Q   T   E   *     
 
 
 
A10. IL2ss-FLAG-TAT3-NBD-V5 
 
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA  
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I    
 
TCA GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAT GCT CGT GCT GCT GCT CGT CAA  
S   G   G   D   Y   K   D   D   D   D   K   G   G   Y   A   R   A   A   A   R   Q    
 
GCT CGT GCT GGA GGT ACC ACG GCC CTA GAC TGG AGC TGG TTA CAG ACG GAA GGT GGA GGT AAG  
A   R   A   G   G   T   T   A   L   D   W   S   W   L   Q   T   E   G   G   G   K       
 
CCT ATC CCT AAC CCT CTC CTC GGT CTC GAT TCT ACG TGA 
P   I   P   N   P   L   L   G   L   D   S   T   *      
 
 
 
A11. LAP-MMP 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
 
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
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CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCC TGA  
S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   *       
 
 
 
A12. LAP-MMP-TAT-HA-RBD 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
 
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCC GCC GCC  
S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A      
 
TAC GGC CGC AAG AAA CGC CGC CAG CGC CGC CGC GGT GGA TCC ACC ATG TCC GGC TAT CCA TAT 
Y   G   R   K   K   R   R   Q   R   R   R   G   G   S   T   M   S   G   Y   P   Y 
   
GAC GTC CCA GAC TAT GCT GGC TCC ATG GCC GGT ACC CCT TCT AAG ACA AGC AAC ACT ATC CGT 
D   V   P   D   Y   A   G   S   M   A   G   T   P   S   K   T   S   N   T   I   R 
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GTT TTC TTG CCG AAC AAG CAA AGA ACA GTG GTC AAT GTG CGA AAT GGA ATG AGC TTG CAT GAC 
V   F   L   P   N   K   Q   R   T   V   V   N   V   R   N   G   M   S   L   H   D 
 
TGC CTT ATG AAA GCA CTC AAG GTG AGG GGC CTG CAA CCA GAG TGC TGT GCA GTG TTC AGA CTT 
C   L   M   K   A   L   K   V   R   G   L   Q   P   E   C   C   A   V   F   R   L 
   
CTC CAC GAA CAC AAA GGT AAA AAA GCA CGC TTA GAT TGG AAT ACT GAT GCT GCG TCT TTG ATT 
L   H   E   H   K   G   K   K   A   R   L   D   W   N   T   D   A   A   S   L   I 
 
GGA GAA GAA CTT CAA GTA GAT TTC CTG TGA 
G   E   E   L   Q   V   D   F   L   *       
 
 
 
A13. LAP-MMP-FLAG-TAT-srΙκΒα-V5 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
   
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCC   
S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A  
 
GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAC GGC CGC AAG AAA CGC CGC CAG CGC 
G   G   D   Y   K   D   D   D   D   K   G   G   Y   G   R   K   K   R   R   Q   R 
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CGC CGC GGA GGT ACC GAG CTC GGA TCC ATG TTC CAG GCG GCC GAG CGC CCC CAG GAG TGG GCC 
R   R   G   G   T   E   L   G   S   M   F   Q   A   A   E   R   P   Q   E   W   A 
 
ATG GAG GGC CCC CGC GAC TGG CTG AAG AAG GAG CGG CTA CTG GAC GAC CGC CAC GAC GCC GGC 
M   E   G   P   R   D   W   L   K   K   E   R   L   L   D   D   R   H   D   A   G 
 
CTG GAC GCC ATG AAA GAC GAG GAG TAC GAG CAG ATG GTC AAG GAG CTG CAG GAG ATC CGC CTC 
L   D   A   M   K   D   E   E   Y   E   Q   M   V   K   E   L   Q   E   I   R   L 
   
GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CCC TGG AAG CAG CAG CTC ACC GAG GAC GGG GAC 
E   P   Q   E   V   P   R   G   S   E   P   W   K   Q   Q   L   T   E   D   G   D 
 
TCG TTC CTG CAC TTG GCC ATC ATC CAT GAA GAA AAG GCA CTG ACC ATG GAA GTG ATC CGC CAG 
S   F   L   H   L   A   I   I   H   E   E   K   A   L   T   M   E   V   I   R   Q 
   
GTG AAG GGA GAC CTG GCC TTC CTC AAC TTC CAG AAC AAC CTG CAG CAG ACT CCA CTC CAC TTG 
V   K   G   D   L   A   F   L   N   F   Q   N   N   L   Q   Q   T   P   L   H   L 
   
GCT GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GCA CTT CTG GGA GCT GGC TGT GAT CCT GAG 
A   V   I   T   N   Q   P   E   I   A   E   A   L   L   G   A   G   C   D   P   E 
 
CTC CGA GAC TTT CGA GGA AAT ACC CCC CTA CAC CTT GCC TGT GAG CAG GGC TGC CTG GCC AGC 
L   R   D   F   R   G   N   T   P   L   H   L   A   C   E   Q   G   C   L   A   S 
   
GTG GGA GTC CTG ACT CAG TCC TGC ACC ACC CCG CAC CTC CAC TCC ATC CTG AAG GCT ACC AAC 
V   G   V   L   T   Q   S   C   T   T   P   H   L   H   S   I   L   K   A   T   N 
 
TAC AAT GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CAC GGC TAC CTG GGC ATC GTG GAG CTT 
Y   N   G   H   T   C   L   H   L   A   S   I   H   G   Y   L   G   I   V   E   L 
   
TTG GTG TCC TTG GGT GCT GAT GTC AAT GCT CAG GAG CCC TGT AAT GGC CGG ACT GCC CTT CAC 
L   V   S   L   G   A   D   V   N   A   Q   E   P   C   N   G   R   T   A   L   H 
   
CTC GCA GTG GAC CTG CAA AAT CCT GAC CTG GTG TCA CTC CTG TTG AAG TGT GGG GCT GAT GTC 
L   A   V   D   L   Q   N   P   D   L   V   S   L   L   L   K   C   G   A   D   V 
 
AAC AGA GTT ACC TAC CAG GGC TAT TCT CCC TAC CAG CTC ACC TGG GGC CGC CCA AGC ACC CGG 
N   R   V   T   Y   Q   G   Y   S   P   Y   Q   L   T   W   G   R   P   S   T   R 
 
ATA CAG CAG CAG CTG GGC CAG CTG ACA CTA GAA ACC CTT CAG ATG CTG CCA GAG AGT GAG GAT 
I   Q   Q   Q   L   G   Q   L   T   L   E   T   L   Q   M   L   P   E   S   E   D 
   
GAG GAG AGC TAT GAC ACA GAG TCA GAG TTC ACG GAG TTC ACA GAG GAC GAG CTG CCC TAT GAT 
E   E   S   Y   D   T   E   S   E   F   T   E   F   T   E   D   E   L   P   Y   D 
 
GAC TGT GTG TTT GGA GGC CAG CGT CTG ACG TTA GGA ATT CCA GGA AAG CCG ATC CCA AAC CCT 
D   C   V   F   G   G   Q   R   L   T   L   G   I   P   G   K   P   I   P   N   P    
 
TTG CTG GGA TTG GAC TCC ACC TGA  
L   L   G   L   D   S   T   *    
 
 
 
A14. LAP-MMP-FLAG-TAT3-srΙκΒα-V5 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
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AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
   
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCC   
S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A  
 
GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAT GCT CGT GCT GCT GCT CGT CAA GCT 
G   G   D   Y   K   D   D   D   D   K   G   G   Y   A   R   A   A   A   R   Q   A 
 
CGT GCT GGA GGT ACC GAG CTC GGA TCC ATG TTC CAG GCG GCC GAG CGC CCC CAG GAG TGG GCC 
R   A   G   G   T   E   L   G   S   M   F   Q   A   A   E   R   P   Q   E   W   A  
 
ATG GAG GGC CCC CGC GAC TGG CTG AAG AAG GAG CGG CTA CTG GAC GAC CGC CAC GAC GCC GGC 
M   E   G   P   R   D   W   L   K   K   E   R   L   L   D   D   R   H   D   A   G 
 
CTG GAC GCC ATG AAA GAC GAG GAG TAC GAG CAG ATG GTC AAG GAG CTG CAG GAG ATC CGC CTC 
L   D   A   M   K   D   E   E   Y   E   Q   M   V   K   E   L   Q   E   I   R   L 
   
GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CCC TGG AAG CAG CAG CTC ACC GAG GAC GGG GAC 
E   P   Q   E   V   P   R   G   S   E   P   W   K   Q   Q   L   T   E   D   G   D 
 
TCG TTC CTG CAC TTG GCC ATC ATC CAT GAA GAA AAG GCA CTG ACC ATG GAA GTG ATC CGC CAG 
S   F   L   H   L   A   I   I   H   E   E   K   A   L   T   M   E   V   I   R   Q 
   
GTG AAG GGA GAC CTG GCC TTC CTC AAC TTC CAG AAC AAC CTG CAG CAG ACT CCA CTC CAC TTG 
V   K   G   D   L   A   F   L   N   F   Q   N   N   L   Q   Q   T   P   L   H   L 
   
GCT GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GCA CTT CTG GGA GCT GGC TGT GAT CCT GAG 
A   V   I   T   N   Q   P   E   I   A   E   A   L   L   G   A   G   C   D   P   E 
 
CTC CGA GAC TTT CGA GGA AAT ACC CCC CTA CAC CTT GCC TGT GAG CAG GGC TGC CTG GCC AGC 
L   R   D   F   R   G   N   T   P   L   H   L   A   C   E   Q   G   C   L   A   S 
   
GTG GGA GTC CTG ACT CAG TCC TGC ACC ACC CCG CAC CTC CAC TCC ATC CTG AAG GCT ACC AAC 
V   G   V   L   T   Q   S   C   T   T   P   H   L   H   S   I   L   K   A   T   N 
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TAC AAT GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CAC GGC TAC CTG GGC ATC GTG GAG CTT 
Y   N   G   H   T   C   L   H   L   A   S   I   H   G   Y   L   G   I   V   E   L 
   
TTG GTG TCC TTG GGT GCT GAT GTC AAT GCT CAG GAG CCC TGT AAT GGC CGG ACT GCC CTT CAC 
L   V   S   L   G   A   D   V   N   A   Q   E   P   C   N   G   R   T   A   L   H 
   
CTC GCA GTG GAC CTG CAA AAT CCT GAC CTG GTG TCA CTC CTG TTG AAG TGT GGG GCT GAT GTC 
L   A   V   D   L   Q   N   P   D   L   V   S   L   L   L   K   C   G   A   D   V 
 
AAC AGA GTT ACC TAC CAG GGC TAT TCT CCC TAC CAG CTC ACC TGG GGC CGC CCA AGC ACC CGG 
N   R   V   T   Y   Q   G   Y   S   P   Y   Q   L   T   W   G   R   P   S   T   R 
 
ATA CAG CAG CAG CTG GGC CAG CTG ACA CTA GAA ACC CTT CAG ATG CTG CCA GAG AGT GAG GAT 
I   Q   Q   Q   L   G   Q   L   T   L   E   T   L   Q   M   L   P   E   S   E   D 
   
GAG GAG AGC TAT GAC ACA GAG TCA GAG TTC ACG GAG TTC ACA GAG GAC GAG CTG CCC TAT GAT 
E   E   S   Y   D   T   E   S   E   F   T   E   F   T   E   D   E   L   P   Y   D 
 
GAC TGT GTG TTT GGA GGC CAG CGT CTG ACG TTA GGA ATT CCA GGA AAG CCG ATC CCA AAC CCT 
D   C   V   F   G   G   Q   R   L   T   L   G   I   P   G   K   P   I   P   N   P 
 
TTG CTG GGA TTG GAC TCC ACC TGA  
L   L   G   L   D   S   T   *    
 
 
 
A15. LAP-MMP-FLAG-MAntp4-srΙκΒα-V5 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
 
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
   
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
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GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCC   
S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A  
 
GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA GGC CGT CAA ATT GCA ATC TGG TTC CAA 
G   G   D   Y   K   D   D   D   D   K   G   G   G   R   Q   I   A   I   W   F   Q 
 
AAT CGT CGC ATG AAG TGG GCT GCT GGA GGC GGT ACC GAG CTC GGA TCC ATG TTC CAG GCG GCC 
N   R   R   M   K   W   A   A   G   G   G   T   E   L   G   S   M   F   Q   A   A 
 
GAG CGC CCC CAG GAG TGG GCC ATG GAG GGC CCC CGC GAC TGG CTG AAG AAG GAG CGG CTA CTG 
E   R   P   Q   E   W   A   M   E   G   P   R   D   W   L   K   K   E   R   L   L 
 
GAC GAC CGC CAC GAC GCC GGC CTG GAC GCC ATG AAA GAC GAG GAG TAC GAG CAG ATG GTC AAG 
D   D   R   H   D   A   G   L   D   A   M   K   D   E   E   Y   E   Q   M   V   K 
 
GAG CTG CAG GAG ATC CGC CTC GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CCC TGG AAG CAG 
E   L   Q   E   I   R   L   E   P   Q   E   V   P   R   G   S   E   P   W   K   Q 
   
CAG CTC ACC GAG GAC GGG GAC TCG TTC CTG CAC TTG GCC ATC ATC CAT GAA GAA AAG GCA CTG 
Q   L   T   E   D   G   D   S   F   L   H   L   A   I   I   H   E   E   K   A   L 
 
ACC ATG GAA GTG ATC CGC CAG GTG AAG GGA GAC CTG GCC TTC CTC AAC TTC CAG AAC AAC CTG 
T   M   E   V   I   R   Q   V   K   G   D   L   A   F   L   N   F   Q   N   N   L 
   
CAG CAG ACT CCA CTC CAC TTG GCT GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GCA CTT CTG 
Q   Q   T   P   L   H   L   A   V   I   T   N   Q   P   E   I   A   E   A   L   L 
   
GGA GCT GGC TGT GAT CCT GAG CTC CGA GAC TTT CGA GGA AAT ACC CCC CTA CAC CTT GCC TGT 
G   A   G   C   D   P   E   L   R   D   F   R   G   N   T   P   L   H   L   A   C 
 
GAG CAG GGC TGC CTG GCC AGC GTG GGA GTC CTG ACT CAG TCC TGC ACC ACC CCG CAC CTC CAC 
E   Q   G   C   L   A   S   V   G   V   L   T   Q   S   C   T   T   P   H   L   H 
   
TCC ATC CTG AAG GCT ACC AAC TAC AAT GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CAC GGC 
S   I   L   K   A   T   N   Y   N   G   H   T   C   L   H   L   A   S   I   H   G 
 
TAC CTG GGC ATC GTG GAG CTT TTG GTG TCC TTG GGT GCT GAT GTC AAT GCT CAG GAG CCC TGT 
Y   L   G   I   V   E   L   L   V   S   L   G   A   D   V   N   A   Q   E   P   C 
   
AAT GGC CGG ACT GCC CTT CAC CTC GCA GTG GAC CTG CAA AAT CCT GAC CTG GTG TCA CTC CTG 
N   G   R   T   A   L   H   L   A   V   D   L   Q   N   P   D   L   V   S   L   L 
   
TTG AAG TGT GGG GCT GAT GTC AAC AGA GTT ACC TAC CAG GGC TAT TCT CCC TAC CAG CTC ACC 
L   K   C   G   A   D   V   N   R   V   T   Y   Q   G   Y   S   P   Y   Q   L   T 
 
TGG GGC CGC CCA AGC ACC CGG ATA CAG CAG CAG CTG GGC CAG CTG ACA CTA GAA ACC CTT CAG 
W   G   R   P   S   T   R   I   Q   Q   Q   L   G   Q   L   T   L   E   T   L   Q 
 
ATG CTG CCA GAG AGT GAG GAT GAG GAG AGC TAT GAC ACA GAG TCA GAG TTC ACG GAG TTC ACA 
M   L   P   E   S   E   D   E   E   S   Y   D   T   E   S   E   F   T   E   F   T 
   
GAG GAC GAG CTG CCC TAT GAT GAC TGT GTG TTT GGA GGC CAG CGT CTG ACG TTA GGA ATT CCA 
E   D   E   L   P   Y   D   D   C   V   F   G   G   Q   R   L   T   L   G   I   P 
 
GGA AAG CCG ATC CCA AAC CCT TTG CTG GGA TTG GAC TCC ACC TGA 
G   K   P   I   P   N   P   L   L   G   L   D   S   T   * 
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A16. LAP-MMP-FLAG-PTD5-srΙκΒα-V5 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S      
 
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCC   
S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A  
 
GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA CGT CGC CAA CGA CGG ACT TCT AAA CTG 
G   G   D   Y   K   D   D   D   D   K   G   G   R   R   Q   R   R   T   S   K   L 
 
ATG AAG AGG GGA GGT ACC GAG CTC GGA TCC ATG TTC CAG GCG GCC GAG CGC CCC CAG GAG TGG 
M   K   R   G   G   T   E   L   G   S   M   F   Q   A   A   E   R   P   Q   E   W 
 
GCC ATG GAG GGC CCC CGC GAC TGG CTG AAG AAG GAG CGG CTA CTG GAC GAC CGC CAC GAC GCC 
A   M   E   G   P   R   D   W   L   K   K   E   R   L   L   D   D   R   H   D   A 
 
GGC CTG GAC GCC ATG AAA GAC GAG GAG TAC GAG CAG ATG GTC AAG GAG CTG CAG GAG ATC CGC 
G   L   D   A   M   K   D   E   E   Y   E   Q   M   V   K   E   L   Q   E   I   R 
 
CTC GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CCC TGG AAG CAG CAG CTC ACC GAG GAC GGG 
L   E   P   Q   E   V   P   R   G   S   E   P   W   K   Q   Q   L   T   E   D   G 
   
GAC TCG TTC CTG CAC TTG GCC ATC ATC CAT GAA GAA AAG GCA CTG ACC ATG GAA GTG ATC CGC 
D   S   F   L   H   L   A   I   I   H   E   E   K   A   L   T   M   E   V   I   R 
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CAG GTG AAG GGA GAC CTG GCC TTC CTC AAC TTC CAG AAC AAC CTG CAG CAG ACT CCA CTC CAC 
Q   V   K   G   D   L   A   F   L   N   F   Q   N   N   L   Q   Q   T   P   L   H 
   
TTG GCT GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GCA CTT CTG GGA GCT GGC TGT GAT CCT 
L   A   V   I   T   N   Q   P   E   I   A   E   A   L   L   G   A   G   C   D   P 
   
GAG CTC CGA GAC TTT CGA GGA AAT ACC CCC CTA CAC CTT GCC TGT GAG CAG GGC TGC CTG GCC 
E   L   R   D   F   R   G   N   T   P   L   H   L   A   C   E   Q   G   C   L   A 
 
AGC GTG GGA GTC CTG ACT CAG TCC TGC ACC ACC CCG CAC CTC CAC TCC ATC CTG AAG GCT ACC 
S   V   G   V   L   T   Q   S   C   T   T   P   H   L   H   S   I   L   K   A   T 
   
AAC TAC AAT GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CAC GGC TAC CTG GGC ATC GTG GAG 
N   Y   N   G   H   T   C   L   H   L   A   S   I   H   G   Y   L   G   I   V   E 
 
CTT TTG GTG TCC TTG GGT GCT GAT GTC AAT GCT CAG GAG CCC TGT AAT GGC CGG ACT GCC CTT 
L   L   V   S   L   G   A   D   V   N   A   Q   E   P   C   N   G   R   T   A   L 
   
CAC CTC GCA GTG GAC CTG CAA AAT CCT GAC CTG GTG TCA CTC CTG TTG AAG TGT GGG GCT GAT 
H   L   A   V   D   L   Q   N   P   D   L   V   S   L   L   L   K   C   G   A   D 
   
GTC AAC AGA GTT ACC TAC CAG GGC TAT TCT CCC TAC CAG CTC ACC TGG GGC CGC CCA AGC ACC 
V   N   R   V   T   Y   Q   G   Y   S   P   Y   Q   L   T   W   G   R   P   S   T    
 
CGG ATA CAG CAG CAG CTG GGC CAG CTG ACA CTA GAA ACC CTT CAG ATG CTG CCA GAG AGT GAG 
R   I   Q   Q   Q   L   G   Q   L   T   L   E   T   L   Q   M   L   P   E   S   E 
 
GAT GAG GAG AGC TAT GAC ACA GAG TCA GAG TTC ACG GAG TTC ACA GAG GAC GAG CTG CCC TAT 
D   E   E   S   Y   D   T   E   S   E   F   T   E   F   T   E   D   E   L   P   Y 
   
GAT GAC TGT GTG TTT GGA GGC CAG CGT CTG ACG TTA GGA ATT CCA GGA AAG CCG ATC CCA AAC 
D   D   C   V   F   G   G   Q   R   L   T   L   G   I   P   G   K   P   I   P   N 
 
CCT TTG CTG GGA TTG GAC TCC ACC TGA  
P   L   L   G   L   D   S   T   *    
 
 
 
A17. LAP-MMP-FLAG-TAT3-NBD 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
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GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
   
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCC   
S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A  
 
GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAT GCT CGT GCT GCT GCT CGT CAA GCT 
G   G   D   Y   K   D   D   D   D   K   G   G   Y   A   R   A   A   A   R   Q   A 
   
CGT GCT GGA GGT ACC ACG GCC CTA GAC TGG AGC TGG TTA CAG ACG GAA TGA  
R   A   G   G   T   T   A   L   D   W   S   W   L   Q   T   E   *     
 
 
 
A18. LAP-MMP-FLAG-TAT3-NBD-V5 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
 
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
   
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
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ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCC   
S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A  
 
GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAT GCT CGT GCT GCT GCT CGT CAA GCT 
G   G   D   Y   K   D   D   D   D   K   G   G   Y   A   R   A   A   A   R   Q   A 
 
CGT GCT GGA GGT ACC ACG GCC CTA GAC TGG AGC TGG TTA CAG ACG GAA GGT GGA GGT AAG CCT 
R   A   G   G   T   T   A   L   D   W   S   W   L   Q   T   E   G   G   G   K   P    
 
ATC CCT AAC CCT CTC CTC GGT CTC GAT TCT ACG TGA 
I   P   N   P   L   L   G   L   D   S   T   *      
 
 
 
A19. LAP-GS-FLAG-TAT3-NBD 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
 
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
   
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC GGA GGT GGC GGT TCG GGT GGA GGG GGC TCA GCG GCC GCC   
S   E   F   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   A   A   A  
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GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAT GCT CGT GCT GCT GCT CGT CAA GCT 
G   G   D   Y   K   D   D   D   D   K   G   G   Y   A   R   A   A   A   R   Q   A 
   
CGT GCT GGA GGT ACC ACG GCC CTA GAC TGG AGC TGG TTA CAG ACG GAA TGA  
R   A   G   G   T   T   A   L   D   W   S   W   L   Q   T   E   *     
 
 
 
A20. LAP-MMP-FLAG-TAT3-eGFP 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
 
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
   
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCC   
S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A  
 
GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAT GCT CGT GCT GCT GCT CGT CAA GCT 
G   G   D   Y   K   D   D   D   D   K   G   G   Y   A   R   A   A   A   R   Q   A    
 
CGT GCT GGA GGT GCA TGC GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG 
R   A   G   G   A   C   V   S   K   G   E   E   L   F   T   G   V   V   P   I   L    
 
GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC GAG GGC GAG GGC GAT 
V   E   L   D   G   D   V   N   G   H   K   F   S   V   S   G   E   G   E   G   D    
   
GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG 
A   T   Y   G   K   L   T   L   K   F   I   C   T   T   G   K   L   P   V   P   W    
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CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG 
P   T   L   V   T   T   L   T   Y   G   V   Q   C   F   S   R   Y   P   D   H   M      
 
AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TTC 
K   Q   H   D   F   F   K   S   A   M   P   E   G   Y   V   Q   E   R   T   I   F    
  
TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC GAC ACC CTG GTG 
F   K   D   D   G   N   Y   K   T   R   A   E   V   K   F   E   G   D   T   L   V    
   
AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG 
N   R   I   E   L   K   G   I   D   F   K   E   D   G   N   I   L   G   H   K   L    
 
GAG TAC AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC AAG CAG AAG AAC GGC ATC AAG 
E   Y   N   Y   N   S   H   N   V   Y   I   M   A   D   K   Q   K   N   G   I   K    
   
GTG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG CAG CTC GCC GAC CAC TAC CAG 
V   N   F   K   I   R   H   N   I   E   D   G   S   V   Q   L   A   D   H   Y   Q    
 
CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC TAC CTG AGC ACC CAG 
Q   N   T   P   I   G   D   G   P   V   L   L   P   D   N   H   Y   L   S   T   Q    
   
TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT CAC ATG GTC CTG CTG GAG TTC GTG ACC 
S   A   L   S   K   D   P   N   E   K   R   D   H   M   V   L   L   E   F   V   T    
 
GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG TAA  
A   A   G   I   T   L   G   M   D   E   L   Y   K   *       
 
 
 
A21. LAP-GS-FLAG-TAT3-eGFP 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
  
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
   
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
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ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC GGG GGA GGC GGA TCC GGA GGT GGC GGT TCG GGT GGA GGG GGC TCA GCG GCC GCC   
S   E   F   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   A   A   A  
 
GGT GGA GAC TAC AAA GAC GAT GAC GAC AAG GGT GGA TAT GCT CGT GCT GCT GCT CGT CAA GCT 
G   G   D   Y   K   D   D   D   D   K   G   G   Y   A   R   A   A   A   R   Q   A    
 
CGT GCT GGA GGT GCA TGC GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG 
R   A   G   G   A   C   V   S   K   G   E   E   L   F   T   G   V   V   P   I   L    
 
GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC GAG GGC GAG GGC GAT 
V   E   L   D   G   D   V   N   G   H   K   F   S   V   S   G   E   G   E   G   D    
   
GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG 
A   T   Y   G   K   L   T   L   K   F   I   C   T   T   G   K   L   P   V   P   W    
   
CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG 
P   T   L   V   T   T   L   T   Y   G   V   Q   C   F   S   R   Y   P   D   H   M      
 
AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TTC 
K   Q   H   D   F   F   K   S   A   M   P   E   G   Y   V   Q   E   R   T   I   F    
 
TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC GAC ACC CTG GTG 
F   K   D   D   G   N   Y   K   T   R   A   E   V   K   F   E   G   D   T   L   V    
   
AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG 
N   R   I   E   L   K   G   I   D   F   K   E   D   G   N   I   L   G   H   K   L    
 
GAG TAC AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC AAG CAG AAG AAC GGC ATC AAG 
E   Y   N   Y   N   S   H   N   V   Y   I   M   A   D   K   Q   K   N   G   I   K    
   
GTG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG CAG CTC GCC GAC CAC TAC CAG 
V   N   F   K   I   R   H   N   I   E   D   G   S   V   Q   L   A   D   H   Y   Q    
 
CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC TAC CTG AGC ACC CAG 
Q   N   T   P   I   G   D   G   P   V   L   L   P   D   N   H   Y   L   S   T   Q    
   
TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT CAC ATG GTC CTG CTG GAG TTC GTG ACC 
S   A   L   S   K   D   P   N   E   K   R   D   H   M   V   L   L   E   F   V   T    
 
GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG TAA  
A   A   G   I   T   L   G   M   D   E   L   Y   K   *       
 
 
 
A22. srIκΒα 
 
ATG TTC CAG GCG GCC GAG CGC CCC CAG GAG TGG GCC ATG GAG GGC CCC CGC GAC TGG CTG AAG 
M   F   Q   A   A   E   R   P   Q   E   W   A   M   E   G   P   R   D   W   L   K 
 
AAG GAG CGG CTA CTG GAC GAC CGC CAC GAC GCC GGC CTG GAC GCC ATG AAA GAC GAG GAG TAC 
K   E   R   L   L   D   D   R   H   D   A   G   L   D   A   M   K   D   E   E   Y   
 
GAG CAG ATG GTC AAG GAG CTG CAG GAG ATC CGC CTC GAG CCG CAG GAG GTG CCG CGC GGC TCG 
E   Q   M   V   K   E   L   Q   E   I   R   L   E   P   Q   E   V   P   R   G   S    
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GAG CCC TGG AAG CAG CAG CTC ACC GAG GAC GGG GAC TCG TTC CTG CAC TTG GCC ATC ATC CAT 
E   P   W   K   Q   Q   L   T   E   D   G   D   S   F   L   H   L   A   I   I   H    
 
GAA GAA AAG GCA CTG ACC ATG GAA GTG ATC CGC CAG GTG AAG GGA GAC CTG GCC TTC CTC AAC 
E   E   K   A   L   T   M   E   V   I   R   Q   V   K   G   D   L   A   F   L   N   
   
TTC CAG AAC AAC CTG CAG CAG ACT CCA CTC CAC TTG GCT GTG ATC ACC AAC CAG CCA GAA ATT 
F   Q   N   N   L   Q   Q   T   P   L   H   L   A   V   I   T   N   Q   P   E   I   
   
GCT GAG GCA CTT CTG GGA GCT GGC TGT GAT CCT GAG CTC CGA GAC TTT CGA GGA AAT ACC CCC 
A   E   A   L   L   G   A   G   C   D   P   E   L   R   D   F   R   G   N   T   P    
 
CTA CAC CTT GCC TGT GAG CAG GGC TGC CTG GCC AGC GTG GGA GTC CTG ACT CAG TCC TGC ACC 
L   H   L   A   C   E   Q   G   C   L   A   S   V   G   V   L   T   Q   S   C   T    
   
ACC CCG CAC CTC CAC TCC ATC CTG AAG GCT ACC AAC TAC AAT GGC CAC ACG TGT CTA CAC TTA 
T   P   H   L   H   S   I   L   K   A   T   N   Y   N   G   H   T   C   L   H   L    
 
GCC TCT ATC CAC GGC TAC CTG GGC ATC GTG GAG CTT TTG GTG TCC TTG GGT GCT GAT GTC AAT 
A   S   I   H   G   Y   L   G   I   V   E   L   L   V   S   L   G   A   D   V   N    
   
GCT CAG GAG CCC TGT AAT GGC CGG ACT GCC CTT CAC CTC GCA GTG GAC CTG CAA AAT CCT GAC 
A   Q   E   P   C   N   G   R   T   A   L   H   L   A   V   D   L   Q   N   P   D    
   
CTG GTG TCA CTC CTG TTG AAG TGT GGG GCT GAT GTC AAC AGA GTT ACC TAC CAG GGC TAT TCT 
L   V   S   L   L   L   K   C   G   A   D   V   N   R   V   T   Y   Q   G   Y   S    
 
CCC TAC CAG CTC ACC TGG GGC CGC CCA AGC ACC CGG ATA CAG CAG CAG CTG GGC CAG CTG ACA 
P   Y   Q   L   T   W   G   R   P   S   T   R   I   Q   Q   Q   L   G   Q   L   T    
 
CTA GAA ACC CTT CAG ATG CTG CCA GAG AGT GAG GAT GAG GAG AGC TAT GAC ACA GAG TCA GAG 
L   E   T   L   Q   M   L   P   E   S   E   D   E   E   S   Y   D   T   E   S   E    
   
TTC ACG GAG TTC ACA GAG GAC GAG CTG CCC TAT GAT GAC TGT GTG TTT GGA GGC CAG CGT CTG 
F   T   E   F   T   E   D   E   L   P   Y   D   D   C   V   F   G   G   Q   R   L   
 
ACG TTA  
T   L    
 
 
 
A23. eGFP 
 
GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG GTC GAG CTG GAC GGC GAC 
V   S   K   G   E   E   L   F   T   G   V   V   P   I   L   V   E   L   D   G   D    
 
GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC GAG GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG 
V   N   G   H   K   F   S   V   S   G   E   G   E   G   D   A   T   Y   G   K   L    
   
ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC 
T   L   K   F   I   C   T   T   G   K   L   P   V   P   W   P   T   L   V   T   T    
   
CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG AAG CAG CAC GAC TTC TTC 
L   T   Y   G   V   Q   C   F   S   R   Y   P   D   H   M   K   Q   H   D   F   F      
 
AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC 
K   S   A   M   P   E   G   Y   V   Q   E   R   T   I   F   F   K   D   D   G   N    
  
TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG 
Y   K   T   R   A   E   V   K   F   E   G   D   T   L   V   N   R   I   E   L   K    
   
GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC 
G   I   D   F   K   E   D   G   N   I   L   G   H   K   L   E   Y   N   Y   N   S    
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CAC AAC GTC TAT ATC ATG GCC GAC AAG CAG AAG AAC GGC ATC AAG GTG AAC TTC AAG ATC CGC 
H   N   V   Y   I   M   A   D   K   Q   K   N   G   I   K   V   N   F   K   I   R    
   
CAC AAC ATC GAG GAC GGC AGC GTG CAG CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC 
H   N   I   E   D   G   S   V   Q   L   A   D   H   Y   Q   Q   N   T   P   I   G    
 
GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC 
D   G   P   V   L   L   P   D   N   H   Y   L   S   T   Q   S   A   L   S   K   D    
   
CCC AAC GAG AAG CGC GAT CAC ATG GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC 
P   N   E   K   R   D   H   M   V   L   L   E   F   V   T   A   A   G   I   T   L    
 
GGC ATG GAC GAG CTG TAC AAG  
G   M   D   E   L   Y   K          
 
 
 
A24. RBD 
 
TCT AAG ACA AGC AAC ACT ATC CGT GTT TTC TTG CCG AAC AAG CAA AGA ACA GTG GTC AAT GTG 
S   K   T   S   N   T   I   R   V   F   L   P   N   K   Q   R   T   V   V   N   V 
 
CGA AAT GGA ATG AGC TTG CAT GAC TGC CTT ATG AAA GCA CTC AAG GTG AGG GGC CTG CAA CCA 
R   N   G   M   S   L   H   D   C   L   M   K   A   L   K   V   R   G   L   Q   P 
 
GAG TGC TGT GCA GTG TTC AGA CTT CTC CAC GAA CAC AAA GGT AAA AAA GCA CGC TTA GAT TGG 
E   C   C   A   V   F   R   L   L   H   E   H   K   G   K   K   A   R   L   D   W 
   
AAT ACT GAT GCT GCG TCT TTG ATT GGA GAA GAA CTT CAA GTA GAT TTC CTG 
N   T   D   A   A   S   L   I   G   E   E   L   Q   V   D   F   L 
 
 
 
A25. mIgG2A 
   
CCA CTC AAA GAG TGT CCC CCA TGC GCA GCT CCA GAC CTC TTG GGT GGA CCA TCC GTC TTC ATC 
P   L   K   E   C   P   P   C   A   A   P   D   L   L   G   G   P   S   V   F   I    
 
TTC CCT CCA AAG ATC AAG GAT GTA CTC ATG ATC TCC CTG AGC CCC ATG GTC ACA TGT GTG GTG 
F   P   P   K   I   K   D   V   L   M   I   S   L   S   P   M   V   T   C   V   V       
 
GTG GAT GTG AGC GAG GAT GAC CCA GAC GTC CAG ATC AGC TGG TTT GTG AAC AAC GTG GAA GTA 
V   D   V   S   E   D   D   P   D   V   Q   I   S   W   F   V   N   N   V   E   V    
   
CAC ACA GCT CAG ACA CAA ACC CAT AGA GAG GAT TAC AAC AGT ACT CTC CGG GTG GTC AGT GCC 
H   T   A   Q   T   Q   T   H   R   E   D   Y   N   S   T   L   R   V   V   S   A    
 
CTC CCC ATC CAG CAC CAG GAC TGG ATG AGT GGC AAG GAG TTC AAA TGC AAG GTC AAC AAC AGA 
L   P   I   Q   H   Q   D   W   M   S   G   K   E   F   K   C   K   V   N   N   R    
 
GCC CTC CCA TCC CCC ATC GAG AAA ACC ATC TCA AAA CCC AGA GGG CCA GTA AGA GCT CCA CAG 
A   L   P   S   P   I   E   K   T   I   S   K   P   R   G   P   V   R   A   P   Q    
   
GTA TAT GTC TTG CCT CCA CCA GCA GAA GAG ATG ACT AAG AAA GAG TTC AGT CTG ACC TGC ATG 
V   Y   V   L   P   P   P   A   E   E   M   T   K   K   E   F   S   L   T   C   M    
 
ATC ACA GGC TTC TTA CCT GCC GAA ATT GCT GTG GAC TGG ACC AGC AAT GGG CGT ACA GAG CAA 
I   T   G   F   L   P   A   E   I   A   V   D   W   T   S   N   G   R   T   E   Q      
 
AAC TAC AAG AAC ACC GCA ACA GTC CTG GAC TCT GAT GGT TCT TAC TTC ATG TAC AGC AAG CTC 
N   Y   K   N   T   A   T   V   L   D   S   D   G   S   Y   F   M   Y   S   K   L    
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AGA GTA CAA AAG AGC ACT TGG GAA AGA GGA AGT CTT TTC GCC TGC TCA GTG GTC CAC GAG GGT 
R   V   Q   K   S   T   W   E   R   G   S   L   F   A   C   S   V   V   H   E   G    
    
CTG CAC AAT CAC CTT ACG ACT AAG ACC ATC TCC CGG TCT CTG GGT AAA 
L   H   N   H   L   T   T   K   T   I   S   R   S   L   G   K 
 
 
A26. NBD 
 
ACG GCC CTA GAC TGG AGC TGG TTA CAG ACG GAA  
T   A   L   D   W   S   W   L   Q   T   E        
 
 
A27. IL2ss 
 
ATG TAC AGG ATG CAA CTC CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACG AAT TCG ATA 
M   Y   R   M   Q   L   L   S   C   I   A   L   S   L   A   L   V   T   N   S   I 
 
TCA  
S   
 
 
 
A28. HA 
   
TAT CCA TAT GAC GTC CCA GAC TAT GCT 
Y   P   Y   D   V   P   D   Y   A    
 
 
 
A29. V5 
 
GGA AAG CCG ATC CCA AAC CCT TTG CTG GGA TTG GAC TCC ACC 
G   K   P   I   P   N   P   L   L   G   L   D   S   T 
 
 
 
A30. FLAG 
 
GAC TAC AAA GAC GAT GAC GAC AAG GGT  
D   Y   K   D   D   D   D   K   G    
 
 
 
A31. TAT 
 
TAC GGC CGC AAG AAA CGC CGC CAG CGC CGC CGC 
Y   G   R   K   K   R   R   Q   R   R   R    
 
 
 
A32. TAT3 
 
TAT GCT CGT GCT GCT GCT CGT CAA GCT CGT GCT 
Y   A   R   A   A   A   R   Q   A   R   A    
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A33. MAntp4 
 
GGC CGT CAA ATT GCA ATC TGG TTC CAA AAT CGT CGC ATG AAG TGG GCT GCT GGA 
G   R   Q   I   A   I   W   F   Q   N   R   R   M   K   W   A   A   G 
 
 
 
A34. PTD5 
 
CGT CGC CAA CGA CGG ACT TCT AAA CTG ATG AAG AGG 
R   R   Q   R   R   T   S   K   L   M   K   R    
 
 
 
A35. LAP 
 
ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L    
   
ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG 
T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K 
   
CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG  
R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P    
 
AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC 
S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T    
   
CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC 
R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A    
 
AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG  
K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q    
 
AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC 
S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P    
  
GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC  
V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H       
 
GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA  
V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A    
 
CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC  
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S    
   
CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC  
R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N    
 
ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT 
T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H    
 
GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA 
G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q    
   
AGC GAA TTC  
S   E   F   
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A36. MMP 
 
GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCC   
G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A  
 
 
 
A37. GS 
GGG GGA GGC GGA TCC GGA GGT GGC GGT TCG GGT GGA GGG GGC TCA GCG GCC GCC   
G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   A   A   A  
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